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Background: States vary widely in their use of newborn screening tests, with some mandating screening for as few
as three conditions and others mandating as many as 43 conditions, including varying numbers of the 40
conditions that can be detected by tandem mass spectrometry (MS/MS). There has been no national guidance on
the best candidate conditions for newborn screening since the National Academy of Sciences report of 19751 and
the United States Congress Office of Technology Assessment report of 1988,2 despite rapid developments since
then in genetics, in screening technologies, and in some treatments. Objectives: In 2002, the Maternal and Child
Health Bureau (MCHB) of the Health Resources and Services Administration (HRSA) of the United States
Department of Health and Human Services (DHHS) commissioned the American College of Medical Genetics
(ACMG) to:
1. Conduct an analysis of the scientific literature on the effectiveness of newborn screening.
2. Gather expert opinion to delineate the best evidence for screening for specified conditions and develop
recommendations focused on newborn screening, including but not limited to the development of a uniform
condition panel.
3. Consider other components of the newborn screening system that are critical to achieving the expected
outcomes in those screened.
Methods: A group of experts in various areas of subspecialty medicine and primary care, health policy, law,
public health, and consumers worked with a steering committee and several expert work groups, using a two-tiered
approach to assess and rank conditions. A first step was developing a set of principles to guide the analysis. This
was followed by developing criteria by which conditions could be evaluated, and then identifying the conditions to
be evaluated. A large and broadly representative group of experts was asked to provide their opinions on the extent
to which particular conditions met the selected criteria, relying on supporting evidence and references from the
scientific literature. The criteria were distributed among three main categories for each condition:
1. The availability and characteristics of the screening test;
2. The availability and complexity of diagnostic services; and
3. The availability and efficacy of treatments related to the conditions. A survey process utilizing a data
collection instrument was used to gather expert opinion on the conditions in the first tier of the assessment.
The data collection format and survey provided the opportunity to quantify expert opinion and to obtain the
views of a diverse set of interest groups (necessary due to the subjective nature of some of the criteria).
Statistical analysis of data produced a score for each condition, which determined its ranking and initial
placement in one of three categories (high scoring, moderately scoring, or low scoring/absence of a newborn
screening test). In the second tier of these analyses, the evidence base related to each condition was
assessed in depth (e.g., via systematic reviews of reference lists including MedLine, PubMed and others;
books; Internet searches; professional guidelines; clinical evidence; and cost/economic evidence and
modeling). The fact sheets reflecting these analyses were evaluated by at least two acknowledged experts for
† A medical food is prescribed by a physician when a patient has special nutrient needs in order to manage a disease or health condition, and the patient is under the physician’s ongoing care. The
label must clearly state that the product is intended to be used to manage a specific medical disorder or condition. An example of a medical food is a food for use by persons with PKU, i.e., foods
formulated to be free of the amino acid phenylalanine.
2TheHealthInsurancePortabilityandAccountabilityActof1996(HIPAA)providesrelevantprotectionsregardingpatientprivacy.Thefederalprivacyregulationsdonotprohibitorinterferewith
newbornscreeningandfollow-up.Coveredentitiesmusttrackdisclosuresmadewithoutwrittenpatientauthorizationforservicesotherthantreatment,payment,andoperations,sothatthecovered
entity can provide accounting on patient request. A discussion of the HIPAA issues relating to newborn screening in the context of public health is available in Appendix 4.
3 This and the following economic analyses may best be done through the funding of special projects due to the expense of documentation
4 Consider collecting data from a subset that includes all screen-positive newborns from which an overall rate can be extrapolated with minimal increased cost to the program. Consider initially
collecting data from a subset that includes all screen-positive newborns for which the data already is needed. From these, an overall rate can be extrapolated with minimal increased cost. The goal
is to know all and is dependant on the development of databases in which this information can be maintained and would be facilitated by inclusion on blood collection cards. Identification of
undocumented newborns is increasingly important to their participation in such programs. This is an important issue that involves States, hospitals, providers, insurers, and mothers.
5 For a guidance article on the HIPAA Privacy Rule and Public Health written by CDC and DHHS. see the Morbidity and Mortality Weekly Report for April 11, 2003, vol. 52 pp. 1-21, and
www.cdc.gov/privacyrules and www.hrsa.gov/website.htm.
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provided corrections where appropriate, assigned a value to the level of evidence and the quality of the
studies that established the evidence base, and determined whether there were significant variances from
the survey data. Survey results were subsequently realigned with the evidence obtained from the scientific
literature during the second-tier analysis for all objective criteria, based on input from at least three
acknowledged experts in each condition. The information from these two tiers of assessment was then
considered with regard to the overriding principles and other technology or condition-specific recommenda-
tions. On the basis of this information, conditions were assigned to one of three categories as described
above:
1. Core Panel;
2. Secondary Targets (conditions that are part of the differential diagnosis of a core panel condition.); and
3. Not Appropriate for Newborn Screening (either no newborn screening test is available or there is poor
performance with regard to multiple other evaluation criteria).
ACMG also considered features of optimal newborn screening programs beyond the tests themselves by
assessing the degree to which programs met certain goals (e.g., availability of educational programs,
proportions of newborns screened and followed up). Assessments were based on the input of experts serving
in various capacities in newborn screening programs and on 2002 data provided by the programs of the
National Newborn Screening and Genetics Resource Center (NNSGRC). In addition, a brief cost-effectiveness
assessment of newborn screening was conducted.
Results:
Uniform panel – A total of 292 individuals determined to be generally representative of the regional
distribution of the United States population and of areas of expertise or involvement in newborn screening
provided a total of 3,949 evaluations of 84 conditions. For each condition, the responses of at least three
experts in that condition were compared with those of all respondents for that condition and found to be
consistent. A score of 1,200 on the data collection instrument provided a logical separation point between
high scoring conditions (1,200– 1,799 of a possible 2,100) and low scoring (1,000) conditions. A group
of conditions with intermediate scores (1,000–1,199) was identified, all of which were part of the differential
diagnosis of a high scoring condition or apparent in the result of the multiplex assay. Some are identified by
screening laboratories and others by diagnostic laboratories. This group was designated as a “secondary
target” category for which the program must report the diagnostic result.
Using the validated evidence base and expert opinion, each condition that had previously been assigned
to a category based on scores gathered through the data collection instrument was reconsidered. Again, the
factors taken into consideration were: 1) available scientific evidence; 2) availability of a screening test; 3)
presence of an efficacious treatment; 4) adequate understanding of the natural history of the condition; and
5) whether the condition was either part of the differential diagnosis of another condition or whether the
screening test results related to a clinically significant condition.
The conditions were then assigned to one of three categories as previously described (core panel,
secondary targets, or not appropriate for Newborn Screening).
Among the 29 conditions assigned to the core panel are three hemoglobinopathies associated with a Hb/S
allele, six amino acidurias, five disorders of fatty oxidation, nine organic acidurias, and six unrelated
conditions (congenital hypothyroidism (CH), biotinidase deficiency (BIOT), congenital adrenal hyperplasia
(CAH), classical galactosemia (GALT), hearing loss (HEAR) and cystic fibrosis (CF)). Twenty-three of the 29
conditions in the core panel are identified with multiplex technologies such as tandem mass spectrometry
(MS/MS) or high pressure liquid chromatography (HPLC). On the basis of the evidence, six of the 35
conditions initially placed in the core panel were moved into the secondary target category, which expanded
to 25 conditions. Test results not associated with potential disease in the infant (e.g., carriers) were also
placed in the secondary target category. When newborn screening laboratory results definitively establish
carrier status, the result should be made available to the health care professional community and families.
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Conditions with limited evidence reported in the scientific literature were more difficult to evaluate, quantify
and place in one of the three categories. In addition, many conditions were found to occur in multiple forms
distinguished by age-of-onset, severity, or other features. Further, unless a condition was already included in
newborn screening programs, there was a potential for bias in the information related to some criteria. In
such circumstances, the quality of the studies underlying the data such as expert opinion that considered
case reports and reasoning from first principles determined the placement of the conditions into particular
categories.
Newborn screening program optimization – Assessment of the activities of newborn screening programs,
based on program reports, was done for the six program components: education; screening; follow-up;
diagnostic confirmation; management; and program evaluation. Considerable variation was found between
programs with regard to whether particular aspects (e.g., prenatal education program availability, tracking of
specimen collection and delivery) were included and the degree to which they are provided. Newborn
screening program evaluation systems also were assessed in order to determine their adequacy and
uniformity with the goal being to improve interprogram evaluation and comparison to ensure that the expected
outcomes from having been identified in screening are realized. Conclusions: The state of the published
evidence in the fast-moving worlds of newborn screening and medical genetics has not kept up with the
implementation of new technologies, thus requiring the considerable use of expert opinion to develop
recommendations about a core panel of conditions for newborn screening. Twenty-nine conditions were
identified as primary targets for screening from which all components of the newborn screening system
should be maximized. An additional 25 conditions were listed that could be identified in the course of
screening for core panel conditions. Programs are obligated to establish a diagnosis and communicate the
result to the health care provider and family. It is recognized that screening may not have been maximized for
the detection of these secondary conditions but that some proportion of such cases may be found among
those screened for core panel conditions. With additional screening, greater training of primary care health
care professionals and subspecialists will be needed, as will the development of an infrastructure for
appropriate follow-up and management throughout the lives of children who have been identified as having
one of these rare conditions. Recommended actions to overcome barriers to an optimal newborn screening
system include:
● The establishment of a national role in the scientific evaluation of conditions and the technologies by
which they are screened;
● Standardization of case definitions and reporting procedures;
● Enhanced oversight of hospital-based screening activities;
● Long-term data collection and surveillance; and
● Consideration of the financial needs of programs to allow them to deliver the appropriate services to the
screened population. Genet Med 2006:8(5, Supplement):12S–252S.
INTRODUCTION
The work reported here is pursuant to the HRSA/MCHB
Contract No. 240-01-0038, Standardization of Outcomes and
Guidelines for State Newborn Screening Programs. In 1999, the
American Academy of Pediatrics (AAP) Newborn Screening
Task Force recommended that, “HRSA should engage in a na-
tional process involving government, professionals, and con-
sumers to advance the recommendations of this Task Force
and assist in the development and implementation of nation-
ally recognized newborn screening system standards and pol-
icies.” The Task Force was concerned about the lack of unifor-
mity among states, particularly with regard to their newborn
screening condition panels.
In 2001, in response to that recommendation, HRSA/MCHB
requestedthatACMGoutlineaprocessofstandardizationofout-
comes and guidelines for State newborn screening programs and
defineresponsibilitiesforcollectingandevaluatingoutcomedata,
includingarecommendeduniformpanelofconditionstoinclude
in State newborn screening programs. It was expected that the
analytical endeavor and subsequent recommendations be defini-
tiveandthattherecommendationsbebasedonthebestscientific
evidence and analysis of that evidence. ACMG was specifically
asked to develop recommendations to address:
ACMG Newborn Screening Expert Group
14S Genetics IN Medicine1. A uniform condition panel (including implementation
methodology);
2. ModelpoliciesandproceduresforStatenewbornscreen-
ing programs (with consideration of a national model);
3. Model minimum standards for State newborn screening
programs (with consideration of national oversight);
4. A model decision matrix for consideration of State new-
born screening program expansion; and
5. Considerationofthevalueofanationalprocessforqual-
ity assurance and oversight.
This report is a product of the work undertaken by ACMG
for HRSA. A methods section begins by providing the broad
contextforthenewbornscreeningsystemandtheoverarching
principles for developing newborn screening guidelines. It
then provides the criteria that were used in the analyses of
conditions under consideration for newborn screening pro-
grams. This is followed by a description of the development
and use of tools to collect data that would complement evi-
dence gathered from a review of the scientific literature, and
also by a description of the process for obtaining additional
expert information and opinion. The results of these analyses
areprovided,aswellasrecommendationsformovingforward.
Although the criteria by which the conditions are evaluated
andtheresultsofthoseevaluationsaretheprimarygoalsofthis
effort, associated and supporting goals also are described be-
cause of their relevance to the newborn screening system. In
order to realize the expected outcomes for newborns and their
families, the full system must be operating efficiently and
effectively.3–6 Efforts have been made to assess the newborn
screening system based on its component parts, which allows
for the development of specific standards for program perfor-
mance and for an assessment of status of the programs. This
assessment also provides the opportunity to determine the ex-
tent to which a systematic national approach to quality assess-
ment and assurance is possible.
SECTION I: DEVELOPING A UNIFORM
SCREENING PANEL
A. Background
In the United States, newborn screening is a highly visible
andimportantState-basedpublichealthprogram2,7–10thatbe-
gan over 40 years ago. Since the early 1960s, when Robert
Guthrie11,12 devised a screening test for phenylketonuria
(PKU) using a newborn bloodspot dried onto a filter paper
card, more than 150 million infants have been screened for a
number of genetic and congenital disorders. States and terri-
tories mandate newborn screening of all infants born within
their jurisdiction for certain treatable disorders that may not
otherwisebedetectedbeforedevelopmentaldisabilityordeath
occurs.Newbornswiththesedisorderstypicallyappearnormal
atbirth.Thetestingandfollow-upservicesofnewbornscreen-
ingprogramsaredesignedtoprovideearlydiagnosisandtreat-
mentbeforesignificant,irreversibledamageoccurs.Appropri-
ate compliance with the medical management prescribed can
allow most affected newborns to develop normally. The gen-
erally acknowledged components of a newborn screening
system4,6,13 include the following:
1. Education of professionals and parents;
2. Screening (specimen collection, submission, and test-
ing);
3. Follow-up of abnormal and unsatisfactory test results;
4. Confirmatory testing and diagnosis;
5. Medical management and periodic outcome evaluation;
and
6. Systemqualityassurance,includingprogramevaluation,
validity of testing systems, efficiency of follow-up and
intervention, and assessments of long-term benefits to
individuals, families, and society.
Based on cumulative data from newborn screening pro-
grams, reported annually to the HRSA-funded NNSGRC, it is
estimated that about 1 in every 800 newborns in the United
States—or 5,000 of 4.1 million newborns each year—is born
with a potentially severe or lethal condition for which screen-
ing and the treatment for the prevention of many or all of the
complications of the condition are available. As the model for
public health-based population genetic screening, newborn
screening is nationally recognized as an essential program that
aimstoensurethebestoutcomeforthenation’snewbornpop-
ulation.
NEWBORN SCREENING PROGRAMS: THE CHANGING
LANDSCAPE
The infrastructure landscape.
In the United States, every State (hereafter, the term “State”
will include both States and territorial jurisdictions) presently
hasastatuteorregulationmandatingorallowingpublichealth
newborn screening. As such, newborn screening is universally
available in varying forms to all infants born in the United
States,regardlessofabilitytopayorotherfamilialfactors(e.g.,
ethnicity, area of residence, literacy level, or language). It is
importantthatuniversalaccesstothisscreeninganditscentral
publichealthfocusaremaintained,whileeffortsmoveforward
to bring uniformity and equity to State screening efforts.
Since the inception of newborn screening, the conditions
screened for and the systems developed for follow-up have
varied among States. Due to a dearth of national newborn
screening standards (aside from the National Committee for
Clinical Laboratory Standards (NCCLS) “Standard on Blood
CollectiononFilterPaper”),guidancefromtheHRSA-funded
Council of Regional Networks for Genetic Services (CORN)
andlimitedadvicefromnationaladvisorycommitteesandna-
tional medical or public health professional organizations re-
garding newborn screening policies and conditions to be in-
cluded in screening mandates, each State independently
determines the conditions and screening procedures for its
program.
Many States utilize advisory committees and seek input
from experts and other State newborn screening laboratories
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the available scientific evidence before making recommenda-
tions for test panels. In some States, decisions about newborn
screening are in the hands of the State legislature, which con-
trolstheStatepublichealthsystemanditsfinances.EveryState
has a statute or regulation that allows or mandates universal
newborn screening—sometimes specifying the conditions to
be screened, the consent/dissent process, the laboratory, and
the laboratory testing procedure to be used. In most cases,
decisions about the newborn screening panel are delegated to
State health officials, a State board of health, or a genetics or
newborn screening advisory committee. Sometimes the deci-
sion-makingprocessmightinvolveacombinationofagencies,
advisory bodies, and policy makers.
Pilot studies usually precede the formal implementation of
changes to the newborn screening panels. In addition, the mech-
anism to expand testing panels, change testing protocols, and
fund newborn screening varies among the States, with the basic
criteria from the inception of newborn screening being used by
many.14 Due to these factors and a lack of national consensus or
guidelines,thereispresentlyalargedisparityinscreeningservices
available to newborns. For example, at the present time, eight
States mandate screening for as few as four conditions, while a
number of States screen for as many as 30 conditions (informa-
tion taken from NNSGRC website www.genes-r-us.uthscsa.edu/
nbsdisorders.pdf July 20, 2004). This divergence among States
regardingwhichconditionsshouldbemandatedforscreeninghas
resulted from several factors, including differences in: 1) the level
of resources available (personnel, equipment and service capac-
ity); and 2) interpretations of the available data concerning given
conditions (incidence, treatability, impact) and new screening
methodologies.15
Approaches to calculating the number of conditions in-
cluded in screening also are variable, with some programs
countinghemoglobinopathyscreeningasasingletestandoth-
ers including it as one of several tests (given the simultaneous
ability to detect over 700 variant conditions including SS-dis-
ease, SC disease, S-thalassemia, etc.). The expert group
concluded that there should be standardization of what con-
stitutesascreenedcondition.(Thisissueisdiscussedingreater
detail in the section describing the conditions evaluated.)
It is clear that States must retain strong oversight of man-
dated screening programs in order to ensure the appropriate
delivery of quality screening and ancillary services to the
screenedpopulation.However,howlocalancillaryservicesare
to be directly provided within programs is less clear, particu-
larly given the nationwide lack of the specialized medical ex-
pertise and laboratory testing that is needed to definitively di-
agnose many of these rarer inherited genetic conditions. One
suggestion to address the maldistribution of needed medical
expertisehasbeenthroughtheorganizationofthatexpertiseat
the regional level, as with the newly funded HRSA/MCHB Re-
gional Genetics and Newborn Screening Collaboratives. This
effortissupportedbythehistoryofregionalization(geograph-
ically close) and consolidation (geographically dispersed) of
newborn screening laboratory testing services, which has been
advantageous for States with low numbers of births. Regional
programs have higher numbers of laboratory tests, which re-
sults in cost savings and decreased analytical variability.
Another challenge raised by the expansion of newborn
screening is the lack of interconnecting relationships between
childhealthprofessionalsandsubspecialists,particularlyinru-
ral areas—a problem complicated by the diversity of very rare
conditionsidentifiedbytheprograms.Therearelimitationsin
the local availability of specific expertise for many conditions,
and considerable needs exist in the areas of training and edu-
cation throughout the health care system. Furthermore, im-
provements in the newborn screening system and the expan-
sionofthenumberofconditionsforwhichscreeningisoffered
have costs, and these costs and the associated benefits seem to
accrue independently of the public and private health care de-
livery systems, which complicates their integration. Many
Statesprovidetheprogramsnecessarytoensurethatscreening
and diagnosis will occur, but they are limited in their ability to
ensure long-term management, including the provision of the
necessary long-term treatments and services.
The societal implications of expanding newborn screening
alsoaresignificant.Forexample,screeningforadditionalcon-
ditions that occur with greater frequency in different ethnic
groups could lead to discriminatory practices against individ-
uals as well as the ethnic groups associated with particular dis-
orders.Inaddition,difficultdecisionsmustbemadeaboutthe
nature of the benefits that might be realized from newborn
screening. Historically, screening has focused on conditions
forwhichtheimprovementinoutcomefortheinfanthasbeen
substantial. However, newborn screening could identify many
conditions for which the improved outcomes may be more
incremental,includingdisordersthatareassociatedwithmen-
tal retardation, such as fragile X syndrome, for which early
intervention programs can improve long-term cognitive out-
comes, but not with the expectation of a normal outcome.16
Finally, the nature of genetic disease is such that knowledge of
its presence can be of value to other family members. Previ-
ously, this factor has not been considered by newborn screen-
ing programs.
Other considerations arise from private sector testing avail-
ability and competition. Often, private laboratories—either
commercially- or university-based laboratories—offer an ex-
panded number of conditions screened through the technolo-
giestheyemploy.Theymayprovidecontractedservicestopro-
grams or offer additional screening for conditions not
mandated in the program in the State in which the family re-
sides. As a result, some States now mandate that all parents be
informed of the availability of additional screening tests. This
typeofinformationoftenisdeliveredatthelastminuteandits
use may not be supported by hospital staff and medical per-
sonnel. However, even though additional screening may be
available when initiated by consumers, it is only through State
public health that access to newborn screening for all babies
can be assured at the present time.
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Three major technological challenges have occurred over
the past few decades with regard to newborn screening. The
firstistheexpansionofknowledgeofthecausesandtreatment
ofgeneticdiseases.Thesecondistherapidexpansionofdiverse
technologies that may be used in screening. The third is the
proliferationoftieredtestingstrategiestoenhancethepositive
predictive value of screening.
The sequencing of the human genome as a public/private
partnership has allowed for a better understanding of the ge-
netic bases of many diseases. This fundamental biological
knowledge has led to the proliferation of new therapies stem-
ming from intensive research efforts in both the private and
public sectors. The pace of Food and Drug Administration
(FDA) approval of innovative therapies has quickened. These
andotherfactorsarelikelytocontinuetoleadtoanexpanding
panel of conditions for which newborn screening may be of
benefit.
Simultaneously, there are new technological developments
that allow more types of testing at reasonable cost that can be
considered for application to universal newborn population
screening.Examplesincludehearingscreening,EKGscreening
forlongQTsyndrome,acylcarnitinescreening,screeningwith
molecular arrays, and screening with immunoaffinity col-
umns. Particularly notable is the implementation of multiplex
platformsthatallowasingletypeofspecimenpreparationand
simultaneous (or nearly simultaneous) screening for multiple
differentdisorders.Goingfromonetestforonedisordertoone
testformultipledisordershasthepotentialtoreducecostsper
condition tested and can lead to test expansion if these new
technologies can be integrated safely and effectively into new-
born screening programs. One potential concern associated
with expansion of screening panels is the impact on follow-up
testing and tracking. If the proportion of false positive cases
requiring additional tests that are identified in screening labo-
ratories rises excessively, this could undermine the acceptance
ofsuchtestingbyboththeparentalandmedicalcommunities,
as well as potentially diminish the cost benefit of additional
testing.
Multiplex testing technologies are emerging that can simul-
taneously identify multiple analytes from a single analytical
process.Somemultiplextestingrequiresthatananalyticaltar-
get first be identified and placed in the multiplex test (e.g.,
genomic arrays). Other multiplex testing provides the addi-
tional testing information without the need for specific target
selection (e.g., DNA sequencing). For example, testing for he-
moglobinopathiesbyisoelectricfocusing(IEF)providesinfor-
mation not only about hemoglobin S, the primary target of
screening, but also about more than 700 other possible hemo-
globin variants, some of which may be clinically significant
(e.g., Hb C and E).17
In the case of MS/MS, the multiplex testing can occur in
different modes, because it is possible to operate the instru-
ment by either selecting specific targets or analyzing full
profiles.18 When used on selected targets, it is referred to as
selectivereactionmonitoring(SRM),whichisalsocalledmul-
tiplereactionmonitoring,aprocessthatallowsfortheselective
evaluation of specific ion species instead of a profile within a
mass range. Increasingly, MS/MS is being used in newborn
screening laboratories.19 The technology is appealing for sev-
eral reasons, including sensitivity for detecting ion species in
low concentration, ability to quantify results relative to inter-
nal standards, high-throughput and precision, and the oppor-
tunity to simultaneously measure multiple ion species.15,20
However, MS/MS is a complex testing platform requiring spe-
cific training and experience in order to optimize its use.18
Although multiplex testing allows the addition of many
more conditions to a screening panel, it presents a series of
issues that influence the screening and health care system, ul-
timatelyaffectingthescreeningservicesthatmightbeavailable
tothepublic.Theavailabilityofmultiplextestingincreasesthe
number of conditions that can be considered for newborn
screening that otherwise might not have been considered for
screening using traditional criteria, such as incidence and
treatability. Thus, our perception of screening performance
characteristics is also modified. For example, multiplex tech-
nology might also reveal clinically significant conditions other
thanthosethatweretheprimarytargetsofscreeningbutwhich
aredeterminedinthecourseofdiagnosticconfirmationofthe
screening test results. The screening laboratory may not have
optimizedthescreeningforthedetectionoftheseothercondi-
tionsbuttheyaretypicallypartofthedifferentialdiagnosisofa
primary target condition. Rather than evaluate single condi-
tions for their inclusion in newborn screening, we must now
considerhowbesttousetheadditionalinformationrevealedin
the diagnostic laboratory about other related conditions.
Although information about conditions for which treat-
ment options are scarce or not yet reported can lead to in-
creased stresses on families and the health care system, early
informationcanalsoleadtoknowledgeoftheconditionforthe
family, thus avoiding a potential diagnostic odyssey or inap-
propriate therapies. In addition, early information provides
opportunity for better understanding of disease history and
characteristics, and for earlier medical interventions that
mightbesystematicallystudiedtodeterminetherisksandben-
efits.Multiplextestingandtheidentificationofconditionsfall-
ingoutsideoftheuniformscreeningpanelprovidestheoppor-
tunityforsuchconditionstobeincludedinresearchprotocols.
Therefore, the criteria used to include a condition in a man-
datednewbornscreeningpanelarenotnecessarilystraightfor-
ward scientific or clinical criteria, but often involve complex
ethical, legal, and social policy decisions.
Aside from new multiplex technology for screening, there
has also been the introduction of tiered testing strategies to
enhance the positive predictive value of screening and reduce
the number of infants referred for additional testing.21 For ex-
ample, in the United States, the primary analyte used for con-
genital hypothyroidism (CH) newborn screening has been
thyroxin(T4),becausemostnewbornsarescreenedbeforethe
optimaltimeforscreeningwiththyrotropin(thyroidstimulat-
ing hormone, TSH). TSH primary screening offers improved
Newborn screening panel and system
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identifycasesofcentralhypothyroidism.Todecreasetherecall
rate, most screening programs have utilized a second-tier test
with TSH following the identification of a certain number of
increased-risk newborns through T4 initial testing.22 In such
cases, secondary hypothyroidism may also be detected on the
basisofthetestresults,eventhoughitisnottheprimarytarget
of screening. Similarly, it has been shown that the rate of false
positive results in CAH screening can be significantly reduced
by profiling steroids by MS/MS as a second-tier test.23
In addition, the testing of specific DNA mutations in new-
bornscreening(e.g.,CFscreeningalgorithmsutilizeasecond-
tier DNA mutation panel following initial screening for
immunoreactive trypsinogen (IRT) and hemoglobinopathy
screening algorithms that include DNA testing) can minimize
the recall rates.24 The testing of DNA mutations also has led to
a new category that includes unaffected or minimally affected
cases (e.g., carriers, benign hyperphenylalaninemias, and de-
tection of hemoglobin Barts). Confirmation of such results
and explanation of their significance can be costly. These ex-
amples highlight the ongoing process that occurs in newborn
screening laboratories whereby analytes are identified that are
clearly abnormal in a particular condition but still need to be
analytically and clinically validated in a population screening
setting.
The evidence based landscape
Assessing the evidence on conditions as to their appropri-
ateness for newborn screening is complex, and there are limi-
tations in the availability and interpretation of data about
many of the conditions. The incidence of rare genetic diseases
isoftenvariableamongdifferentpopulationsandcanbebiased
by the nature of the populations involved in research and the
severity of the conditions in those coming to the attention of
healthcareprofessionals.Manyoftheconditionsareultra-rare
andtheymayhavemultiplegeneticetiologies.Forinstance,the
tetrahydrobiopterin (BH4) deficiencies are a heterogeneous
group of disorders that affect phenylalanine homeostasis.25
BH4 deficiencies are detected as a by-product of screening for
phenylketonuria due to hyperphenylalaninemia. They include
disorders that affect the regeneration or biosynthesis of BH4.
The condition referred to as biopterin cofactor biosynthesis
defect is caused by one of two genes-GTP cyclohydrolase I
(GTPCH)and6-pyruvoyl-tetrahydrobiopterinsynthase(PTPS)-
and the condition referred to as biopterin cofactor regeneration
defectiscausedbyoneoftwogenes-pterin-4-carbinolaminede-
hydratase (PCD) and dihydropteridine reductase(DHPR). Due
to the biochemical similarities of the deficiencies resulting
fromblocksintheseinterrelatedpathways,theclinicalcourses
are similar in those with the typical severe forms of GTPCH,
PTPS, and DHPR deficiencies. Approximately 57% of the rare
BH4 abnormalities involve PTPS deficiency. However, due to
the similarities in phenotype and treatment, the BH4 abnor-
malities are commonly combined with the two aforemen-
tionedgroupsandthetreatmentsaresimilar.Hence,incidence
as it relates to the genetic etiology is usually combined for the
two subtypes. Treatment for the conditions is related to the
degree of hyperphenylalaninemia and to the degree of impair-
mentofbiogenicamineproduction,whichvariesamongthose
affected.Further,atreatmentinvolvingBH4administrationis
nowapprovedinEurope,followingclinicaltrials,thatdemon-
strated that both GTPCH and PTPS are responsive to BH4.
Due to the fact that GTPCH is very rare, yet quite similar to
PTPS, the affected are aggregated when treatment is assessed.
In any case, due to the rarity of these conditions, it is not until
a very large general population has been identified through
screeningthatpenetranceandexpressivityofdiseasearedeter-
mined and a true incidence figure becomes available. In order
to ensure that new therapies for these rare and severe genetic
diseaseswillbeavailable,regulatoryagenciessometimesaccept
premarketevidencefromsmallertreatmentgroupswhileshift-
ing the burden for the collection of additional information to
FDAPhaseIVpostmarketsurveillance,aswasreportedinFDA
News for Fabrezyme® for the treatment of Fabry disease. (See
http://www.fda.gov/bbs/topics/NEWS/2003/NEW00897.html)
Having such treatments available earlier means that it be-
comes increasingly difficult to collect information on the nat-
ural history of the untreated condition. In fact, there has not
beenanaturalhistorystudyofPKUconductedsincethe1970s
because the affected infants are routinely identified in screen-
ing are treated, respond well to the treatment. Understanding
the genetic basis of these conditions has led to this relatively
rapid transition between ability to diagnose and the develop-
ment of treatments based on the underlying biology and pa-
thology of genetic diseases, particularly those that involve the
replacement of defective enzymes. Hence, it becomes increas-
ingly important to develop national systems for the collection
of clinical information about those individuals identified in
screeningtofurtherinformourunderstandingofthescreened
conditions and to further evaluate treatment modalities
through an iterative process.
The assessment of the evidence on the performance charac-
teristics(analyticalandclinicalsensitivity,specificity,andpos-
itive predictive values) of the tests, as used in newborn screen-
ing is complex. Many of the screening tests use technologies
that are the gold standard in the diagnostic setting, such as
HPLC or IEF for hemoglobinopathies or MS/MS for the acyl-
carnitinedisorders.Althoughonecandemonstrateverystrong
analyticalandclinicalperformanceinadiagnosticsetting,clin-
ical performance in screening is a function of the cut-offs that
are used by the screening laboratories to capture the most af-
fected persons. States often assign varying cut-offs to analyte
levelsandoftenusedifferentscreeningtestalgorithms,includ-
ingsecond-tiertestsorrepeatteststoarriveatadetermination
of whether the specimen is within the normal range, with
highly variable case definitions at screening. This lack of stan-
dardization makes it quite complex to assign a level of perfor-
mance to the screening tests at a national level or to compare
the performance of programs.
Finally, the evidence base for newborn screening is compli-
catedbythedifferingviewsoftheinterestgroupsinvolved.For
purely scientific and medical issues, the scientific literature
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ditions, such as incidence, treatment efficacy, and diagnostic
confirmation. However, some criteria have significant subjec-
tive aspects that require the consideration of more than just
scientificandexpertopinion.Costisanexampleofasubjective
criterion because it is a contextual concern and can only be
measuredagainstthevalueoftheoutcome.Othercriteriamay
be perceived differently by the professional community or by
other nonscientific or nonmedical interest groups. For exam-
ple, parents often consider difficult the impact of treatments
thathealthcareprofessionalsconsidertobesimple(e.g.,main-
taining a child on a specified diet). Some criteria are perceived
differently among varying groups of professionals. For exam-
ple,primaryhealthcareprofessionalsinurbanareasoftenhave
greateraccesstosubspecialiststhandothoseinruralareas.Itis
oftendifficulttobalancethescientificevidenceagainsttheval-
uesthatdifferentgroupsplaceonnewbornscreeningtoreduce
mortality and morbidity of diseases.
Theneedforevaluationofnewbornscreeningsystems
Thelackofequitablenewbornscreeningservicesofferedfor
infants, the changing dynamics of emerging technology, and
thecomplexityofgeneticsrequireanassessmentofthestateof
the art in newborn screening and a perspective on the future
directions such programs could take. In addition, programs
must include an assessment of the availability of needed re-
sources, both public and private, when determining which
conditions should be included. A national, organized ap-
proach to differentiating among these many competing needs
would help create a more informed process for deciding what
tests should be included in newborn screening programs.
SincethefirstStatenewbornscreeningprogramsbegan,pe-
riodicassessmentshavebeenmade.Asearlyas1968,theWorld
Health Organization (WHO) issued a report urging that
screening tests be appropriate and straightforward.26 In 1975,
the National Academy of Sciences (NAS) redefined genetic
screeningandestablishedthefundamentalprinciplesandrules
of procedure for genetic testing (these did not vary signifi-
cantly from the 1968 WHO recommendations). NAS also
made recommendations regarding the aims of testing and
screening, criteria for testing, and the quality of testing.13 In
1997, the Task Force on Genetic Testing, created by the Na-
tional Institutes of Health-Department of Energy Working
Group on Ethical, Legal and Social Implications of Human
Genome Research, focused on the quality of testing and rec-
ommended that screening tests demonstrate analytical and
clinical validity and utility27 (Holtzman and Watson, 1997
available at http://www.genome.gov/10001733). In 1999, at
the request of HRSA, AAP convened a Newborn Screening
Task Force that provided a comprehensive evaluation of the
current state of newborn screening programs in the United
States.13 The Task Force recommendations covered the public
health and clinical care system, the roles of professionals and
the public, issues of disease surveillance and research, and the
economics of newborn screening. The report recommended
that“HRSAshouldengageinanationalprocessinvolvinggov-
ernment,professionals,andconsumerstoadvancetherecom-
mendations of this Task Force and assist in the development
andimplementationofnationallyrecognizednewbornscreen-
ing system standards and policies.” In addition, the AAP Task
Force13thoughtthatgreateruniformitywouldbenefitfamilies,
health care professionals, and the newborn screening pro-
grams. In 2000, the March of Dimes, an organization that has
advocated on behalf of newborn screening programs, recom-
mendedthattestsberapid,highquality,andaccurateandthat
cost should not be a major consideration.28 Subsequently, the
MarchofDimesrecommendedthatallStatesscreenforninecon-
ditionsplusnewbornhearingloss(seewww.marchofdimes.com/
professionals/580.asp).
B. Methods used for assessing conditions
Asaninitialstepintheprocess,ACMGconvenedanewborn
screening expert group that included participants with exper-
tise in various areas of subspecialty medicine, primary care,
health policy, law, ethics and public health, and consumers.
The expert group also formed two expert work groups to pro-
vide more in-depth analysis in two specific areas: the uniform
panel and its criteria, and the diagnosis and follow-up system.
Membersoftheexpertgroupandworkgroupsarelistedatthe
beginning of this report. Work group members were selected
based on their abilities to bring a strong scientific and clini-
cal—ratherthanorganizational—perspectivetotheissuesun-
der consideration. Not only were efforts made to ensure cul-
tural, ethnic, and geographic diversity, there also were efforts
toinvolvehealthcareprofessionalsandotherinterestedparties
from a wide range of fields and backgrounds, including expert
representation from public health laboratories and program
administration;individualswhoareinvolvedinthedeliveryof
specialty care; primary care and nonphysician health care pro-
fessional groups that are involved with the patients and fami-
lies; and parents who have been directly affected by newborn
screening programs.
Theprojectdependedonavarietyoftypesofinputobtained
through expert reviews of the scientific literature, presenta-
tions from international and national invitees at six meetings
of the expert group, solicitations for public and professional
comment, and detailed assessments provided by the work
groups. Considerable information was acquired through the
use of disease-specific surveys that were broadly distributed
and augmented by direct requests for input from acknowl-
edgedexpertsfortheconditionsunderconsideration.Areasin
which deficiencies were found in the information available in
the scientific literature were identified as well.
The expert group followed a two-tiered approach to assess-
ing conditions that allowed for the views of experts of various
types, including consumers, to be considered while still defer-
ring to the evidence in the scientific literature. In the first level
of the assessment, the expert group sought broad input
through a survey of individuals and organizations with an in-
terest in newborn screening. The expert group utilized a data
collection instrument, distributed through a survey and di-
rectlytoexperts,toseekunpublisheddataandviewsrelatedto
Newborn screening panel and system
May 2006   Vol. 8   No. 5, Supplement 19Sthe criteria by which conditions were to be evaluated. The
opinions of experts and others were quantified using the scor-
ing system assigned to each criterion in the data collection
instrument. Conditions were then placed preliminarily into
categories reflecting their overall scores on the data collection
forms. In the second level of the assessment, the scientific and
medical evidence bases relating to the conditions under con-
siderationweredeveloped.Eachconditionwasthenreassessed
to ensure that the evidence base confirmed that three critical
evaluation categories were met in order to define a uniform
panel of conditions to be targeted by newborn screening pro-
grams.
Establishingprinciplesforthedevelopmentofnewborn
screeningguidelines
Many factors could influence a decision to include a given
condition in a newborn screening program, including, for ex-
ample,theseverityofthecondition,theavailabilityofeffective
treatment, the age of onset, and the complexity or cost of the
test.29 In developing the criteria to evaluate conditions and
make recommendations, the expert group relied on a set of
basicprinciplesdevelopedattheonsetoftheproject.Theorder
of these principles is not intended to suggest a prioritization.
An overarching concept is utility—that is, an approach that
delivers the greatest good to the greatest number of people,
while recognizing the need for some flexibility and the use of
alternative mechanisms by screening programs. Newborn
screening policies and practices have national, regional, and
local implications. Although national uniformity is a goal for
newborn screening programs, there also may be a need, in
limited and specific circumstances (such as meeting local and
community public health needs), to screen for certain genetic
conditions identified only in given populations.
Newbornscreeninginvolvesmanyparties.Inadditiontothe
child and his or her family or guardian, these include public
healthofficials,healthcareprofessionals,privateinsurers,gov-
ernment officials, researchers, policymakers, educators, and
others. This report seeks to acknowledge the full range of par-
ticipants involved.
1. Universal newborn screening is an essential public
health responsibility that is critical to improve the
healthoutcomeofaffectedchildren.
ToensurethatallUnitedStatesnewbornshaveaccessto
screening and to promote a systems approach to popu-
lation-based health care, it is critical that newborn
screening remain a public health function.
2. Newborn screening policy development should be
primarily driven by what is in the best interest of the
affected newborn, with secondary consideration
given to the interests of unaffected newborns, fami-
lies,healthprofessionals,andthepublic.
A key factor determining the inclusion of particular
conditions in newborn screening programs is the po-
tential for the affected newborn to realize a significant
improvement in quality of life as a result of the screen-
ing. Although the expert group gives primary consider-
ationtonewbornsthatarebeingscreened,itisclearthat
many others are also affected by newborn screening.
Newborns that do not screen positive can benefit from
the elimination of certain diagnoses, and families ben-
efitindependentofthenewbornthatwasscreened.Fur-
thermore,becausetheseprogramscandecreasemortal-
ity and morbidity, public health professionals, the
public, and the health care system may derive benefits
from newborn screening programs, such as cost reduc-
tions for overall health care services. There may also be
negative consequences for newborns and families that
result from screening, including the potential negative
impact of a false-positive screening result. Aside from
the financial cost of a medical work-up to confirm that
asuspectedconditiondoesnotexist,theremaybeasso-
ciated anxiety and stress for the family.
3. Newborn screening is more than testing. It is a coor-
dinatedandcomprehensivesystemconsistingofedu-
cation,screening,follow-up,diagnosis,treatmentand
management,andprogramevaluation.
To realize the benefits from newborn screening, all
components of the program must function well to-
gether. The six critical components of newborn screen-
ing programs—education, screening, follow-up, diag-
nosis,treatmentandmanagement,andevaluation—are
importanttotheoverallfunctioningofindividualnew-
born screening programs and the system in which they
operate.30 There must be assurance of timely and accu-
rate reporting and tracking of abnormal results. In or-
der to know whether a program is functioning effec-
tively and efficiently, it is important to know whether
the expected health benefits are being realized.
4. The medical home and the public and private com-
ponents of screening programs should be in close
communication to ensure confirmation of test re-
sults and the appropriate follow-up and care of
identified newborns.
The medical home concept has evolved as the central
focus for the care of patients in their communities
and should be the center of communication, primary
care, and coordination of care for individuals.31
There is increased recognition that enhanced com-
munication between the clinical care system and
publichealthprogramsisnecessarytoensureoptimal
care and outcomes for the affected newborns. It is
essential to establish close communication among
State public health programs, the newborn’s medical
home, and the subspecialists commonly involved in
the diagnosis and follow-up of affected newborns.
5. Recommendationsabouttheappropriatenessofcon-
ditionsfornewbornscreeningshouldbebasedonthe
evaluationofscientificevidenceandexpertopinion.
There are ever-increasing numbers of relatively rare
conditions for which clinical knowledge is rapidly
growing but for which the published literature may be
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ingmanyoftheseconditionsmaybelimited.Giventhat
allscreeningprogramsmustrelyonthesamepublished
knowledge base and a limited number of experts, a na-
tional process of scientific evaluation seems most prac-
tical. As new evidence emerges and opinions change,
thereshouldbeasysteminplaceforpromptreviewand
release of updated recommendations.
In 2003, the Secretary’s Advisory Committee on Heri-
table Disorders and Genetic Diseases in Newborns and
Children was established by the Department of Health
and Human Services (DHHS). Its mandate was to ad-
vise and guide the Secretary of DHHS regarding the
most appropriate application of universal newborn
screening tests, technologies, policies, guidelines, and
programs in order to effectively reduce morbidity and
mortality in newborns and children who have or who
areatriskforheritabledisorders.Thecommittee’spur-
pose is to provide the Secretary with: “.advice and rec-
ommendations concerning the grants and projects and
technical information needed to develop policies and
priorities that will enhance the ability of State and local
health agencies to provide for newborn and child
screening and counseling and health care services for
newborns and children having or at risk for heritable
disorders.” (Available at http://mchb.hrsa.gov/pro-
grams/genetics/committee/)
6. Tobeincludedasaprimarytargetconditioninanew-
bornscreeningprogram,aconditionshouldmeetthe
followingminimumcriteria:
● Itcanbeidentifiedataperiodoftime(24to48hours
afterbirth)atwhichitwouldnotordinarilybeclinically
detected.
● A test with appropriate sensitivity and specificity is
available.
● There are demonstrated benefits of early detection,
timely intervention, and efficacious treatment.
Determining the appropriateness of a condition for
newborn screening is a complex process. Although the
emergence of new technologies such as MS/MS has al-
tered views of which conditions should be included in
mandated screening programs, in this report the pri-
mary targets of screening are those that meet the three
criteria previously specified. A secondary target is one
that is identified while searching for the primary target
(e.g., HbC results from IEF while looking for HbS) or a
clinically significant condition that is likely to be de-
tected when performing a comprehensive profile of a
given group of biochemical markers (e.g., GA2 may be
identifiedwhiledeterminingMCADstatus(C8acylcar-
nitine is elevated in both)).
7. The primary targets of newborn screening should be
conditions that meet the criteria listed in #6 above.
The newborn screening program should report any
otherresultsofclinicalsignificance.
Many technologies can be applied to screening for pri-
mary targeted conditions. Some allow for more than
oneconditiontobeidentifiedinasingleprocedure,and
some provide important information about the pres-
ence of conditions that may not meet all of the criteria
neededtobeconsideredaprimarytargetcondition.The
adventofmoleculararraysandMS/MShassignificantly
broadened this potential. It is not necessarily the re-
sponsibility of the screening program to monitor the
long-term follow-up of patients identified with clini-
callysignificantconditionsthatarenottheprimarytar-
gets of newborn screening. However, the significant
costs of the diagnostic odysseys that may ensue follow-
ing the birth of a child whose condition may have been
suspected based on newborn screening results, and the
related costs to families and the system of introducing
futile therapies might be avoided if clinically significant
results from newborn screening programs are shared
with the newborn’s primary caretaker.
8. Centralized health information data collection is
needed for longitudinal assessment of disease-
specific screening programs.
Mechanismsandsystemsthatallowforthecollection
of short- and long-term data on affected individuals
while protecting their right to privacy will allow for
assessment and improvement of program perfor-
mance and individual health outcomes. The pooling
of information about health outcomes, treatment
protocols, case definitions, and diagnosis and confir-
mation algorithms will improve care for the infants
identified in the programs. Furthermore, it is often
difficult to ascertain the natural history of rare dis-
easesbecauseoftheirlowfrequencyandbecausethey
often exhibit genetic variability in severity and ex-
pression.Hence,datacollectionandshareddataeval-
uation can significantly inform program decision-
making and medical science. General population
data are also needed to better understand certain ap-
proaches to screening (e.g., genomics), where the
variability in expression of mutations is not entirely
clear until individuals without the classical presenta-
tion of a condition are tested.
9. Total quality management should be applied to new-
bornscreeningprograms.
As with any programmatic effort, improvements result
fromcarefulandcontinuousmonitoringofkeystepsin
theprocess,theassessmentofthatinformation,andthe
introduction of changes that continuously improve
program performance. Uniform and consistent moni-
toring of system quality indicators can provide infor-
mation about the relative performance of screening
programs.
10. Newborn screening specimens are valuable health
resources. Every program should have policies in
place to ensure confidential storage and appropri-
ate use of specimens.
Specimens obtained for newborn screening have tre-
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poses of program quality management, to help in-
form deliberations about program expansion, for
researchontestingtechnologyandtreatment,andfor
epidemiologic studies. This is not to imply that every
State should store all specimens forever but, rather,
that there should be a sufficient number of States
with diverse populations and long-term storage of
residual specimens to provide this critical resource.
Regardless, it is important to ensure the confidenti-
ality of those persons whose specimens are stored.
The use of specimens for nontherapeutic purposes
must not alter the willingness of the public to partic-
ipate in newborn screening programs and related ac-
tivities.
11. Public awareness, coupled with professional training
andfamilyeducationaresignificantprogramrespon-
sibilities that must be part of the complete newborn
screeningsystem.
Because newborn screening can have a significant im-
pact on health outcomes for affected newborns, it is
essentialthatthepublicaswellashealthcareandpublic
health professionals be informed of the availability of
the programs and of changes that are made. Education
and awareness are essential to both the quality of the
screeningprogramsandparticipationbythepublicand
byhealthcareprofessionals.Assuch,informationshar-
ing and education are critical program responsibilities.
Choosingtheconditions
Eighty-four conditions were evaluated using these criteria
(see Table 1). The conditions were chosen for several reasons.
Any condition currently included in private, State, or national
newborn screening programs was considered. Other condi-
tions were included because they are known to be coinciden-
tally revealed by some of the technologies used in newborn
screening. Still others were identified by members of the pub-
lic, the expert group, and work groups as worthy of consider-
ation because they are important from a public health stand-
point and/or there is a high level of public and/or scientific
interest in screening for the condition. Hemoglobinopathy
screening was mainly driven by the conditions associated with
a hemoglobin S allele. Among these, Hb SS, Hb SC and Hb
S-thalassemia were considered separately. Variant hemoglo-
binopathiesincludedotherconditionsassociatedwithanHbS
allele. Additional hemoglobinopathies revealed by screening,
such as Hb E, are not the conditions to which screening cur-
rentlyistargeted.Asdiscussedbelow,compromisesweremade
in the lumping or splitting apart of conditions to be listed for
assessment.
To a limited extent, the conditions listed as considered by
the expert group represent a compromise among the various
options. The intent was to distinguish many of the more com-
mon forms of the condition from others though there are still
situations in which some very rare conditions are subsumed
under a more general name for the condition.
The group considered it important to fully assess all condi-
tions and to ensure that any apparent deficiencies were prop-
erly recognized so that disease-specific advocacy groups and
the research community could focus on these deficiencies in
developing their research agendas.
Developingevaluationcriteriaandtheircomparative
values
Generally, a medical condition is assessed by itself to deter-
minewhetheritshouldbeincludedinapublichealthnewborn
screeningprogram,14,29ratherthanbeingassessedalongwitha
numberofotherconditionsinawaythatwouldallowforcom-
parative ranking. Historically, this is primarily because indi-
vidual conditions have been identified by individual testing
platforms. Although conditions have usually been compared
on the basis of relative incidence, there was little need for ad-
ditionaldiscriminatingcriteriagiventhegeneralavailabilityof
traditional testing methodologies and treatments. Thus, com-
parative analyses of screened conditions or evaluations of the
scientific evidence for or against inclusion of the conditions
have not been formally conducted nationally, though this has
often been done within individual programs.
Until recently, the capability of the currently available test-
ingtechnologylimitedtheconditionsthatcouldreasonablybe
includedinascreeningpanel.Now,however,newinformation
emerging from the clinical and scientific literature, combined
with evolving technologies, has made it possible for increasing
numbers of rare conditions to be detected simultaneously
from single screening tests, making it reasonable to attempt
more complex relative comparisons when deciding on condi-
tions that should be added to a screening panel. Thus, it is no
longer a simple matter to decide which condition should be
addedtoascreeningpanelbasedonincidence,whenagroupof
conditions may be simultaneously detected from a single ana-
lytical procedure and the group incidence (or impact to soci-
ety)maybeofhigherrelativeimportancethananyofthesingle
conditionswithinthegroup.Inaddition,evenifmultiplecon-
ditions could be detected, the question of whether they should
be detected remains, when, for example, no efficacious treat-
mentexists.Increasingthecomplexityofthisdecision-making
process is the fact that all of the conditions detected may not
have similar clinical outcomes for all children.
In recent years, professional groups in other countries have
attempted to develop an organized, national approach to de-
termining which conditions should be included in newborn
screeningpanels.TheHealthTechnologyAssessmentProgram
of the National Health Service of the United Kingdom has
initiatedanationalprogramtosystematicallyreviewthescien-
tific and medical literature on inborn errors of metabolism,
neonatalscreeningtechnology,andscreeningprograms.Their
goalistoanalyzethecostsandbenefitsofintroducingMS/MS-
based screening of amino acid disorders, fatty acid oxidation
defects, and organic acid disorders, as well as other conditions
screened on an individual test basis within the United King-
dom health system.10 This extensive analysis assigned weights
to various aspects of specific conditions and their associated
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Individual conditions considered in the data collection instrument
Group Condition Code
Endocrinology Congenital adrenal hyperplasia CAH
Congenital hypothyroidism CH
Diabetes mellitus, insulin dependent IDDM
Hematology, Hemoglobinopathies Hb SS disease (Sickle cell anemia) Hb SS
Hb S/C disease Hb S/C
Hb S/ -thalassemia Hb S/ß-Thal
Other variant Hb-pathies (including Hb E) Var Hb
Glucose-6-phosphate dehydrogenase deficiency G6PD
Infectious Diseases Human HIV infection HIV
Congenital toxoplasmosis TOXO
Congenital cytomegalovirus infection CMV
Alpha 1-antitrypsin deficiency A1AT
Adenosine deaminase deficiency ADA
Biliary atresia BIL
Cystic fibrosis CF
Duchenne and Becker muscular dystrophy DMD
Familial hypercholesterolemia (heterozygote) FHC
Miscellaneous Genetic Conditions Fragile X FX
Hearing loss HEAR
Hyperbilirubinemia* HPRBIL
Neuroblastoma NB
Severe combined immunodeficiency SCID
Turner syndrome TURNER
Wilson disease WD
Amino Acid Disorders Phenylketonuria PKU
I
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Benign hyperphenylalaninemia H-PHE
Defects of biopterin cofactor biosynthesis BIOPT BS
Defects of biopterin cofactor regeneration BIOPT REG
Homocystinuria HCY
Hypermethioninemia MET
Maple syrup (urine) disease MSUD
Tyrosinemia type I TYR I
Tyrosinemia type II TYR II
Tyrosinemia type III TYR III
Carbamylphosphate synthetase deficiency CPS
Ornithine transcarbamylase deficiency OTC
Citrullinemia CIT
Citrullinemia type II CIT II
(continued)
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Continued
Group Condition Code
Argininosuccinic acidemia ASA
Argininemia ARG
Carbohydrate Disorders Classic galactosemia GALT
Galactokinase deficiency GALK
Galactose epimerase deficiency GALE
Congenital disorder of glycosylation type Ib CDG Ib
Fatty Acid Oxidation Disorders Carnitine uptake defect CUD
Carnitine palmitoyltransferase Ia deficiency (L) CPT IA
Carnitine palmitoyltransferase Ib deficiency (M) CPT IB
Carnitine/acylcarnitine translocase deficiency CACT
Carnitine palmitoyltransferase II deficiency CPTII
Very long-chain acyl-CoA dehydrogenase def. VLCAD
Long-chain 3-OH acyl-CoA dehydrogenase def. LCHAD
Trifunctional protein deficiency TFP
Dienoyl-CoA reductase deficiency DE-RED
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Glutaric acidemia type II GA2
Medium-chain acyl-CoA dehydrogenase deficiency MCAD
Medium/short-chain 3-OH acyl-CoA DH def. M/SCHAD
Medium chain ketoacyl-CoA thiolase deficiency MCKAT
Short-chain acyl-CoA dehydrogenase deficiency SCAD
Lysosomal Storage Diseases Fabry disease FABRY
Krabbe disease KRABBE
Pompe disease POMPE
Hurler-Scheie disease MPS-1H
Lysosomal storage diseases LSD
Organic Acid Disorders Propionic acidemia PA
Multiple carboxylase deficiency (Holocarboxylase Synthetase deficiency) MCD
Methylmalonic acidemia (mutase) MUT
Methylmalonic acidemia (Cbl A, B) Cbl A,B
Methylmalonic acidemia (Cbl C,D) Cbl C,D
Isobutyryl-CoA dehydrogenase deficiency IBG
2-Methylbutyryl-CoA dehydrogenase deficiency 2MBG
2-Methyl 3-hydroxy butyric aciduria 2M3HBA
-Ketothiolase deficiency KT
Isovaleric acidemia IVA
3-Methylcrotonyl-CoA carboxylase deficiency 3MCC
3-Methylglutaconic aciduria 3MGA
3-hydroxy 3-methyl glutaric aciduria HMG
Glutaric acidemia type I GA I
Malonic aciduria MAL
(continued)
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published information available. This effort has highlighted
the difficulties inherent in attempts to balance costs and ben-
efitsagainstthevaluethatthepublicandfamiliesplaceonsuch
screening.
The Human Genetics Society of Australasia developed criteria
forplacingconditionsintooneoffourtiers.Thesetiersaredeter-
mined by the nature of the benefit of the screening to the new-
born, the benefit of the screening balanced against the cost, the
suitabilityofthetest,andtheavailabilityofappropriateandorga-
nized diagnostic and follow-up services (available at http://www.
hgsa.com.au/Word/HGSApolicyStatementNewborn-
Screening0204-18.03.04.doc).
Morerecently,BelgiumhassoughttoassignvaluestotheWil-
son and Jungner criteria,14 in order to weigh conditions against
each other (see Box 1). Although novel, this system was consid-
ered to be less detailed than needed because many of the Wilson
andJungnercriteriaaresubjectiveandthereforelessamenableto
the application of a metric and therefore quantification.
IntheUnitedStates,severalstates,includingNebraska,Ten-
nessee, and Washington, recently developed criteria and sys-
tems for assessing and comparing conditions. With the estab-
lishmentofthe2003federalAdvisoryCommitteeonHeritable
DisordersandGeneticDiseasesinNewbornsandChildren,the
potentialfordevelopmentofnationalpoliciesandrecommen-
dations should lead to a more uniform or equitable approach
to newborn screening.
None of the existing systems allowed for adequate compar-
ative analysis of conditions being considered for newborn
screening. Further, the evolution of screening programs and
thescreeningtechnologiesusedhaveaddednewvariablestobe
considered when assessing conditions. The ACMG expert
groupchosetodevelopamodifiedsystemfortheassessmentof
conditions for their appropriateness for newborn screening.
The Uniform Panel Work Group developed the data collec-
tioninstrumenttouseduringtheproject’sfirstphasetoquan-
titatively evaluate the features of conditions under consider-
ation for inclusion in a potential uniform screening panel.
Using a weighted scoring system, the conditions were evalu-
ated according to criteria in three main categories:
1. The clinical characteristics of the condition;
2. The analytical characteristics of the test; and
3. Diagnosis,follow-up,treatment,andmanagementofthe
condition.
Withineachofthesecategories,19componentcriteriainclud-
ing six characteristics of the analytical tests were considered for
assigning a comparative value, or score. Conditions already in-
cluded in newborn screening programs were used to model the
scoring system. Each of the criteria was weighted to reflect the
presumed importance of the particular criteria to the overall as-
sessments of conditions. Experts in the conditions under consid-
eration for newborn screening were then asked to consider the
criteriaandtheextenttowhichtheycovertherangeofissuesthat
ariseamongdisparatetypesofconditions.Theywerealsoaskedto
Table 1
Continued
Group Condition Code
Other IEM Biotinidase deficiency BIOT
X-linked Adrenoleukodystrophy ALD
Smith-Lemli-Opitz syndrome SLO
Guanidinoacetate methyltransferase deficiency GAMT
Arginine: glycine amidinotransferase deficiency AGAT
Creatine transporter defect CR TRANS
NOTE: Neonatal hyperbilirubinemia (Kernicterus) (code HPRBIL) was added to this list after the completion of the data collection instrument.
Box 1 Wilson and Jungner Criteria for Appraising
the Validity of a Screening Program
1. The condition being screened for should be an
important health problem.
2. The natural history of the condition should be
well understood.
3. There should be a detectable early stage.
4. Treatment at an early stage should be of more
benefit than at a later stage.
5. A suitable test should be devised for the early
stage.
6. The test should be acceptable.
7. Intervals for repeating the test should be deter-
mined.
8. Adequate health service provision should be
made for the extra clinical workload resulting
from screening.
9. The risks, both physical and psychological,
should be less than the benefits.
10. The costs should be balanced against the bene-
fits. SOURCE Wilson, J.M., and G. Jungner.
Principles and Practice of Screening for Disease.
(Public Health Paper Number 34.) Geneva:
World Health Organization, 1968.
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therebyacknowledgingthecriteriaconsideredmostrelevant.The
languagedescribingthecriteriaandthescoresassociatedwiththe
range of responses to the criteria were adjusted by the expert
group (see Table 2 for the criteria and the possible scores). Then,
theweightaccordedtoeachcriterionwasrevised(i.e.,thehighest
possible score within each category was the same). The criteria
thatwereidentifiedwithineachcategorywereassignedarangeof
possible responses and related scores ranging from 0 to a maxi-
mum score that varied according to each criterion’s overall im-
portance.Conditionsalreadyincludedinnewbornscreeningpro-
grams were then assessed for their performance in the system.
Results were compared with those obtained by other systems de-
velopedforthispurposetodeterminewhethertheoutcomeswere
similar.
The scoring system recognizes the strengths and limitations
found in each condition and summarizes them in a ranking
system. Thus, a low score in a particular area does not neces-
sarilymeanthatscreeningforthatconditionwillneverbecon-
ducted. In fact, low scores could be radically overruled by sci-
entific evidence of new advances in testing and treatment and
should be recognized as opportunities for targeted clinical or
basic research endeavors and subsequent reconsideration of
the condition for inclusion.
The criteria that were developed to differentiate the appro-
priateness of conditions for newborn screening include some
Table 2
Combined criteria and distribution of scores in the data collection instrument(Highest possible score: 2100)
I. Condition/Disorder (subtotal score 700)
Criterion Categories in criterion Score
Incidence of condition 1:5x000 100
1:25,000 75
1:50,000 50
1:75,000 25
1:100,000 0
Signs and symptoms clinically
identifiable in the first 48 hours
Never 100
25% of cases 75
50% of cases 50
75% of cases 25
Always 0
Burden of disease (natural history if
untreated)
Profound 100
Severe 75
Moderate 50
Mild 25
Minimal 0
Individual benefits of early intervention Clear scientific evidence that early intervention resulting
from screening optimizes outcome
200
Some scientific evidence that early intervention resulting
from screening optimizes outcome
100
No scientific evidence that early intervention resulting
from screening optimizes outcome
0
Familial and societal benefits of early
intervention
Early identification provides clear benefits to family and
society (education, understanding prevalence and
natural history, cost effectiveness)
100
Early identification provides some benefits to family and
society
50
No evidence of benefits 0
Early diagnosis and treatment prevent
mortality
Yes 100
No 0
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moresubjective.Totheextentpossible,theexpertgrouprelied
onthescientificliteraturetoprovidetheinformationonwhich
its recommendations are based. Survey respondents were pro-
vided with the data collection instrument, questionnaires
about the criteria themselves, the weight assigned to criteria,
and the distribution of scores within a criterion. The respon-
dentswereaskedtoprovideinformationonbothobjectiveand
subjective criteria as a way of determining a respondent’s fa-
miliarity with the condition(s).
THE THREE MAIN CATEGORIES AND THEIR CRITERIA
Clinical characteristics of the condition
Three criteria were developed for this category:
Table 2
Continued
II. Screening Test (subtotal score 700)
Criterion Categories in criterion Score
Does a sensitive AND specific screening test
algorithm currently exist?
Yes 200
No 0
Test characteristics (Yes  apply score; No  0) Doable in neonatal bloodspots OR by a simple, in-nursery physical method 100
High throughput (200/day/FTE) 50
Overall analytical cost 1$ per test per condition 50
Multiple analytes relevant to one condition are detected in same run 50
Other conditions identified by same analytes 50
Multiple conditions detected by same test (multiplex platform) 200
III. Treatment & Management (subtotal score 700)
Criterion Categories in criterion Score
Availability of treatment (*) Treatment exists and is widely available in most
communities
50
Treatment exists but availability is limited 25
No treatment available or necessary 0
Cost of treatment (*) Inexpensive 50
Expensive ($50,000/patient/year) 0
Potential efficacy of existing treatment To prevent ALL negative consequences 200
To prevent MOST negative consequences 100
To prevent SOME negative consequences 50
Treatment efficacy not proven 0
Diagnostic confirmation Providers of diagnostic confirmation are widely available 100
Limited availability of providers of diagnostic confirmation 50
Diagnostic confirmation is available only in a few centers 0
Acute management Providers of acute management are widely available 100
Limited availability of providers of acute management 50
Acute management is available only in a few centers 0
Simplicity of therapy Management at the primary care or family level 200
Requires periodic involvement of a specialist 100
Requires regular involvement of a specialist 0
NOTE:Thetwocriteriamarkedwith(*)abovewerecombinedinthedatacollectioninstrument,ascoreof100wasattributedtoatreatmentthatisinexpensiveand
widely available, 50 if expensive or limited availability, 0 if expensive and limited availability. The final version was prompted by feedback from several survey
respondents who felt that not all options were actually considered (e.g., no treatment necessary).
Newborn screening panel and system
May 2006   Vol. 8   No. 5, Supplement 27S1. IncidenceOfTheCondition
The incidence of the various conditions varies widely. In
terms of public health importance, the more common
the condition, the higher the justification for screening.
Accordingly, any condition with a documented (or esti-
mated) incidence of 1:100,000 or less received a score of
zero, while an incidence of 1:5,000 or more received a
score of 100. When technology allows for the condition
to be detected in the course of screening for other condi-
tions, points were added back through the appropriate
testing criteria. (See “Screening Test: Availability and
Characteristics,” below.)
2. Clinically Identifiable Signs And Symptoms In The
First48Hours
In the context of public health, it is more important to
screen for conditions that generally would not be de-
tected in the newborn period based solely on routine
clinicalevaluation.However,itisimportanttorecognize
that there could be differences of opinion regarding
whetheraparticularphenotypecouldberecognizedbya
typical health care provider and/or specialist, and the
phenotypic variability expected among newborns with a
particular condition must be considered. Nonetheless, if
clinical symptoms are never detectable within 48 hours
after birth, the condition received a score of 100. If clin-
ical manifestations are always detectable, the condition
received a score of zero.
3. BurdenOfDisease(NaturalHistoryIfNotTreated)
This is an important criterion for prioritizing the use of
public health resources because it favors screening for
conditions that constitute greater burdens to those af-
fected (if the burden is profound, for example, a score of
100 was given). It is recognized that some conditions
have a wide range of severity and that the test may not
necessarily discriminate the milder forms from the more
severe forms.
The screening test: availability and characteristics
Seven criteria are included in this category:
1. AvailabilityOfASensitiveAndSpecificTestAlgorithm
Thiscriterionisacentralconsiderationwhenassigninga
test or a condition to a uniform screening panel. The
expert group chose to define this criterion as a test algo-
rithm because some tests might require that additional
analytes or second-tier tests be incorporated to achieve
sufficient specificity (e.g., the use of T4 and TSH for the
screeningofCHortheuseofasecond-tiermoleculartest
to improve the specificity of the IRT test for CF). This
criterion was considered the first step in a decision tree
without which further consideration for inclusion in
newborn screening would not be possible. One hundred
points were allotted to this feature of a condition. If a
conditionhadnosensitiveandspecifictestavailablethat
could be used in population screening, it was assigned a
score of zero. However, it is acknowledged that there is
no agreed-upon level of sensitivity and specificity and
that this may vary with the burden of the condition and
its importance for screening.
2. Ability To Test On Either Neonatal Bloodspots Or An
AlternativeSpecimenTypeOrByASimple,In-Nursery
Procedure
Valuewasassignedifatestcanbedoneonadriedblood-
spot, which is a highly stable specimen type already inte-
grated into newborn screening and on which many tests
can be performed. Equal consideration was given to a
screening test that could be conducted using a simple
procedure or method, as with hearing screening, that
would be appropriate for population screening. One
hundred points were allotted to this feature of a test.
3. Test Is Based On A Platform That Offers High-
ThroughputCapability
Valuewasplacedontheabilityofatechnologytooperate
inahigh-throughputformatthatallowstestingofatleast
200 specimens per full-time employee equivalent per
day. The ability to test a large number of specimens in a
short time offers cost savings to programs and increases
efficiency, both important for public health screening.
Fifty points were allotted to this criterion.
4. CostOfTestIsLessThan$1PerInfantScreened
Value was placed on low-cost technologies. Cost was
based on the personnel, reagents and other costs associ-
ated with testing only. Differences in the scoring of con-
ditionsdetectedbyMS/MSwerelikelyduetohighercosts
when a multiplex technology is used to screen for only a
few conditions rather than for a larger number of condi-
tions. Fifty points were allotted to this feature of a test.
5. Multiple Analytes Relevant To One Condition Can Be
DetectedInTheSameRun
The ability to detect multiple markers of a given condi-
tion within the same test increases the specificity of the
method by allowing the calculation of ratios that have been
showntoimprovethedifferentiationbetweentruepositives
andpotentialfalsepositives.Fiftypointswereallottedtothis
feature of a test.
6. Other Conditions (Secondary Targets) Can Be Identi-
fiedByTheSameAnalytes
Value was assigned to the ability of a test to provide in-
formationaboutmultipleconditionsusingthesameana-
lyte(s). Although these secondary targets may not inde-
pendently meet all of the other criteria for inclusion in
the uniform screening panel, they add value to the pri-
marytargetconditionbecausetheirdetectionconstitutes
a clinically significant result leading to tangible benefits
to the affected newborn, family, and society. Fifty points
were allotted to this feature of a test.
7. Multiple Conditions Can Be Detected By The Same
Test(MultiplexPlatform)
Technologycanaddvaluetotesting,particularlyifitpro-
vides the ability to screen for many conditions in a single
test. This can have public health importance above and
beyond the features of the disease itself (i.e., by detecting
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ogies such as MS/MS, IEF, and HPLC for hemoglobin
variants, DNA arrays used in sequencing, and labeled
beadtechnologies.Technologieswithmultiplexingcapa-
bility offer improved efficiency and cost-effectiveness to
programs. Because of the public health importance of
technologies with multiplex capabilities, this criterion
was allotted two hundred points.
Diagnosis, follow-up, treatment, and management
Nine criteria were developed to assess the combined aspects
of diagnostic confirmation and treatment and management:
1. AvailabilityOfTreatment
The availability of treatment is considered an important
criterion for conditions in a core newborn screening
panel. Fifty points were allotted to this feature of a con-
dition, though additional value is assigned later depend-
ing on the effectiveness of the treatment.
2. CostOfTreatment
The cost of treatment is an important consideration in
newbornscreening.Althoughthiscriteriondoesnotnec-
essarily differentiate cost from value, it should be fac-
tored into decision-making. Fifty points were allotted to
this feature of the treatment.
3. PotentialEfficacyOfExistingTreatment
More effective preventive or therapeutic interventions
for a given condition increase the value of testing. For
manyconditions,treatmentscouldresultinnearnormal
or normal outcomes. For others, the treatment may af-
fect only a subset of the negative phenotypes possible or
allow for only incremental improvements in optimal
outcome. Moreover, treatment might not be equally ef-
fective in all individuals. This was considered a critical
criterion and was assigned a value of 200 points.
4. IndividualBenefitsOfEarlyIntervention
This criterion is important because the benefit to the
childbeingscreenedistheoverridingconsideration.This
was considered an objective criterion based on the qual-
ity of available evidence showing that early intervention
optimizesoutcome.Twohundredpointswereallottedto
this feature of a treatment.
5. FamilialAndSocietalBenefitsOfEarlyIdentification
Early identification of an infant with a condition can
bringbenefitstofamiliesand/orsocietybeyondthepros-
pect of treatment. Because so many of the conditions
detectedthroughnewbornscreeningaregenetic,families
can benefit from establishing that there may be a genetic
risk to others in the family. Society could benefit by a
reduction in medical diagnostic odysseys that are costly
to the health care system. One hundred points were al-
lotted to this feature of a condition.
6. PreventionOfMortalityThroughEarlyDiagnosisAnd
Treatment
Prevention of mortality was assigned a value indepen-
dent of reduction of morbidity. One hundred points
were allotted to this feature of a condition.
7. AvailabilityOfDiagnosticConfirmation
Many conditions included in newborn screening pro-
grams are rare, and there may be poor access to diagnos-
tic confirmation testing in the United States or even in-
ternationally. In such cases, it is more difficult to
follow-up on cases with positive results, and the results
provided by research laboratories may be more difficult
tointerpretandcommunicatetochildhealthprofession-
als and families than those from diagnostic laboratories.
Furthermore, in the United States it may be ethically or
legallyproblematictoreportresultsfromtestsconducted
by laboratories that are not certified by the Clinical Lab-
oratory Improvement Amendments (CLIA). On the
other hand, some conditions can be confirmed locally
because of the wide availability and relative simplicity of
the confirmatory test or service. Thus, different values
were assigned based on the ease of diagnostic confirma-
tion. One hundred points were allotted to this feature of
a condition.
8. AcuteManagement
Aswithdiagnosticconfirmation,theavailabilityofhealth
care professionals who have expertise in the acute man-
agement of the condition could be limited. Thus, higher
values were assigned to conditions for which acute dis-
ease management is readily available. One hundred
points were allotted to this feature of a condition.
9. SimplicityOfTherapy
Therapeutic interventions range from highly specialized
(e.g., bone marrow/umbilical cord blood transplanta-
tion) to extremely simple (e.g., vitamin supplementa-
tion,avoidanceoffasting).Ahighervaluewasassignedto
simplertherapiessincesimplicitydetermineswhetherin-
fants requiring follow-up can be managed locally or
whether subspecialist care is required. The acute man-
agement of many metabolic disorders often requires the
involvementofmetabolicdiseasephysicianswhoarenot
readily available in many geographic locations. On the
other hand, for example, aspects of CH may be managed
by child health professionals, and when specialists are
required, they are more widely available. Some condi-
tionsalsomightallowforgreaterlevelsoffamilyinvolve-
ment in treatment. One hundred points were allotted to
this feature of a condition.
Collectingthedata
One goal of the data collection process was to include a
broadly representative group of participants. A second goal
was to use a method that would allow quantification of expert
opinion. In addition to data gleaned from the scientific litera-
ture,inputandopinionweresoughtfromawidearrayofchild
health professionals, subspecialty care experts and individuals
interested in newborn screening. Respondents were not anon-
ymous, and were asked to select one or more of the following
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role(s) in relation to newborn screening:
1. Provider of screening services (TESTING)
2. Provider of screening services (FOLLOW-UP)
3. Provider of screening services (ADMINISTRATION)
4. Provider of screening services (POLICY)
5. Provider of diagnostic services
6. Child health professional
7. Specialty care provider
8. Consumer
Asdiscussedpreviously,manycriteriawereperceiveddiffer-
ently by these diverse constituencies. Distinguishing among
respondents allowed the expert group to independently assess
the views of these different groups.
For each condition, steps were taken to ensure that those
asked to provide information and those who provided infor-
mation were broadly representative of the interest groups in-
volved.Alargenumberofacknowledgedexpertsforeachcon-
dition and specific consumer and professional organizations
were asked to provide input through multiple professional
groups (e.g., the Society for Inherited Metabolic Disease
(SIMD),ACMG).Individualsfrompublichealthandnewborn
screening programs were offered the opportunity to partici-
pate through listservs of their representative organizations.
This included listservs managed by HRSA/MCHB, NNSGRC,
the Association of Public Health Laboratories, and others. To
ensure that the perspectives of consumers were available for
consideration, consumers were reached through listservs of
NNSGRC, Genetic Alliance, and others. To ensure that there
were several scientific and clinical experts for each condition,
specific individuals were identified from recent publications,
disease support groups, and professional groups. In addition,
the data collection instrument used was made widely available
throughtheACMGwebsite(www.acmg.net).Duetothelarge
and overlapping numbers of individuals participating in these
listservs, it is not possible to state the number of potential par-
ticipants who were contacted. Geographic origin and role or
interestinnewbornscreeningofsurveyparticipantswasmon-
itored to ensure that respondents were broadly representative.
Respondents were given the opportunity to score each cri-
terion or mark it as unknown “U,” an important option, be-
cause not all of those asked to participate were sufficiently fa-
miliar with the many aspects of all of the diseases for which
responses were sought. However, the option also had implica-
tions for how the data were aggregated for analysis. The data
were analyzed as means and medians for each criterion, as the
average of total scores for each responder, and as sums of
meansandmediansofallrespondentstoaparticularcriterion.
After considering these different possibilities, it was decided
that the results for any given condition would be expressed as
the sum of the mean of the scores for each criterion. (The
difficulty with using the sums of the means arises from differ-
entnumbersofscorers,andscoresvaryinginthecomparisons,
whichobscuresthedistributionandconfidenceintervalsofthe
final scores. The alternative approach using the sum of the
medians was not used as the primary statistic because it tends
to minimize dissent from the consensus. In later figures, con-
ditionsareorderedaroundthesumofthemeansandmedians
are otherwise shown. However, as previously discussed, for
purely objective criteria, the data as evidenced by the scientific
literaturewasappliedandincludedinthesumsratherthanthe
survey information.)
Developing and integrating the evidence base
Inthesecondtieroftheassessment,theevidencebaseforthe
conditions was established and an algorithm through which
conditions were reassessed was developed. The quantification
of expert opinion or scoring system then becomes part of a
broader assessment of the scientific literature related to the
conditions, tests, and treatments in the second level of the as-
sessments. The evidence from the scientific literature, with
supportingreferencesforeachcriterionofeachcondition,was
reviewed as shown in the fact sheets (Appendix 1). Evidence
was derived from a systematic review of:
1 Clinical evidence;
2. Cost/economic evidence and modeling;
3. Reference lists obtained from PubMed and Medline;
4. Books;
5. Health technology assessments commissioned by the
U.K. National Screening Committee;
6. The Internet, including disease-specific support groups;
and
7. Professional guidelines.
Epidemiology studies, when available, were assessed for
study design, the nature of the subjects and the outcomes that
were measured, and the effectiveness of the treatment.
Statistical analysis of survey results allowed for a score to be
assigned to each condition which determined its ranking and
initialplacementinoneofthreecategories(highscoring,mod-
erately scoring, and low scoring or lacking a newborn screen-
ingtest).Aftertheassignmentofconditionstooneofthethree
categories, the evidence base on the condition, as validated by
acknowledged experts in the conditions in question, was used
to determine if the conditions met critical criteria categories.
Experts in specific conditions were identified by the Condi-
tionsandCriteriaWorkGroupandincludedmanyindividuals
who had participated in the data collection process.
Several critical criteria were identified that reflected the pri-
orities and principles of the expert group. These include:
1. Theexistenceofasensitiveandspecifictestthathasbeen
validated in a large general population;
2. The availability of an efficacious treatment;
3. A determination that the natural history was sufficiently
well understood to justify placement in a core panel of
conditions;
4. Determination of whether a clinically significant condi-
tionnotinthecorepanelwouldbeidentifiedbecauseitis
part of the differential diagnosis of a core panel condi-
tion; and
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vealedbyamultiplextechnologyandwhetheritwaspart
of the differential diagnosis of a core panel condition.
6. Further, it was recognized that some tests allow for the
definitive identification of unaffected carriers, and that
such results should be communicated to a responsible
individual in the health care system.
The fact sheets for each condition were reviewed by at least
twoexpertsforeachconditiontovalidatetheinformationand
assign a level of quality to the evidence. Levels of evidence
correspond to those defined by the AAP Steering Committee
on Quality Improvement and Management32 as follows:
Level1:Evidenceisderivedfromwell-designedrandomized
controlled trials or diagnostic studies on relevant populations.
Level 2: Evidence is derived from randomized controlled
trialsordiagnosticstudieswithminorlimitations;overwhelm-
ing, consistent evidence from observational studies.
Level3:Evidenceisderivedfromobservationalstudies(case
control and cohort design).
Level 4: Evidence is derived from expert opinion, case re-
ports, and reasoning from first principles.
The evidence was aggregated into four groups (the condi-
tion, the test, the diagnosis and the treatment) and a level of
evidence quality was assigned to each group by the experts for
each of the conditions. Each fact sheet includes the names of
theexpertswhovalidatedthedataandthelevelofqualityofthe
studies from which the evidence is derived.
C. Results
Responses were received from 289 individuals, many of
whomrepresentedmorethanasingleinterestgroup,foratotal
of582representedareasofinterest.Themajorityofthesurvey
information was provided by experts in the clinical and scien-
tific aspects of the individual conditions. The regional distri-
bution of responses and areas of expertise of the respondents
from the United States are shown in Table 3. The table also
correlates the number of responses to the birth rate in each
region (based on Census 2001 data). In the United States, no
responseswerereceivedfromthefollowingStates:Idaho,Kan-
sas, Montana, North Dakota, South Dakota, West Virginia,
and Wyoming. International responses were from Australia
(4),Brazil(1),Canada(5),Chile(1),Croatia(1),Denmark(1),
Finland (1), France (1), Germany (1), Italy (3), The Nether-
lands (1), Switzerland (1), and the United Kingdom. Most
were from recognized experts in the field who were actively
solicited by members of the working group for their input
about specific conditions. At least three experts provided in-
formation on each condition.
Overall,atotalof3949conditionprofileswereobtained.On
average,sevenconditionswerescoredperresponder.Ofthe84
conditions, 30 (36%) received more than 50 responses, and 5
(6%)  20. The average number of profiles per condition was
47  20; the range was 14-120. The corrected total for the 84
conditions was 3796; the number of responses for each condi-
tionislistedinTable4.Thistablealsoshowstheproportionof
respondentswhowereunabletorespondtooneormoreofthe
individual criteria and is reflected as “missing data” for each
condition. This option was most frequently used in scoring
criteria related to attributes of the screening test itself, with
11% of respondents not including all of the requested infor-
mation.
Additionalinput,bothdomesticandinternational,waspro-
vided by individuals who were asked to discuss many of the
broad issues under consideration by the work groups. The
committeeisparticularlygratefulfortheassistanceofDr.Rod-
neyPollitt(Sheffield,UK),whoprovidedinsightsintothesys-
tem used in the United Kingdom; Dr. Adelbert Roscher (Mu-
nich,Germany),whoprovidedinsightintotherecentnewborn
screeningandMS/MSdecision-makingprocessundertakenby
the German Democratic Republic; and Dr. Edwin Naylor
(Pittsburgh,PA),whoprovidedinsightintothedecision-mak-
ingprocessofNeoGenScreening(nowPediatrix).Inaddition,
Table 3
Geographical distribution of respondent profiles
Region
Provider screening services
Consumers
Diagnostic
services
Primary
care
Specialty care provider
Total Testing Follow-up Administration Policy Endocrinology Hematology
Inf.
diseases Genetics
Inborn
Errors of
Metabolism
West 5 17 5 8 10 11 0 8 2 1 4 12 83
Midwest 8 23 4 16 14 20 1 5 2 1 12 18 124
Northeast 13 29 8 14 22 30 3 11 6 1 20 25 182
South 4 10 2 5 15 6 4 3 0 0 7 6 62
Southeast 2 6 2 6 22 9 1 5 3 0 7 6 69
TotalUS 32 85 21 49 83 76 9 32 13 3 50 63 520
International 11 11 5 5 0 15 1 0 3 0 0 9 60
Not provided 0 0 0 0 2 0 0 0 0 0 0 0 2
Total 43 96 26 54 85 91 10 32 16 3 50 72 582
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Survey scores of all conditions (sorted by score in descending order)
Condition Code Responses
Missing data
(%)
Score (sum of
the means)
Rank
(%ile)
Medium-chain acyl-CoA dehydrogenase deficiency MCAD 90 4 1799 1.00
Congenital hypothyroidism CH 84 3 1718 0.99
Phenylketonuria PKU 120 3 1663 0.98
Neonatal hyperbilirubinemia (Kernicterus) HPRBIL 8 5 1584 0.96
Biotinidase deficiency BIOT 68 2 1566 0.95
Sickle cell anemia (Hb SS disease) Hb SS 55 8 1542 0.94
Congenital adrenal hyperplasia CAH 93 7 1533 0.93
Isovaleric acidemia IVA 53 3 1493 0.89
Very long-chain acyl-CoA dehydrogenase deficiency VLCAD 58 2 1493 0.89
Maple syrup (urine) disease MSUD 84 10 1493 0.89
Galactosemia GALT 85 3 1473 0.88
Hb S/ß-thalassemia Hb S/ßTh 43 8 1455 0.87
Hb S/C disease Hb S/C 45 4 1453 0.86
Long-chain L-3-OH acyl-CoA dehydrogenase deficiency LCHAD 58 3 1445 0.84
Glutaric acidemia type I GA I 58 3 1435 0.83
3-hydroxy 3-methyl glutaric aciduria HMG 28 4 1420 0.82
Trifunctional protein deficiency TFP 42 5 1418 0.81
Multiple carboxylase deficiency MCD 46 2 1386 0.80
Benign hyperphenylalaninemia H-PHE 76 3 1365 0.78
Methylmalonic acidemia (mutase deficiency) MUT 60 2 1358 0.77
Homocystinuria HCY 80 2 1357 0.76
3-Methylcrotonyl-CoA carboxylase deficiency 3MCC 48 4 1355 0.75
Hearing loss HEAR 45 4 1354 0.73
Methylmalonic acidemia (Cbl A,B) Cbl A,B 46 2 1343 0.72
Propionic acidemia PROP 68 2 1333 0.71
Carnitine uptake defect CUD 46 2 1309 0.69
Galactokinase deficiency GALK 47 7 1286 0.69
Glucose-6-phosphate dehydrogenase deficiency G6PD 42 5 1286 0.67
ß-Ketothiolase deficiency ßKT 33 6 1282 0.66
Citrullinemia CIT 63 3 1266 0.65
Argininosuccinic acidemia ASA 60 4 1263 0.64
Tyrosinemia type I TYR I 68 4 1257 0.63
Short-chain acyl-CoA dehydrogenase deficiency SCAD 51 7 1252 0.61
Tyrosinemia type II TYR II 57 3 1249 0.60
Glutaric acidemia type II GA2 52 4 1224 0.59
Medium/short-chain L-3-OH acyl-CoA dehydrogenase
deficiency
M/SCHAD 21 11 1223 0.58
Cystic fibrosis CF 65 12 1200 0.57
Variant Hb-pathies (including Hb E) Var Hb 41 3 1199 0.55
Human HIV infection HIV 29 8 1193 0.54
Defects of biopterin cofactor biosynthesis BIOPT (BS) 60 3 1174 0.53
(continued)
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Continued
Condition Code Responses
Missing data
(%)
Score (sum of
the means)
Rank
(%ile)
Medium-chain ketoacyl-CoA thiolase deficiency MCKAT 23 13 1170 0.52
Carnitine palmitoyltransferase II deficiency CPT II 45 5 1169 0.51
Methylmalonic acidemia (Cbl C,D) Cbl C,D 45 4 1166 0.49
Argininemia ARG 54 5 1151 0.48
Tyrosinemia type III TYR III 42 5 1149 0.47
Defects of biopterin cofactor regeneration BIOPT (Reg) 58 5 1146 0.46
Malonic acidemia MAL 22 5 1143 0.45
Carnitine: acylcarnitine translocase deficiency CACT 38 5 1141 0.43
Isobutyryl-CoA dehydrogenase deficiency IBG 28 7 1134 0.42
2-Methyl 3-hydroxy butyric aciduria 2M3HBA 18 3 1132 0.41
Carnitine palmitoyltransferase IA deficiency (liver) CPT IA 40 4 1131 0.40
2-Methylbutyryl-CoA dehydrogenase deficiency 2MBG 27 18 1124 0.39
Hypermethioninemia MET 45 3 1121 0.37
Dienoyl-CoA reductase deficiency DE RED 18 11 1119 0.36
Galactose epimerase deficiency GALE 38 7 1066 0.35
3-Methylglutaconic aciduria 3MGA 21 5 1057 0.34
Severe combined immunodeficiency SCID 69 6 1047 0.33
Congenital toxoplasmosis TOXO 28 12 1041 0.31
Familial hypercholesterolemia (heterozygote) FHC 25 2 1038 0.30
Carnitine palmitoyltransferase IB deficiency (muscle) CPT IB 28 4 1009 0.29
Citrullinemia type II CIT II 38 2 1001 0.28
Ornithine transcarbamylase deficiency OTC 64 7 942 0.27
Guanidinoacetate methyltransferase deficiency GAMT 23 1 922 0.24
Wilson disease WD 25 4 922 0.24
Diabetes mellitus, insulin dependent IDDM 51 16 891 0.23
Neuroblastoma NB 14 4 864 0.22
Arginine: glycine amidinotransferase deficiency AGAT 21 2 861 0.20
Turner syndrome TURNER 36 4 847 0.19
Adenosine deaminase deficiency ADA 20 4 841 0.18
Carbamylphosphate synthetase deficiency CPS 55 2 833 0.17
Alpha 1-antitrypsin deficiency A1AT 18 12 819 0.16
Congenital cytomegalovirus infection CMV 18 12 779 0.14
Duchenne and Becker muscular dystrophy DMD 29 3 776 0.12
Fragile X syndrome FX 35 4 776 0.12
Congenital disorder of glycosylation type Ib CDG Ib 34 5 766 0.11
Smith-Lemli-Opitz syndrome SLO 45 3 759 0.10
Biliary atresia BIL 15 4 744 0.08
Hurler-Scheie disease MPS-1H 48 7 707 0.07
X-linked adrenoleukodystrophy ALD 38 2 705 0.06
Fabry disease FABRY 46 6 661 0.05
(continued)
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the course of these deliberations.
Based on responses to an independent survey that inquired
as to the appropriateness of the criteria and the weights as-
signed, the expert group adjusted the scores assigned to some
of the criteria. In particular, ambiguous language was clarified
andagreaterweightwasassignedtothebenefitoftreatmentto
theinfant.Scoresfortheparametersofthescreeningtestswere
increasedtorecognizetheinherentvalueofmultiplextechnol-
ogies to public health.
Figures 1 and 2 display the raw data for MCAD and PKU,
which were selected as representative conditions for demon-
strating how the data collected for individual criteria are
charted and aggregated to reach the final scores. Each respon-
dent is listed over columns and the score offered for each cri-
terion is shown. The sums of the mean and median scores are
shown. Figures 3a through 3e display side-by-side summary
dataforeachofthecriteriausedtoevaluatetheconditionswith
MCAD on the left and PKU on the right. In the top panel, the
totalscoreforeachrespondentisshown.Theremainingpanels
show the scores for 18 of the 19 individual criteria (the avail-
ability of test criterion is not included) used to evaluate the
conditions.Thecompletedataintabularformaredisplayedin
Table 4, in which the scores are reflected as sums of the means
for all conditions. The number of respondents for each condi-
tion is shown. The sums of the mean scores for all of the con-
ditions evaluated, regardless of whether a screening test is
available, are shown in Figure 4, Figure 5.
Figure 6 separates those conditions that have an acceptable,
validated, population-based screening test from those lacking
atest.Theleftsideofthegraphshowstheconditionsthathave
an adequate screening test currently available, while those
shown on the right side lack a screening test. Among the con-
ditions with a test, MCAD deficiency, CH, and PKU score the
highest in this analysis, followed by BIOT, sickle cell anemia,
CAH, isovaleric acidemia, VLCAD deficiency, MSUD, GALT,
hemoglobinS/-thaldisease,hemoglobinSCdisease,LCHAD
deficiency, glutaric acidemia type 1, and HMG. Conditions
without a test are included because they reflect the need to
focus on particular aspects of the disease in order for it to be
considered for newborn screening.
D. Discussion
A number of considerations influenced the final decisions
regarding which conditions should be included in a core
screeningpanel.Aspreviouslydiscussed,usingatwo-steppro-
cess, the information gathered with the data collection instru-
ment and the review of the scientific literature provided infor-
mation used to assign a score for each condition. This
approachalsoallowedforthoseconditionswithscreeningtests
that have been validated in general populations to be distin-
guished from those conditions for which a population-based
validated test was not available. The scores were first used to
makesomegeneraldecisionsbasedonthehighestscoringcon-
ditions. In particular, the inclusion of several conditions that
arescreenedbyeitherIEForHPLC(hemoglobinopathies)and
MS/MS (acylcarnitines and fatty acid oxidation disorders) led
the expert group to make decisions regarding multiplex tech-
nologiesandhowtheresultsshouldbehandled.Oncethecon-
ditions were separated into groups defined by either the indi-
vidual condition or by the multiplex test that detects many
conditions, the scoring system could be overlaid to see how
conditions compare to one another within these groupings, or
in total.
Definingandcountingtheconditions
Carefulconsiderationofseveralfactorsisrequiredtoanswer
the seemingly basic question of how many conditions should
bescreenedforinanewbornscreeningprogramandhowthey
should be defined. These factors include: 1) the clinical, bio-
chemical, and molecular complexity of the conditions under
consideration; 2) the progress constantly made in our under-
standing of their natural history and etiology; 3) the impact of
implementing multiplex platforms that allow the simulta-
neousdetectionofnumerousbiochemicalmarkers;and4)the
gaps that appear to exist in the level of clinical knowledge
among stakeholders involved with, or advocating for, the de-
cision to pursue ever greater numbers of conditions. Indeed,
counting has become increasingly problematic to the point
that a competition seems to be taking place in which the ap-
parent superiority of a newborn screening program or private
laboratory is staked on the sole basis of quantity, with dispro-
portionate consideration given to quality. This concept has
caught the attention of the media that constantly tell the pub-
Table 4
Continued
Condition Code Responses
Missing data
(%)
Score (sum of
the means)
Rank
(%ile)
Lysosomal storage diseases LSD 38 8 638 0.02
Creatine transport defect CR TRANS 20 0 646 0.04
Pompe disease POMPE 46 7 613 0.01
Krabbe disease KRABBE 44 9 447 0.00
NOTE: Figure 5 shows the scores for all conditions that were evaluated, separated into groups based on the testing platforms (MS/MS for metabolic diseases, IEF or
HPLC, for hemoglobinopathies, and all others).
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particular State, the better that program must be. As a direct
consequenceofthisbehavior,thenumberofconditionsisper-
ceived by the public and policy-makers as a scorecard, often
leadingtoeitherinflatedorinaccuratefigures.Forexample,22
States offering screening by MS/MS have included LCHAD
deficiency in their panels, yet only half of the same programs
claim to be screening for trifunctional protein deficiency, per-
haps being unaware that the biochemical phenotype in blood-
spotsisessentiallyidenticalbetweenthetwoconditions.Thus,
the context in which screening is “quantitated” must be stan-
dardized.
This situation is not a new development brought on by
modern technologies. Since the beginning of PKU screening,
this has been a complex issue. The screening method for PKU
led to follow-up testing to separate the patients with tyrosine-
mia and/or biopterin defects. Thus, many programs included
tyrosineintheirscreenedconditions,andconsideredbiopterin
defects as merely an anomaly of PKU screening that should be
combined with PKU and given an asterisk when counting the
numberofPKUcasesdetected.Thisishardlysatisfactorywhen
questions are asked about the incidence of the secondary tar-
gets or the outcomes of those subtypes.
When screening for sickle cell anemia became an important
addition to screening panels, the singular condition of SS disease
was usually counted even though the testing methodologies used
could detect many different clinically significant hemoglobinop-
athies.Screeningforsicklecellanemiaprogressedtoscreeningfor
sickle cell diseases (SC and S-thal) but this screening was still
counted as screening for a single disorder with many other con-
ditionsdetectedsecondarily.Further,althoughthesearethethree
primary targets of hemoglobinopathy screening, the methodolo-
gies of IEF or HPLC employed in hemoglobinopathy screening
can reveal over 700 variant hemoglobins, of which about 25 are
considered to be of clinical significance and are reported out by
somescreeninglaboratories.SomeStatesmayonlyreportSSdis-
ease,someSS,SCandS-thal,andothersavariablenumberofthe
otherclinicallysignificantvariants.Hence,justforthisonegroup
ofconditions,onecanarguethataprogramthatreportsout28of
thesevariantsactuallyscreensfor28conditions.Foratestinvolv-
ing a functional endpoint such as severe hearing loss, there are a
large number of “conditions” for which the test screens.33 There
areover77locifornonsyndromalhearinglossconditions,31loci
forsyndromalhearinglossconditions,aswellassomeofthe“en-
vironmental” causes of hearing loss that would be amenable to
DNA-based testing such as presence of the cytomegalovirus or
other infectious agent genomes. Hence, what is considered a sin-
gleconditionscreen,congenitalhearingloss,maybeconsidereda
screen for at least 108 individual conditions at the etiologic level.
If one takes the set of conditions included in both the pro-
posed core panel and secondary target groups, each entity re-
flects the significance given to a spectrum of possible criteria.
Intheproceedingsoftheworkinggroupchargedwiththistask,
choices were made to strike the best compromise between es-
tablished practices, the expert opinions, and scientific evi-
dence.Inreality,countingcouldhavebeenverydifferentifthis
had been approached in a pragmatic way using any of the fol-
lowing criteria:
1. Phenotype of the condition;
2. Established groups of conditions (e.g., organic acidurias,
hyperphenylalaninemias);
3. Primary marker (e.g., tyrosine, C8 acylcarnitines);
4. Test (e.g., MS/MS, IEF);
5. Response to treatment (e.g., responsiveness to cofactors,
vitamins); and
6. Number of loci linked to a common phenotype (e.g.,
hearing loss genes as discussed above).
Table 5 shows how different “counting” could be if the cri-
teria above were applied independently. For instance, hearing
lossisasinglephenotypeofonegroupofconditionsforwhich
the primary marker is hearing loss that is detected by one test-
Table 5
Discrepancies in counting conditions using different criteria
Countingconditionsaccordingto COREPANEL
(NOTincludedifoverlappingwithcore
panel)SECONDARYTARGETS TOTAL
Clinical phenotype (1) 27 14 42
Established groups of conditions (2) 10 0 10
Primary marker (3) 22 29 51
Test platform (4) 9 2 11
Response to treatment (5) 32 14 46
Number of loci (6) 142 28 170
Expert group (7) 29 25 54
(1)All clinical subsets (e.g., severe, mild) considered as a single entity.
(2)Organic acids disorders, hemoglobinopathies, endocrine disorders.
(3)Analyte with best sensitivity and specificity (e.g., C8 for MCAD or phenylalanine for the hyperphenylalaninemias).
(4)Either singleton test or multiplex platform count as one.
(5)Significant in a few cases (e.g., responsive versus non-responsive forms to a particular treatment).
(6) Based on OMIM (), with modifications.
(7)Selected from a total of 84 conditions.
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the group is improved hearing or communication. However,
as previously discussed, there are at least 108 genes for condi-
tions associated with hearing loss. Similarly, while C8 is a pri-
mary marker of MCAD, it’s also a primary marker for GA-II,
M/SCHAD and MCKAT. It is detected in a single multiplex
platform, MS/MS. Treatments are similar but as indicated
above,andmultipleconditionsareassociatedwiththemarker.
Itisevidentthatquantitationandcategorizationofnewborn
screening disorders remains imperfect and inconsistent and
that, until standardized, there will continue to be confusion
about the extent of screening in individual programs and the
nation. The expert panel recognizes these disparities and their
rationale,andrecommendstheimplementationofastandard-
ized and common nomenclature for an objective and scientif-
ically sound description of the screening test panel being of-
fered and the reporting of results. Such a classification system
would require some consensus among the newborn screening
and subspecialty communities, but should be possible. Stan-
dardization of panels, and consistent screening methods and
casedefinitionswillallowmorepoolingofavailabledataonthe
utility of screening.
Integratingtheevidencebasewiththesurveyresults
Information obtained from the scientific literature and the
surveys was used to create the fact sheets that were developed
for each condition (see Appendix 1). The fact sheets are struc-
tured to provide summary information describing:
1. The type of condition;
2. The test;
3. The extent to which United States newborns are being
screened for the condition;
4. Whetherthereisapparentethnicvariabilityinincidence;
5. Thenumberofindividualsprovidinginformationonthe
condition;
6. The proportion of scores from survey respondents con-
sidered valid; and
7. Citations in PubMed as of February 2004.
Information obtained from the surveys is shown on the left
side of the first page. The percent of maximum score of the
survey respondents is shown next to each criterion. The data
fromthetwocriteriaforwhichtherewasthelowestcorrelation
amongrespondentsisalsoshownontheleftsideofpage1.The
evidence from the literature is shown on the right side of the
first page. Additional summary information including the
scores(maximumof2,100)isshownalongwithanassessment
of whether the data from the surveys are consistent with the
evidence from literature. Significant discrepancies are dis-
cussed in the comment box. Although the language of the cri-
terion is often not identical to that expressed in the literature,
therewassignificantcorrelationbetweenthesurveyresultsand
the evidence from the literature. The fact sheets for all other
conditions evaluated are provided in Appendix 1.
Influenceoftestingtechnology
New technology has been one of the driving forces in the
evolutionofnewbornscreeningprogramsintheUnitedStates
andisacriticalfactorintheevaluationofaconditiontodeter-
mine how appropriate for screening it is. Typically, determin-
ingtheappropriatenessofnewbornscreeningwasbasedonthe
conditions themselves and their associated testing methods.
However,newtechnologiesoftenraisequestionsthathavenot
yetbeenaddressed.Multiplexmethodssuchasgenomicarrays
require that the sequence tested deliberately be placed in the
array. This is distinct from technologies that look globally at a
class of molecules, for example, IEF or HPLC that reveal all
hemoglobinvariants,oranMS/MSruntodetectacylcarnitines
that reveal compounds in the C2 through C18 range. Compli-
cating the use of MS/MS is the fact that many of the com-
poundsidentifiedareassociatedwithmorethanonecondition
and these conditions may not have similar clinical and labora-
tory features. Thus, the criteria used to judge whether to in-
clude a condition in a newborn screening panel will vary
among the conditions. It becomes difficult to compare a con-
dition that has a unique test/technology that tests only for the
conditionofinteresttoatechnologythatcandetectmanycon-
ditions, some of which are related through their differential
diagnosis,whileothersinvolveindependentcompoundsinthe
MS/MS profile. The use of MS/MS for acylcarnitines, for ex-
ample, differs from its use for detection of amino acid disor-
ders in which there is little overlap between the analytes asso-
ciated with the conditions. Table 6 shows the relationships
between analytes for high scoring conditions and those of
lower scoring conditions.
Independent decisions were made about conditions
screened using MS/MS and HPLC or IEF for hemoglobinopa-
thies. One reason is that among the acylcarnitine disorders
there is little differentiation between the highest and lowest
scoring conditions. For many conditions, the difference is ac-
counted for by differing incidence figures—a criterion that
loses some of its importance when the test for the more com-
mon conditions also can detect less common conditions.
It is important to note that two approaches are currently
being used in screening with MS/MS. A majority of screening
laboratories now run full profiles that allow them to visualize
the full range of acylcarnitines or amino acid compounds.
However, a minority operate their systems in a selective reac-
tion monitoring (SRM) mode, which allows them to obtain
results only on the subset of compounds that are associated
with those conditions that are being targeted in the screening
programs.SomeprogramsuseacombinationofSRMandpro-
filingwitheitherapproach,thescreeningtestisdrivenmoreby
analytesthanbytheconditionswithwhichtheyareassociated.
An assessment of the advantages and disadvantages of the test
resultsforeachapproachledtoanexpertgrouppreferencefor
the full-profile approach for four reasons.
First,inreviewingthoseacylcarnitine-associatedconditions
that were high scoring in this analysis (MCAD, IVA, VLCAD,
LCHAD, GA1, HMG and TFP) (see Table 4), it was apparent
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mizeassayspecificityandsensitivity.Amajorityoftheremain-
ing conditions detected by MS/MS were also included in the
differential diagnoses of the higher scoring conditions. Thus,
screening for a core set of conditions ultimately results in
screening for a much wider range of conditions.
Second, the use of MS/MS profiles allows for the maximal
use of the technology for the identification of clinically signif-
icant conditions.
Third, the use of MS/MS profiles offers better quality con-
trol of preanalytic and analytic aspects of testing. Allowing all
information to be assessed can reveal the presence of spurious
signals and/or contaminants in the specimens or reagents and
devices used in the test system.
Fourth, the use of MS/MS profiles enhances clinical inter-
pretation of results by revealing anomalies in associated com-
pounds or in compounds that provide internal standards
againstwhichexcessesordeficienciescanbebetterinterpreted.
Hence, the expert group recommends that a full MS/MS pro-
file should be analyzed, and any clinically significant results
should be reported by the laboratory to the health care pro-
vider and family of the infant. Some of the conditions detect-
able by acylcarnitine profiling may turn out to be benign in a
number of cases (i.e., SCAD, 2MBCAD, and 3MCC). The sec-
ondary conditions detectable by a multiplex technology such
asMS/MSorHPLCandincludedinadifferentialdiagnosisfor
the primary target conditions can be screened at minimal ad-
ditional cost and are, in fact, determined in the diagnostic set-
ting during follow-up. There could be additional cost associ-
ated with diagnosis and follow-up, although many of these
cases would be detected clinically after birth and higher costs
wouldinevitablybeincurredbythehealthcaresystemandthe
family, although not as a result of the newborn screening pro-
gram.
The expert group also devoted considerable discussion to
the question of how best to present the results of analyses of
conditions.Aspreviouslydiscussed,thelistsofconditionsused
are inherently longer than the lists many States use to describe
the newborn screening tests they offer because the expert
group chose to break down the heterogeneity of conditions by
listingthembyetiologictypeorbytheanalytesassociatedwith
theconditions.Itwouldbeinappropriatetoconsiderthislistof
conditions as a scorecard for the number of conditions
screened.Itisonlybyconsideringeachconditionineachofits
etiologic forms that a direct analysis can be done.
In the following section, diseases are assigned to categories
asameansofconductingtheanalyses(seeTables7and8).The
main category, referred to as the core panel, includes those
conditionsconsideredappropriatefornewbornscreening.The
29conditionsinthiscorepanelaresimilarinthattheyallhave:
1. Specific and sensitive screening tests;
2. A sufficiently well understood natural history; and
3 Available and efficacious treatments.
Table 6
Differential diagnosis between core panel and secondary target conditions
PRIMARYTARGETS SECONDARYTARGETS
HigherScoring LowerScoring
MCAD GA2
M/SCHAD
MCKAT
PKU H-PHE
BIOPT (BS)
BIOPT (REG)
Hb SS Hb S/ß-Th
Hb S/C
VAR Hb
IVA 2MBG
VLCAD LCHAD
TFP
CPT II
CACT
GALT GALK
GALE
BIOT (*) MCD
PROP
MUT Cbl A,B Cbl C,D
HCY MET
HMG 3MCC
BKT
2M3HBA
3MGA
CUD CPT IA
CIT ASA CIT II
TYR I TYR II
TYR III
NOTE: Codes are as listed in Table 2. A differential diagnosis is required
between conditions listed in the same row. (*) indicates that biotinidase defi-
ciency is occasionally diagnosed by MS/MS.
Table 7
The core condition panel
MS/MS
Acylcarnitines Amino acids
9OA 5FAO 6AA 3HbPathies 6Others
COREPANEL
IVA MCAD PKU Hb SS* CH
GAI VLCAD MSUD Hb S/ß-Th* BIOT
HMG LCHAD HCY* Hb S/C* CAH*
MCD TFP CIT GALT
MUT* CUD ASA HEAR
3MCC* TYR I* CF
Cbl A,B*
PROP
BKT
CodesareaslistedinTable4.OA,disordersoforganicacidmetabolism;FAO,
disorders of fatty acid metabolism; AA, disorders of amino acid metabolism;
Hb Pathies, hemoglobinopathies. (*) See individual condition discussions.
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validatedscoresequaltoorabove1,200meetthesekeycriteria
and should be considered appropriate for newborn screening.
Analysis of the distribution of scores among the conditions
inFigure7showsthataroundascoreof1,250,onemovesinto
a group of conditions that are part of the differential diagnosis
of higher scoring conditions, but for which natural history is
less well understood or efficacious treatment is lacking. These
conditions occupy the middle third of the curve. CF (1,200) is
the only condition currently screened that scores in this range
but is not part of the differential diagnosis of a higher scoring
condition. (Its lower score may reflect the ongoing debate
aboutthebenefitsofscreeningforCF,despitetheevidencefor
screening and the lack of evidence of significant harms from
screening.)34–35 Otherwise, all conditions in this middle third
scoring between tyrosinemia type I (score  1,257; 63rd cen-
tile) and galactose epimerase deficiency (score  1,066; 35th
centile) are part of the differential diagnosis of another higher
scoring condition. The expert group recognizes that it is diffi-
cult to draw a line in a continuum that would reasonably dis-
criminate between groups of conditions. Programs should ap-
preciate that scoring cut-offs may have wide and varying
confidencelimitsduetodifferencesinnumbersofresponders.
The final scores represent a rough relative approximation of
ranking of disorders and serve only as an initial step to guide
decision-making; analysis of the evidence base for the score
needs to be included in the decision-making process.
Conditions then were redistributed between the core panel
and the secondary target category on the basis of the evidence
relatedtotheavailabilityofanefficacioustreatmentandawell
understood natural history. Other conditions were moved
from the “not appropriate for newborn screening category” to
secondary targets if they were revealed by the multiplex tech-
nology used to identify core panel conditions. SCAD, IBG,
ARG and DE RED were moved into the secondary target cate-
gory on this basis. Among conditions initially placed in the
corepanelcategoryonthebasisofthesurveyscore,CPT-IIwas
shiftedtothesecondarytargetcategoryonthebasisofthelack
of a proven efficacious treatment. Several conditions were
moved to the secondary target category on the basis of scien-
tific evidence indicating that the natural history was not suffi-
ciently well understood. These include TYR-II, GA-2, and
M/SCHAD.GALKdeficiencywasmovedtothesecondarytar-
get category on the basis of the relatively limited burden of
disease and the fact that a second test is usually required to
screen for the condition. G6PD was moved to the category of
conditions not recommended for newborn screening because
of a limited knowledge of the natural history of the mutations
in the G6PD gene found in the United States. There is also
limited knowledge of the implications of these mutations with
regard to development of severe hemolytic disease in the
United States population. Additionally, because G6PD is not
identified in the course of screening for other core conditions,
it was not placed in the secondary target category. Finally, a
subset of conditions was identified for which carrier status
couldbeestablishedonthebasisofthescreeningtestresultand
for which reporting is considered appropriate. These include
MCAD, VLCAD, Hb-pathies, 3MCC, CUD, and CF.
The next group of conditions includes those that are clini-
cally significant and are part of the differential diagnosis of a
conditionlistedinthecorepanelorthatarerevealedthrougha
multiplex technology. Note that secondary hemoglobinopa-
thiesarerevealedinthescreeninglaboratorywhilemostothers
arerevealedinthediagnosticsettingduringfollow-up.Table8
lists the conditions in this secondary category. Table 5 shows
the relationships among many of the core conditions and the
conditions included in their differential diagnoses (or second-
ary targets). In particular, some of the metabolic conditions in
this group are characterized by having a sensitive and specific
test, but a deficiency in the availability of an efficacious treat-
mentorlimitedknowledgeofthenaturalhistoryofthecondi-
tion, although there may be sufficient knowledge to justify the
reporting of test results to the family and health care provider
of the infant.
The recommendation to report all clinically significant re-
sults is an approach similar to that taken for hemoglobinopa-
Table 8
The secondary target condition panel
SECONDARYTARGETS
6OA 8FAO 8AA 1HbPathies 2Others
Cbl C,D* SCAD HYPER-PHE Var Hb* GALK*
MAL GA2 TYR II GALE
IBG M/SCHAD BIOPT (BS)
2M3HBA MCKAT ARG
2MBG CPT II TYR III
3MGA CACT BIOPT (REG)
CPT IA MET
DE RED CIT II
Codes are as listed in Table 4. OA, disorders of organic acid metabolism; FAO, disorders of fatty acid metabolism; AA, disorders of amino acid metabolism; Hb
Pathies, hemoglobinopathies. (*) Identifies conditions for which specific discussions of unique issues are found in the main report.
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technologies of choice in many laboratories for hemoglobi-
nopathyscreeningareIEFandHPLC,whichcandetectthefull
range of more than 700 hemoglobin variants, including those
in the core panel, for which clinically significant variants are
reported.36 By handling hemoglobinopathies in a way similar
to the acylcarnitine and amino acid disorders screened for by
MS/MS,theexpertgroupwasleftwithamuchsmallergroupof
conditionstoconsiderindependentlyforscreeningsuitability.
Theseconditionshaveadequatescreeningtestsandefficacious
treatments, but they are detected by methods other than MS/
MS, and usually as singleton tests.
Table9liststheconditionsthatweredeterminedtobewith-
out a screening methodology that has been adequately vali-
datedforgeneralpopulation-basedscreening.Kernicterusrisk
as determined by the identification of hyperbilirubinemia
standsoutinthisgroupasbeingaveryhighscoringcondition.
Figure 8 shows the distribution of conditions into the: core
panel (29 conditions); secondary target category (25 condi-
tions); no test available (23 conditions), those excluded from
newborn screening categories due to other inadequacies in
meetingthecriteria(4conditions),andthethreeconditionson
which we deferred decision-making.
Selectedconditiondiscussions
The following conditions represent a group for which there
was either deviation from the adopted data processing plan or
for which unusual issues justify additional discussion. It is im-
portanttorealizethatthedataonthelaboratorysensitivityand
specificity of many conditions identified by MS/MS is subop-
timal, though it was sufficient to lead the expert group to clas-
sify them as it has done.
Congenital Adrenal Hyperplasia (CAH)
Table7CAHincludesanumberofformsofthedisease.The
most common is 21 hydroxylase (21-OH) deficiency, which
accountsfor95%ofcasesandisthegeneralformthathasbeen
considered. The primary marker used in newborn screening
for21-OH,17-hydroxyprogesterone(17-OHP),ismostsensi-
tive in identifying infants with the severe salt-wasting form in
whichelevationsareveryhigh.Thedegreetowhich17-OHPis
elevated in the nonsalt-wasting forms is variable. Hence, sen-
sitivityindetectingthisformbynewbornscreeningisreduced.
The 21-OH forms of CAH were not subdivided as were the
hyperphenylalaninemias because the forms of 21-OH are
caused by the same gene. However, many programs consider
the identification of newborns with the nonsalt-wasting form
to be a by-product of screening for the primary target, the
salt-wasting form. In the salt-wasting form, most virilized fe-
males should be clinically detectable because of “ambiguous
genitalia” or as virilized females. However, it is important to
identify the males by screening to prevent early morbidity and
mortality. The other CAH types found in the remaining 5% of
patientsarenotdetectablegenerallybycurrentscreeningstrat-
egies.
Galactokinase Deficiency (GALK)
Table 8 Galactokinase deficiency scored 1,286 points in the
analysis. However, the only consistent phenotype is cataracts.
Further, in order to screen for GALK, an additional test is re-
quired. Most screening laboratories include a combination of
the Beutler fluorescent spot screening test and a fluorometric
or bacterial inhibition assay for total galactose. Because GALK
is very rare and is part of the differential diagnosis of GALT, it
has been designated as a secondary target.
Glucose 6-Phosphate Dehydrogenase Deficiency (G6PD)
Table 9 G6PD deficiency is included in newborn screening
programsinsomecountries,particularlyinAsiaandtheMed-
iterranean, where it is the most common enzymopathy. New-
born screening programs in the Philippines and in Taiwan
havereportedincidencefiguresof1in65.IntheUnitedStates,
G6PD screening is provided as part of the screening panel for
the District of Columbia – the only program to mandate and
provide screening for G6PD deficiency (Missouri has man-
datedG6PDscreeningbuthasnotyetimplementedthescreen-
Table 9
Conditions for which Newborn Screening is NOT Indicated at this Time
MS/MS
Acylcarnitines Amino acids
OA FAO AA Hb Pathies Others
No Test
CPT-1B OTC HPRLBIL FX
CPS FHC CDG-1b
SCID SLO
IDDM ALD
GAMT MPS-1H
WD FABRY
AGAT CR TRANS
NB LSD
TURNER POMPE
BIL KRABBE
Excluded
ADA
A1AT
DMD
G6PD*
Deferred
HIV
TOXO
CMV
CodesareaslistedinTable4.OA,disordersoforganicacidmetabolism;FAO,
disorders of fatty acid metabolism; AA, disorders of amino acid metabolism;
Hb Pathies, hemoglobinopathies. (*) Identifies conditions for which specific
discussions of unique issues are found in the main report.
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which the risk factors (e.g., ingestion of fava beans, infections,
and drugs such as sulfonamides and antimalarials) associated
with G6PD status are more common and in which the preva-
lence is higher (e.g., tropical Africa, Middle East, tropical and
subtropical Asia and in some areas of the Mediterranean).
There is very limited data available from any screening pro-
gram in the United States, and the opinion of hematology ex-
perts is that the variants that exist in the United States African
American population are clinically benign unless the individ-
ual is in a severely compromised (i.e., oxidized) state, usually
resulting from drug exposure./ Additional data are needed
from programs now screening for G6PD before this condition
canreasonablybeconsideredforinclusioninamandatedcore
panel of screening conditions. Programs currently screening
for G6PD are encouraged to collect and publish the data for
determining clinical relevancy and analytical specificity and
sensitivity of tests being used. Further, and as discussed below
in the context of hyperbilirubinemia, some conditions are not
mutuallyexclusive.Appropriatemonitoringandmanagement
ofjaundicecouldidentifythosecasesatriskforKernicterusor
biliary atresia.
Hemoglobinopathies (Hb Pathies)
Table 8 Hemoglobinopathies are screened by HPLC or IEF
inmostprograms.Theprimaryfocusofthereviewofscientific
literature was on sickling disorders, since they have been the
primarytargetsofnewbornscreening.However,thereareover
700 hemoglobin variants identified by the methods used for
screening, and 25-30 are considered clinically significant.
Many of these conditions are associated with an Hb SS allele,
but not all. Among these variant hemoglobinopathies, Hb E is
by far the most common. The expert group agreed with the
current recommendations that all clinically significant hemo-
globinopathyvariantsbereportedtohealthcareprofessionals.
It is appreciated that there may be conditions that occur more
commonly in subpopulations, such as the case of Hb E in the
Hmong population, and that may alter local screening prac-
tices.
Homocystinuria (HCY)
Table 7 Homocystinuria is screened for by detection of an
elevated concentration of methionine, a secondary biochemi-
cal marker of the condition. The differential diagnosis of HCY
includes other defects of methionine metabolism, unrelated
liver disease, common dietary artifacts (total parenteral nutri-
tion), and analytical issues (lability of methionine internal
standard).37 Hence, screening for HCY has a lower sensitivity
than other amino acid disorders included in the core panel,
and requires special attention in result interpretation to mini-
mize the rate of false positive results. Although a primary
screening based on methionine is less than ideal, the identifi-
cationofnewbornswithapotentiallytreatableconditionwasa
determining factor for the high score assigned to HCY in the
survey and its inclusion in the core panel. This situation is
likely to evolve when a second tier test capable of measuring
total homocysteine in bloodspots becomes routinely available
by MS/MS or other methods; an improvement that will
strengthen the inclusion of HCY in the core panel.
Hyperbilirubinemia (HPRLBIL)
Table 9 Based on the responses of seven experts asked to
complete the data collection instrument, this was among the
highest scoring conditions. However, the expert group deter-
mined that there was not a screening methodology that was
sufficiently well validated in a large newborn population to
justify mandated universal screening at this time. Although
bilirubintestresultnomogramshavebeenvalidatedinsmaller
studies, the current nomograms are not sufficiently reflective
of the broad population. There are also risk factors for hyper-
bilirubinemia associated with other conditions such as G6PD
deficiencythatareassessedindependently.Additionally,inor-
der for bilirubin to be used as a marker of this condition, a
specimenwouldhavetobetakenandtestingwouldlikelyhave
to occur in the local nursery, because results would need to be
rapidly available based on current understanding of hyperbil-
irubinemia. Therefore, the question is raised whether this
shouldbeamandatednewbornscreenor,rather,beinstituted
asanappropriatestandardmedicalpracticeforanynewborn.38
Currently, universal testing for hyperbilirubinemia is not rou-
tinely conducted in most hospitals.
Methylmalonic Acidemia
Methylmalonic acidemia (MMA) exists in several etiologic
forms caused by defects of either the apoenzyme (MMA-CoA
mutase) or the biosynthesis of the coenzyme (adenosyl-cobal-
amin).Theformsassociatedwithacoenzymedefectmayover-
lap biochemically with acquired dietary deficiencies. The bio-
chemicalmarkerofMMAispropionylcarnitine.Overall,there
is credible evidence of less than ideal sensitivity with the cur-
renttestingtechnology(affectedcaseswithnormalconcentra-
tionwhentestedatbirth)andspecificity(relativelyhighrateof
false-positiveresults,includingcaseswithrelativelyhighlevels
that are followed up by perfectly normal plasma acylcarnitine
and urine organic acid profiles). It is likely that the introduc-
tion of a second-tier test capable of measuring methylmalonic
acidinbloodspotscouldimprovethesensitivityandspecificity
of newborn screening for MMA and reinforce the inclusion of
this condition in the core panel. Because newborn screening is
considered a program that extends beyond the screening test
itself, it was decided that the disorders characterized by an
elevated propionylcarnitine (mutase deficiency, cobalamin A,
B,C,andDdeficiencies,aswellpropionicacidemia)shouldbe
subdivided, particularly since they have quite different natural
histories and treatment options.
3-Methylcrotonyl-CoA Carboxylase Deficiency (3MCC)
Table7Thenaturalhistoryof3MCChasbeendrivenbythe
clinical ascertainment of patients presenting with severe acute
episodes. However, since newborn screening with MS/MS be-
gan, several individuals have been identified with the analytes
associated with the condition but without apparent clinical
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mal metabolites found in the neonatal bloodspot were of ma-
ternal origin, subjects who are usually biochemically affected
but symptom-free. All elements being considered, it is in the
best interest of newborns affected with 3MCC that the condi-
tion be identified in all cases. 3MCC was therefore included in
the core screening panel with the expectation that long term
follow-up will lead to a better understanding of this condition
and its clinical significance.
Tyrosinemia Type I (TYR I)
Table 7 TYR I is a condition caused by fumarylacetoacetate
hydrolase deficiency that presents with severe liver and renal
disease and peripheral nerve damage. If left untreated, most
patients die of liver failure in the first years of life. Treatment
with the drug NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-
1,3,-cyclohexanedione),diet,andlivertransplantarenowcon-
sideredtobeveryeffective.Newbornscreeningisbasedonthe
detection of an elevated concentration of tyrosine. There is
evidence of less than ideal sensitivity with the current testing
technology (affected cases with normal concentration when
tested at birth) and poor specificity (very high rate of false
positive results, mostly premature babies and newborns with
liverdiseaseofvariableetiology).Althoughtheintroductionof
a second-tier test capable of measuring succinylacetone in
bloodspots could improve the sensitivity and specificity of
newbornscreeningforTYR-I,thequestionofwhetheraffected
but asymptomatic newborns are being identified with any de-
gree of consistency remains to be answered. It is a general and
acceptedconcernthathepatorenaltyrosinemiamaynotbede-
tected by MS/MS analysis of tyrosine concentration alone.
However, TYR-I is included in the core panel for historical
reasons and because of the effectiveness of treatment. It re-
mains important not to exclude the diagnosis of tyrosinemia
on the basis of a screen negative result.
Limitationsofmethodology
Over the course of this project a number of limitations be-
came apparent. Conditions with limited available evidence re-
ported in the scientific literature were more difficult to score
and place in one of the three categories. Some conditions had
been reported in 10 or fewer families in the world, and for
other conditions, there were gaps in the evidence base in the
literature. Many conditions were found to occur in multiple
forms distinguished by age-of-onset, severity, or other fea-
tures. In most cases, decisions related to newborn screening
were based on the more severe and treatable forms of the con-
ditions.
The knowledge base about genetic diseases grows through a
common pathway and, unless a condition was already in-
cluded in newborn screening programs, there was a potential
for bias in the information related to some criteria. The most
severeformsofgeneticdiseasesareusuallythosefirstnoted.As
onemovesintothefamiliesoftheseprobands,thisbiastoward
severity is reduced. However, it is not until a large general
population has been studied that the true performance char-
acteristics of the various screening tests are appreciated. Be-
causemanyoftheconditionsunderconsiderationareveryrare
and the genetic etiologies may vary by ethnicity and other pa-
rameters, a population of considerable size is required to ac-
quire a broad understanding of the condition.
Due to the aforementioned limitations, expert opinion that
considered reasoning from first principles and the quality of
thestudiesunderlyingthedatacontributedsignificantlytothe
placement of the conditions into particular categories.
Numerous barriers to implementing an optimal screening
and follow-up program were identified. Recommended ac-
tionstoovercomethesebarriersincludetheestablishmentofa
national role in scientific evaluation of conditions and the
technologies by which they are screened, standardization of
casedefinitionsandreportingprocedures,enhancedoversight
of hospital-based screening activities, long-term data collec-
tion and surveillance, and consideration of the financial needs
ofprogramstoallowthemtodelivertheappropriateservicesto
the screened population.
Finally, there were limitations in both time and resources
available to accomplish a project as broad and comprehensive
as this. A large number of conditions commonly managed by
differingsubspecialistswereassessedand,duetotheirrarity,it
was not unusual that there may only be a handful of acknowl-
edged experts of particular conditions in the world. It was also
necessary to include a significant number of experts not di-
rectlyinvolvedintheexpertgrouporitsworkgroups.Inorder
to broaden the number of individuals from whom we might
draw for assistance with data collection and validation, it was
necessary to consult with international experts.
In many ways, the analyses done under this project provide
a current snapshot of the knowledge base from which recom-
mendations are drawn. Decisions were made as to the ade-
quacy of the evidence on which the recommendations are
based. However, as is common for rare diseases, the acquisi-
tionofnewknowledgeisongoingandlong-termsurveillanceis
needed to ensure that the evidence continues to support the
recommendations.
Decisionmakingforconditionsbeingevaluated
A primary consideration in evaluating conditions is the
availability of the test. The parameters that determine “avail-
ability” are numerous and vary considerably among condi-
tions.Itisalsodifficulttocomparetestsbecauseofthediffering
“value” of a technology (e.g., multiplex capability, appropri-
atenessofthesitetoconductthescreeningservice).Theexpert
groupconsideredwhetherthetestsareamenabletoascreening
laboratory; for example, some tests are functional, such as
those for hearing screening, and must be performed in the
nursery. Other tests may have significant time constraints and
arethereforebetterconductedinthehospitalorbirthingfacil-
ity laboratory, as would likely be the case for bilirubin screen-
ingforkernicterusrisk.Italsoshouldbenotedthatsomeofthe
conditions considered by the expert group did not meet the
criterionthatthetestmustbeperformedinthe24-to48-hour
period after birth (e.g., Wilson disease, familial hypercholes-
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ders of glycosylation, Turner syndrome screened by FSH lev-
els). However, such conditions may be appropriate for
screening at a later time in infancy or later in childhood. Al-
thoughearlyandcontinuousscreeningofinfantsandchildren
is a critical public health goal—as is lifelong screening—the
expert group analysis was limited to conditions that should be
and could be evaluated some time within the first few days of
life. For the most part in the United States, the focus of tradi-
tional newborn screening programs has been on disorders de-
tectable in the first 12 to 48 hours prior to discharge from the
nursery. As such, the analyses were all predicated on testing
done during this time frame. Initial screens in the neonatal
period (i.e., first 28 days of life) would constitute a separate
program with different costs and yields of cases and therefore
should be separately analyzed.
Within this framework, the basis for decision-making as
shown in Figure 9 starts with whether a screening test is avail-
able, a criterion without which decisions to screen cannot be
made.Clearly,thefirstdecisiontoscreenisbasedontheavail-
abilityofasensitiveandspecificscreeningtestthatcanbedone
in the 24- to 48-hour interval after birth. However, there is
occasional disagreement as to whether a test is adequately val-
idated for use in general populations. Hence, survey respon-
dentsmaynotnecessarilygivea200-pointscorebutmaygivea
score between zero and 200. We defined the existence of the
screening test as corresponding to a score between 100–200
points.Conditionsdeterminedtohaveascreeningtestarethen
evaluated with respect to the criteria.
Understanding that the evidence for each criterion needs to
be evaluated, conditions with validated scores, scoring above
1,200 are considered appropriate for inclusion as primary tar-
getsinascreeningprogram.However,theexpertgroupdistin-
guishes between those that are primary target conditions and
those that are included in the differential diagnoses for those
primary target conditions. Those with tests available and scor-
ingbetween1,000and1,200aresecondarilyreconsideredasto
whetheranefficacioustreatmentisavailableand,ifso,theyare
thenreconsideredastowhetherthenaturalhistoryofthecon-
dition is well understood. If one of these is answered “no” but
theconditionispartofthedifferentialdiagnosisofacorecon-
dition, it is placed in the secondary target category. If it is not
part of the differential of another core panel condition, the
condition would not be considered appropriate for newborn
screening at this time. Conditions falling between 1,000 and
1,200 are also considered appropriate for the secondary target
category while those with an overall score under 1,000 are not
considered appropriate for newborn screening at this time. At
the bottom of the algorithm, the expert group acknowledges
thattherearecurrentlysignificantresearchstudiesandclinical
trials in process involving screening tests and therapeutics for
diseases that might make the condition amenable to newborn
screening(e.g.,lysosomaldisorders).Theinformationthatde-
termined the current recommendation of the expert group is
not static. Conditions not considered appropriate for the core
panel at this time should be reevaluated periodically to deter-
mine if their status has changed.
Thedatacollectioninstrumentusedinthisprojectprovides
information on only one aspect of a broader decision-making
process required for evaluating conditions and establishing a
uniform newborn screening panel (see decision tree in Fig. 9).
There are also features of tests, such as costs, that are not fac-
toredintothisdiagramthatStatenewbornscreeningprograms
may take into account. The algorithm can be used prospec-
tively as a tool to evaluate conditions for their appropriateness
for addition to or removal from a screening panel (Appendix
2). Reference information about each condition the expert
group evaluated and the summary information can be com-
pared to the results of an independent assessment of a condi-
tion. Review of the scientific literature should be conducted
and expert opinion should be gathered for any condition eval-
uated.Thepreferenceistousedatafromtheliterature.Forthe
most subjective criteria, expert opinion is supplemented with
theviewsofindividualsinvolvedwithnewbornscreeningpro-
grams and child health professionals and families.
Reportingresponsibilities
Manyfactorsaffectthedecisionsaboutreportingofindivid-
ualtestresultsmadebylaboratoriesandprograms.SomeState
newborn screening programs report directly to child health
professionals, while others report to designated subspecialists.
Some also report test results to families. Reporting also varies
according to whether the results are screen-positive or screen-
negative. As noted earlier, all results of likely clinical signifi-
cance that are apparent in the testing platforms targeting spe-
cific conditions should be reported. As recommended by the
SickleCell,ThalassemiaandOtherHemoglobinVariantsSub-
committee of CORN (1995), each screening program should
developguidelinesforfollow-upofcarriersofallclinicallysig-
nificant conditions. This currently includes hemoglobinopa-
thiesandalsowouldnowapplytoCF,becauseforbothcondi-
tions the primary- or second-tier tests reveal carrier status.
Similarly, second-tier testing for molecular causes of MCAD
and other disorders can lead to the identification of carriers of
the conditions (for autosomal recessive disorders). The differ-
ences in expectations between the conditions in the core panel
and those in the secondary target category should be noted.
Inherent to conditions in the core panel is the need to maxi-
mize detection in screening while minimizing excessive false
positivesbeingreferredintothehealthcaresystem.Forcondi-
tions in the core panel that are positive on screening due to
specificanalytesbeingelevated,thesecondarytargetsareiden-
tified in the diagnostic laboratory. It was on the basis of firm
knowledge about these conditions that most decisions were
made. The identification of conditions in the secondary target
categoryisbasedonthefactthatresultsareavailableduetothe
multiplex or multianalyte nature of the screening technology
used. However, it does not presume that screening tests have
been maximized for the detection of these conditions or that
the knowledge base is sufficient to have developed an expecta-
tion of maximum health outcomes following interventions.
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about following patients after initial screening and reporting.
For instance, false-positives are treated as true positives until
proven otherwise. However, once shown to be a real false-
positive result, the State newborn screening program often
treats the infant as they would a screen-negative infant, with-
outpursuingfurtherfollow-up.Theexpertgroupbelievesthat
this situation warrants additional postconfirmation decision-
making but acknowledges that the programs must minimally
understand final diagnoses in order to discriminate false-pos-
itives from real-positives for these “secondary” targets.
State programs must decide whether the individual preva-
lence,costsandburdensofidentifyingtheseadditionaldiseas-
es—which may not be treatable and may take resources away
from the treatable diseases originally targeted through these
programs—can justify their inclusion in the program. They
also must take into consideration the issues raised by child
health professionals who will receive results about very rare
conditions about which they have limited knowledge. Regard-
less of whether the State newborn screening program chooses
to integrate secondary target cases into their full newborn
screeningprogram,itisimportantthatanorganizedsystemof
datacollectionandsurveillancebeavailable.Theissuesinnew-
bornscreeningaresimilartothosethattheFDAhasfacedwith
therapeutics for rare diseases, in which a shift toward phase IV
(postmarket) surveillance during clinical trials has emerged.
This shift recognizes that the most critical data about genetic
diseases arise in the context of full population analysis. How-
ever,clinicaldataaboutthe“normal”populationisveryscarce
because the research focus has been on those with disease and
on the diseases themselves. The significant variability inherent
in genetic diseases requires significant knowledge of the ex-
pressionofgeneticvariantsinageneralpopulationbeforethey
arewellunderstood.Suchdatacollectionhasnotbeenaprior-
ity of funding agencies.
E. Summary
Significant variability exists in the types of newborn screen-
ing available and the conditions screened across the United
States. This project was intended to evaluate the scientific and
medical evidence in order to identify conditions appropriate
for newborn screening. After articulating overarching princi-
ples to guide decision-making, the current practices and sys-
tems in the States/regions and other countries were assessed.
Allanalysesweredonefromtheperspectiveofnationaldata,
since one of the goals of the project was to bring standardiza-
tion and uniformity to newborn screening. It is appreciated
thatsomeconditionsmayoccurmorecommonlyinsubpopu-
lations, such as is the case for IBG and HbE in the Hmong
population, and that that may alter local screening practices.
Criteria were defined that would be used to compare the
manyconditionsunderconsideration.Thescientificliterature
relatedtoeachcriterionwasreviewedforeachof84conditions
and the opinions of at least three acknowledged experts for
every condition was evaluated. At the first level of analysis, an
assessment was made as to the availability of a screening test
that had been validated in a large general population. Scores
were then established for each condition and they were as-
signed to one of three groups:
1. Core Panel (shared in common a high score [1,200],
the availability of an efficacious treatment, a knowledge
of natural history adequate for inclusion in a public
health screening program);
2. Secondary Targets ([1,000–1,200] conditions that are
part of the differential diagnosis of a core panel condi-
tion); and
3. Not Appropriate for Newborn Screening ([1,000] ei-
ther no newborn screening test is available or there is
poor performance with regard to multiple other evalua-
tion criteria).
Thescientificevidencewasoverlaidonaninitialcategoriza-
tion of conditions to ensure that all conditions in the core
panel had a sufficiently well understood natural history and
that an efficacious treatment was available.
The expert group recommends that State newborn screen-
ing programs:
1. Mandate screening for all core panel conditions defined
by this report;
2. Mandatereportingofallsecondarytargetconditionsde-
finedbythisreportandofanyabnormalresultsthatmay
beassociatedwithclinicallysignificantconditions.Some
are identified in screening laboratories (e.g., hemoglobi-
nopathies) and others in the diagnostic laboratory (e.g.,
MS/MS screened conditions). Clinically significant con-
ditionsalsoincludethedefinitiveidentificationofcarrier
status;
3. Maximize the use of multiplex technologies; and
4. Consider that the range of benefits realized by newborn
screening includes treatments that go beyond an infant’s
mortality and morbidity.
SECTION II: THE NEWBORN SCREENING SYSTEM:
PROGRAM EVALUATION, COST-EFFECTIVENESS,
INFORMATION NEEDS, AND FUTURE NEEDS
A. The newborn screening system
In order to successfully expand the number of mandated
disorders screened for in newborns, the full breadth of the
screening process and its components must be fully opera-
tional.ThustheexpertgroupanditsDiagnosisandFollow-up
WorkGroupsoughttoexaminethecurrentstatusofscreening
systems throughout the United States, with particular atten-
tionpaidtothediagnosisandfollow-upcomponentsandtheir
interface with the newborn screening program and primary
healthcareprofessionals.Inaddition,thegroupwasinterested
in identifying the key components of screening and highlight-
ing some best practices that appear to improve outcomes. The
six components of the newborn screening process that were
assessed are:
1. Education, including prenatal education;
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3. Follow-up, including result reporting;
4. Diagnostic confirmation;
5. Management; and
6. Program evaluation and continuous quality improvement.
Much of the information reported in this section was ob-
tained from a survey of State newborn screening programs
conducted by the NNSGRC and reported at a November 2002
meeting sponsored by HRSA/MCHB and University of Cali-
fornia, Los Angeles (UCLA), entitled “Educating Parents and
the Informed Decision-Making Process Regarding Newborn
Screening Procedures and the Use and Storage of Residual
Bloodspots.” NNSGRC has updated this information through
June 2004.
Education
Asscreeningincreasesthereisagrowingneedforeducation
acrossallgroupsofconstituents,includingparentsandguard-
ians, obstetrical providers, infants’ medical homes, pediatric
specialists, and emergency room/labor-delivery/neonatal in-
tensivecareunit(NICU)staffs.Educationshouldoccurinsev-
eral places and times in the screening system, appropriate to
the needs of patients, families, and health professionals.
Newborn screening programs typically provide educational
materials during the perinatal period. The materials include
information about newborn screening in general and brief de-
scriptions of the conditions that are screened. Nineteen of 50
programs indicated that distribution of their newborn screen-
ing brochures was mandatory in birthing hospitals. Only one
program reported not having an informational newborn
screeningbrochure.Allbutthreeofthe50programsindicated
that their brochures included a list of disorders screened, and
all but two described the specimen collection procedures and
timing. Twenty provided information about when results
would be available, 31 discussed the manner in which the re-
sultswerereportedtophysicians,and36indicatedhowparents
might obtain these results. As the number of conditions in-
cluded in screening continues to expand, there has been a
move toward providing more general information about the
types of conditions screened rather than detailed information
about each condition.
PrenatalEducation
Few programs actively support education programs about
newborn screening during the prenatal period. Ten of 50 State
programsreportedthatnewbornscreeningbrochurestypically
were distributed in obstetrical offices, and 14 of 50 indicated
that there was routine distribution in birthing classes. No in-
formation was available concerning quality, readability or un-
derstanding of the brochure information. The growing num-
ber of conditions for which newborn screening can be
expected, combined with the existing limitations (e.g., famil-
iarityofchildhealthprofessionalswiththenewbornscreening
system) to delivering education during the perinatal period,
argues for a focus on enhanced education during the prenatal
period. This area of need is currently being addressed by
HRSA/MCHB through a contract with UCLA.
Screening
The timing of specimen collection and delivery to laborato-
ries also varied. According to the NNSGRC 2000 National
Newborn Screening Information Report, which included in-
formation from 28 programs at the time of this report, 74% of
newbornswereknowntohavebeenscreenedpriorto48hours
of age and 22% were screened after 48 hours. Twenty-two
States reported that 2.7% of infants were screened prior to 12
hoursofage,and12.2%werescreenedbetween12to24hours
of age. In several States as many as 30% to 40% of infants were
screened between 12 and 24 hours of age. These timing issues
mayhavedirectimplicationsforthepredictivevaluesoftesting
for some conditions.
Information about the timing of specimen delivery to labo-
ratories was not readily available. The majority of programs
relyontheUnitedStatesPostalServiceforspecimentransport,
withservicevaryingfromovernightdeliverytouptoaweekin
some areas. Most specimens arrive in the laboratories within
72 hours. However, in United States territories, such as Guam
andStateswithrelativelyisolatedandruralpopulations,deliv-
ery may take a week or more. It is suggested that specimens be
transported by courier services that allow for receipt at the
testing laboratories within 24 hours.
The timing of specimen collection and delivery is variably
tracked. For diagnosed cases, programs generally record date
ofbirth,dateandtimeofspecimencollection,dateofreceiptin
thescreeninglaboratory,dateoflaboratoryreport,anddateof
diagnosis. However, since establishing an etiologic diagnosis
may be an iterative process that increasingly refines diagnosis,
it can be difficult to define the time at which “diagnosis” is
established. The date when initial diagnostic tests are ordered
has been used as a substitute for date of diagnosis. Some pro-
grams monitor the date of initiation of treatment, but varia-
tions in the treatments for different conditions and the ten-
dency to institute low-risk treatments in ambiguous,
nonclassical cases renders this less useful unless viewed in the
contextofindividualdiagnoses.Mostnewbornscreeningpro-
grams presently operate on a 5-day work week. Some condi-
tions can be life-threatening (e.g., MSUD, CAH, GALT, or-
ganic acidurias, fatty acid oxidation disorders, urea cycle
disorders) within a few days after birth, so it is desirable to
initiate specimen processing within 24 hours of specimen re-
ceipt in the laboratory, with a 5-day turnaround time between
birth and the availability of the test results. However, it should
beemphasizedthatdetectionofdiseaseinthepresymptomatic
phase is one of the basic principles and values of screening.
The handling of screen-positive cases also was evaluated.
Essentially, all newborn screening laboratories utilize a fol-
low-upcoordinatorforreportingandtrackingscreen-positive
results.Forthemostpart,apositiveresultisreportedonlyafter
the laboratory has verified the original finding through a sec-
ond analysis of the original specimen. However, for some of
the most time-sensitive conditions characterized by short-
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isovaleric acidemia, MCAD, maple syrup disease, and some of
theothermetabolicdiseases),preliminarypositiveresultsmay
be reported prior to repeat testing. These results are generally
reported by telephone to the health professional identified by
thenewbornscreeningsubmittalformorbythebirthingfacil-
ityand/orthenewbornscreeningconsultant.Theexpertgroup
recommendsstandardizationofreportingprocedures,includ-
ing:theresult,thereferencerange,thenatureoftheabnormal-
ity, and an indication of the speed and progression of clinical
symptoms in the absence of intervention.
Screen-negative cases are often handled quite differently
from the screen-positive cases. Some programs group normal
results for batch reporting, waiting until all assays have been
completed. Among the more significant potential problems
identified in reporting of results is the risk of interpreting
screening results as equivalent to diagnostic testing results.
Screeningresultsthatareinthenormalrangemaynothavethe
samenegativepredictivevalueasisthecasefordiagnosticspec-
imens obtained due to symptoms.39 Additionally, it is increas-
ingly apparent that age (developmental, chronological) and
condition(acuteaffected,feedingstatus,transfusionstatus)of
the newborn when the specimen was collected can affect the
test results and their interpretation.40
Further, the use of general terms such as “amino acids nor-
mal” or “acylcarnitines normal” in reporting of screen-nega-
tive results is an issue. The general lack of knowledge among
clinicians of newborn screening programs and the screened
conditionsmakesthesetypesofresultsnotuseful.Ontheother
hand,cliniciansmaynotwanttotakethetimetoreadthrough
long, detailed, normal reports. A report indicating all that was
normal in an MS/MS screening profile could require consid-
erable information to reflect the varying degree to which dif-
ferent conditions had been ruled out. At the same time, it can
bearguedthatdetailedreportsarenecessary.Forexample,ifan
infant moves from one State to another that has a different
screening panel, the results may be misinterpreted if they refer
toageneralgroupoftestsratherthanbeingdelineatedbycon-
dition.
The fact that two categories of screening tests and result
reporting are proposed also complicates this issue. States vary
in which primary-target conditions they choose to detect and
the technology they use to detect them. In addition, there is
variability in the testing strategies (e.g., use of second tier test-
ing) and the cutoffs the program chooses to define cases. Di-
agnosis and Follow-up continues to consider these reporting
issues.
Mostprogramsreportscreened-negativeresultstotheloca-
tion identified on the newborn screening collection card,
whichinmanycasesisthehospitalofbirthandnotnecessarily
the infant’s medical home. It has been observed in NNSGRC
reviews of newborn screening programs that many hospitals
do not routinely track the results and when the test results
arrive at the hospitals, they are simply filed in the medical
records without review. In addition, the tracking of newborn
screening results to ensure that results are obtained on all
screened newborns, while desirable, is not a uniform hospital
practice.Asscreeningexpandsforthepediatricpopulation,the
medical home should consider incorporating verification sta-
tus of newborn screening results and keep such records easily
accessibleinamannersimilartothoseusedforpostingimmu-
nization status to medical records. Recent efforts by HRSA/
MCHB to support the development of integrated and linked
informationsystemsthatincludenewbornscreeninginforma-
tion for health care providers’ direct access is an important
development that may improve communication of screening
results to the medical home and other appropriate health care
facilities for the newborn. Additionally, national standards for
the reporting of newborn screening results should be consid-
ered(similartoACMGguidelinesforprenatalDNAandother
test report guidelines).
Theuseofsecond-orthird-tiertestingalsowasaddressedin
the work group’s assessments. This practice is fairly common
in newborn screening laboratories. Almost all States use a sec-
ond-tiertestforCH,eitherT4orTSHdependingonwhichwas
usedintheinitialscreen.Thesesecond-tiertestsarecommonly
done on the original bloodspot sample and are distinguished
from repeat testing, which involves repeating the same test on
theoriginalspecimen,orsecondteststhatrequireafreshsam-
ple.Someprogramsuseasecond-tierfluorometrictestfollow-
inganinitialbacterialinhibitionassayforPKU.DNAtestingas
asecond-tiertesttodetecthigh-frequencymutationsisdonein
someprogramsforCF,hemoglobinopathies,MCAD,LCHAD
and galactosemia, and some are considering second-tier test-
ing by MS/MS for CAH. With expanded newborn screening
(includinghearinglossscreening)identifyingasmanyas1:250
newborns who will require diagnostic confirmation (B. Ther-
rell, personal communication), the need to assess the capacity
of the follow-up system is apparent.
Procedures for repeat testing in the newborn screening lab-
oratory on the original bloodspot also were assessed. Essen-
tially all newborn screening testing laboratories employ a QA
step of retesting the original spot to confirm preliminary pos-
itive results. Some laboratories use a different method on sec-
ond tests as a QA check. Retesting original bloodspots is dis-
tinguished from second-tier testing using a different test, and
also from repeat screening, which uses a new specimen on
which confirmatory testing is done. Routine repeat screening
of all newborns is required in eight States, and several others
strongly suggest second screening. There are specific circum-
stances (e.g., unsatisfactory specimens, acutely ill newborns in
the NICU) under which repeat screening is commonly re-
quired.Becauseofthepossibilityofbiologicfalse-positives,29
Statesrecommend/requireasecondspecimeniftestedpriorto
24 hours of age and seven States require a second specimen if
thenewbornistestedbefore48hoursofage.False-positivesfor
CH and CAH are common in premature infants but can be
dealt with through retesting when the infants are a few days
olderandtheirendocrinesystemsaremoremature.Improved
testing specificity on the initial specimen also can be achieved
byusinganomogrammorespecifictothegestationalageofthe
infant. False-negatives are the greater concern, since they may
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for CH report finding 5% to 15% of their total caseload
throughthesecondtest,butthesecaseshavenotbeenstudied.
Thisnumberisreducedbyabout50%whenTSHisusedasthe
initial screening analyte. Over half of the cases of the classical
simple virilizing form of CAH may go undetected on an initial
screen due to biological factors.
ReportingandFollow-up
Follow-up is the term commonly used to describe the pro-
cess of reporting abnormal screening results to the medical
home, specialist, and/or guardians/parents and the initiation
and tracking of the next steps in evaluation. Follow-up can be
divided into two categories, short- and long-term follow-up.
Short-term follow-up includes those activities that ensure all
infants are screened, abnormal results are appropriately and
expediently handled, and affected infants are promptly identi-
fied, appropriately referred, and treatment initiated where ap-
plicable.Long-termfollow-upextendstheperiodoffollow-up
substantially to monitor continuously the medical manage-
mentandcarecoordinationofthoseaffectedwhorequiresuch
services. Long-term follow-up also allows assessment of effi-
cacy, sustainability, and safety of early treatment intervention,
andcanuncovernewdisease/treatmentoutcomes,andisvalu-
able for demonstrating utility or limitations of screening.
Newborndriedbloodspotscreeningfollow-upgenerallyhas
functioned independently of newborn hearing screening fol-
low-up, although many aspects of the follow-up procedures
are similar and sometimes duplicative in terms of effort. Pro-
grams should minimize the number of places to which health
care professionals must go to get information about their pa-
tients.Advancesininformationtechnologywouldallowdirect
and immediate access to screening test results, benefiting in-
fants, health care professionals and screening programs. The
experience of the newborn dried bloodspot programs could
inform the hearing screening programs that have significant
loss to follow-up of patients.
There is also some variation in how programs follow-up
unsatisfactory specimens. Some State laws and program regu-
lations place the responsibility for a satisfactory specimen on
the specimen submitter. In such cases, the program tends not
to pursue unsatisfactory specimens, electing to let the submit-
terperformitsresponsibilitytotheprogram.Itisnotclearthat
such practices had any impact on the liability issues that seem
to have been the reason for such program practices to have
arisen. In other cases, programs exercise their follow-up re-
sponsibilities in much the same way as they handle screen-
positive cases. CLIA regulations require that a testing labora-
tory show that it has a procedure for improving specimen
submissions in instances where there is unsatisfactory perfor-
mance on the part of the specimen submitter.
Inadequate demographic information (e.g., patient’s name,
weightorageatthetimeofcollection)alsomayrenderaspec-
imen unsatisfactory. Most programs lack a strict enforcement
policy regarding specimen rejection related to their rules gov-
erning certain demographic information. Often the initial re-
sponsibilityfordeterminingtheacceptabilityofthespecimen’s
demographic information falls to the clerical personnel per-
forming the check-in process.
In order to improve the overall quality of specimens pro-
vided to newborn screening laboratories, the best approach is
to minimize the number of unsatisfactory specimens and to
ensure that an appropriate submitter education program is in
place. It is best to have a designated person responsible for
monitoringthequalityofinfantdemographicinformationand
for ensuring that accurate and complete information is part of
atotalqualitymanagementapproachtolaboratoryoperations.
Compliance with requests for specimen demographic infor-
mationmustbemonitoredandactionmustbetakenregarding
noncompliance.
MostlargeStatesusecomputerizedfollow-upsystems.Because
these systems can be adapted to automated error surveillance,
programs are encouraged to pursue routine quality checks using
their computer systems. In the few States with computer gener-
atedsubmitterprofiles,theprofilesareusedtoimprovethequal-
ity of specimens and information submission by, for example,
monitoring periodic error rate reports. Those using computer-
izedreportingandtrackingsystemshavereportedimprovements
on the part of submitters when profiling reports are used and
submitters receive feedback from the reports.
In the event of a screen-positive result, most programs rely
on information submitted with the newborn screening speci-
men to identify the newborn’s physician or medical home.
However, many newborns lack an identified child health pro-
fessional at the time of release from the hospital. Often, the
demographic information submitted with the specimen lists
the nursery physician or on-call physician as the physician of
record. Although identifying the appropriate child health pro-
fessional may be a challenge, most newborn screening pro-
gramsattempttomeetthischallenge.Contactwiththesubspe-
cialistsisusuallyeasier,sincethegroupissmallerandisusually
more intimately involved with the newborn screening pro-
gram.Intheinterestoffurtherclosingthegapsinthesystem,it
wouldbeusefulifhospitalswereabletoensurethatafollow-up
appointment has been made for all newborns prior to their
hospital discharge. At a minimum, the hospital nursery staff
should work with families to identify the infants’ medical
homesandensurethatcontactinformationforallinfantsisup
to date.
Once the screen-positive case has been referred into the
health care system, most programs have follow-up protocols
that include tracking the patient until treatment has been ini-
tiated. Some programs subcontract this responsibility to re-
gional medical centers and do not actively pursue this infor-
mation, having transferred the responsibility for this in their
contracts. However, this practice may complicate ready access
to short- and long-term information that would be useful for
program evaluation. Some States are developing systems that
allowinformationintegrationandprogramlinkagetoimprove
tracking of screening results and patient outcomes. For exam-
ple, some use bar codes that link newborn screening filter pa-
per cards with birth certificates, and others have considered
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of the medical record where vaccination information is placed
to facilitate monitoring. In any case, a plan should be in place
for exhaustive and documented confirmation of follow-up.
Follow-upcoordinatorsshouldlinkrepeatspecimenstoinitial
specimen records, and all programs should obtain short- and
long-term follow-up information.
A variety of methods of screen-positive results notification
have evolved within newborn screening. In most programs,
once the follow-up coordinator has provided results to the
child health professional, the child health professional or a
member of his or her staff informs the family of the screening
results. Some programs notify both the child health profes-
sional and the family. Education is an important aspect of the
notification of parents and health care professionals. Some
States have developed culturally and linguistically appropriate
educationalmaterialsforfamiliesbutthereislimitedavailabil-
ity of similar materials for child health professionals and spe-
cialists.
Once the family is informed of the test results, the child
health professional determines the need for and extent of sub-
specialty involvement, unless the program’s follow-up is con-
ducteddirectlythroughsubspecialists.Notallconditionshave
similardemandsforthetimelinessorcomplexityoffollow-up.
Theavailabilityofinformationalmaterialsforchildhealthpro-
fessionals that would facilitate their ability to participate ac-
tively in a collaborative management approach to their pa-
tients’ care would be useful. Such information could include
immediate management issues and relevant subspecialist re-
ferral sites. The work group on Diagnosis and Follow-up de-
veloped templates for such informational materials that have
been pilot tested at limited sites. They are the basis of ongoing
work developing templates for all conditions in the core pan-
els,aswellasthoseinthesecondarytargetcategory.(Examples
of these templates can be found in Appendix 3.) Although
guidelines for immediate management could be readily devel-
oped,thereislittlestandardizationofparametersbywhichone
would qualify an experienced subspecialty provider. Further,
some parts of the country may have limited availability of ex-
perienced pediatric and subspecialty care health care profes-
sionals. This is particularly apparent in the area of inborn er-
rors of metabolism; there are currently 53% fewer board
certifiedbiochemicalgeneticistsintheUnitedStatesthanwere
practicing in 1990 and a limited number of trainees. In such
circumstances,anorganizedsystemtolinkchildhealthprofes-
sionals with specialty care professionals would be useful. This
could be accomplished through the developing HRSA/MCHB
GeneticsandNewbornScreeningRegionalCollaborativesthat
are intended to make national and regional services and re-
sources accessible at the local community level.
Once confirmation of diagnosis is available to the child
health professional or subspecialist, it is common for this in-
formationtobecommunicatedpromptlytotheStatenewborn
screening program. It is important that all programs obtain
confirmatory outcome reports in order to fulfill their public
health mandate.
Diagnosis
There is a complex relationship between the definition of
screen-positive test results and the definition of the genetic
condition itself. Upon identifying a screen-positive infant, al-
gorithms through which diagnostic confirmation is obtained
are followed. Some steps may involve the screening laboratory
as is the case with second-tier tests while others involve the
clinical and laboratory evaluations that lead to the final diag-
nosis. It is only after significant testing in a general population
that the full breadth of the phenotype of the genetic condition
inquestioniswellunderstood.Hence,itbecomesimportantto
maintain communication between the health care profession-
alsandthescreeningprogramsrelatedtothefalse-positiveand
true-positive results. It will also be important to reconsider
whatconstitutesafalsepositiveresultsinceaparticularscreen-
ing result may be associated with either a core condition panel
or a secondary target condition. Further, it is important to
develop mechanisms through which programs can be made
aware of patients identified outside of the program in order to
adjust program parameters to avoid “missed” cases. Finally,
giventhatgenetictestscanprovideinformationaboutaffected
individualsandcarriers,clearpoliciesshouldbeinplaceabout
communicating such information.
Management
Many programs do not have educational materials to facil-
itate and optimize patient care once a patient is diagnosed.
Such information is commonly in the purview of the experts
whodevelopguidelinesfortreatment.Informationdissemina-
tion practices that facilitate collaborative management be-
tween the child health professionals and specialists would be
useful.
Over the longer term of intervention and treatment there is
usually insufficient information shared between health care
professionalsandtheprograms,andcontactbeyondtheinitial
treatment phase is rare. This gap might only be filled through
the development of information collection systems that facili-
tate the integration of program information with other health
care information.
The availability of and access to therapeutic interventions
variesamongtheStates.SomeStatesprovidefundingformed-
ical foods†
1 either completely or on a sliding scale based on
income. Costs not covered by insurance may be covered
through Title V funds and Medicaid. However, they are less
likely to fund genetic counseling, penicillin for sickle cell dis-
ease, or thyroid hormone replacement therapy.
Adefinitionoftherangeofhealthcareprofessionalsconsid-
ered necessary for managing a particular condition is limited.
Medical and nonmedical services are generally defined by the
health care professionals to whom the infants have been re-
ferred. However, because almost all programs provide no
funding for health outcome evaluation, few long-term studies
exist. Beyond one to three years of age, there is little coordi-
nated or systematic monitoring by the programs.
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Programs use a mix of models for management and devel-
opment of their newborn screening activities. Many States
haveexternaladvisorycommittees,althoughsomerelyonlyon
internal advisory groups, which may not include consumers
and experts for conditions considered by the programs.
B. Program evaluation
Severalofthegoalsofthisprojectareaimedatstandardizing
language and identifying the data or information needed to
evaluate newborn screening program performance. Histori-
cally, newborn screening programs have been evaluated only
internally, with the exception of the screening laboratory,
which generally must meet CLIA requirements even though
some of the analytes may not be specifically covered. Since
1987,HRSA/MCHBhasmadeavailabletotheStatesconsulta-
tiveprogramreviewsbyateamcomposedofexpertsinvarious
aspects of newborn screening activities, and this has been con-
tinued as a responsibility of the NNSGRC. Besides providing
annual State data specific to the Title V Block Grant perfor-
mance measure, programs voluntarily report their program
performance data to the NNSGRC for compilation and publi-
cation as an annual newborn screening data report. These re-
portsareavailableattheNNSGRCwebsiteandcanbeusedfor
inter- and intraprogram comparison (See www.genes-r-
us.uthscsa.edu). Uniform performance measures, however,
could enable better and more standardized comparative as-
sessment of newborn screening programs. Performance stan-
dards should be related to the needs of those with the specific
conditions identified. Uniformity of language and standard-
ization of performance measures will allow programs to move
fromindependentevaluationtoacomparativesystemtargeted
at high quality and efficiency.
ProgramStandards
A fundamental goal of newborn screening is benefit to the
newbornbyidentifyingatreatablecondition.Variabilityexists
among the conditions in the core panel regarding the speed
with which they must be treated in order to minimize or elim-
inate the negative consequences of the condition. In newborn
screeningprograms,speedofscreeningandreportingresultsis
sometimes driven by the conditions that have the most de-
manding time needs. For example, an elevated 17-hy-
droxyprogesterone indicates a high likelihood that classical
CAH is present and should therefore be pursued promptly,
since in some instances death can occur from salt wasting
within the first two weeks of life. Similarly, an elevated C8
acylcarnitineindicatesahighlikelihoodthatMCADispresent
and should therefore be pursued promptly, since in some in-
stances death can occur within the first two weeks of life. This
contrasts with the finding of hearing loss, for which the inter-
ventions can be delayed for two to three months without sig-
nificantly affecting speech development. The importance of
education of families and the medical home about timing and
the consequences of later notifications is apparent.
Appendix4listsspecificstepsinthenewbornscreeningpro-
gramprocessthatshouldbemonitored.Programperformance
can be improved by integrating data monitoring into policies
andproceduresandthenmodifyingprogramsasproblemsare
identified. Furthermore, development of a uniform approach
to data collection and program evaluation allows for the com-
parison of program performance among States.
NationalProgramsofQA
Onanationalbasis,thereisnocomprehensiveQAprogram
for newborn screening aside from that provided for screening
laboratories by CDC (see Fig. 10 ). CDC offers a proficiency
testingandqualityassuranceprogramspecificallyfornewborn
screening laboratories—the Newborn Screening Quality As-
suranceProgram.Thenewbornscreeninglaboratoriesarereg-
ulatedunderCLIAof1988.FDAprovidesadditionaloversight
of manufacturers who provide testing products to newborn
screening laboratories, and CDC provides a service that vali-
dates the filter paper bloodspot collection devices. The NNS-
GRC, funded by HRSA/MCHB, provides consultative pro-
gramreviewsthatincludeallaspectsofthenewbornscreening
system (upon the official invitation of individual State new-
born screening programs), and collects and assimilates na-
tional newborn screening data.
The Joint Commission on Accreditation of Hospital Orga-
nizations (JCAHO) plays a role in the oversight of activities
within hospitals. For several reasons, JCAHO’s activities have
notbeenspecificallydirectedtowardthehospital’sroleinnew-
born screening. Even though birth hospitals collect the vast
majority of screening specimens, record demographic infor-
mation, and receive newborn screening test results, hospitals
have not traditionally been held accountable to JCAHO for
newborn screening activities per se. Historically, hospital re-
sponsibilities for tracking newborn screening testing results
have been varied, particularly since the newborns are usually
not in the hospital when the screening results are completed
and returned. Most State screening regulations are silent on
hospitals’ responsibilities, though some include specific re-
quirements, and hospitals and administrators can in some
Statesbeheldliableifnewbornscreeningpracticesareimprop-
erly performed. Oversight of newborn screening has been
complicatedbythefactthattheoversightofclinicalactivitiesis
limited compared to the regulation of laboratories, which in-
cludesmaintainingrecordsofspecimensubmissionandresult
reporting. In many hospitals, newborn screening specimens
arecollectedandsubmittedtothescreeninglaboratorydirectly
from the newborn nursery, bypassing some areas of this labo-
ratory oversight. Hospitals appear to assume greater responsi-
bilityforscreeningconductedwithinthenursery,forexample,
screening for hearing loss. In such circumstances, hospitals
haveaclearresponsibilitytomakepatientsawareofanycritical
laboratory information stemming from their hospital stay.
However, since hearing screening results are immediately
available, the task of initiating notification and arranging for
next steps in evaluation is simplified.
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proving the ways in which hospitals provide information to
newbornscreeningprogramstoensurethatadequateinforma-
tionisavailableinatimelymannerforrecontactingfamiliesor
health care professionals and establishing follow-up while still
maintainingappropriateprivacyofthepatient’smedicalinfor-
mation.
2Atthelevelofdiagnosisandfollow-up,therearesev-
eralprogramsthathaveworkedtowardensuringquality.Some
organizations, such as CORN, AAP, ACMG, and the Society
forInheritedMetabolicDisorders(SIMD),havebeeninvolved
in the development of practice guidelines for the diagnosis,
treatment, and management of many of these conditions. In
addition, there are programs with “deemed” status through
CLIA that offer proficiency testing and inspections of the lab-
oratories providing diagnostic services for the conditions in-
cluded in newborn screening programs. However, at the
present time most analytes that are screened are not included
inthisprogram,althoughtheiradditionisunderactivediscus-
sion.
Some programs have developed internal QA programs that
variablyaddressthecomponentsofthenewbornscreeningsys-
tem. While all States tabulate the number of tests done, many
cannot relate tests to birthing records in order to ascertain the
percentage of newborns screened. On the other hand, pro-
grams routinely track time from birth to diagnosis and treat-
ment, and the numbers of newborns lost to follow-up, which
are extremely important aspects of the screening system. Most
programs maintain records of unsatisfactory specimens but
they vary in follow-up actions and educational programs to
improve specimen quality. In this respect there is perhaps a
role for the federal government in providing some form of
national program oversight. Furthermore, there are very dif-
ferent forms of oversight for laboratory services than for clin-
ical services. In order to continue to improve the quality of
newborn screening programs, several actions should be taken:
1. There should be uniformity in the types of data collected
(see Appendix 4) by programs in order to compare pro-
gramperformanceamongStates.Inaddition,reportingto
a central authority should be required.
2. Periodic performance reviews of all components of new-
born screening programs should be required. This should
be a federal responsibility.
3. Language and terminology should be standardized in or-
der to better compare performance among programs.
4. Turnaround time in reporting screen-negative results
should be improved.
a. Ataminimum,allresultsfromtheinitialscreeningtest
(some States perform a second test later) should be
availablelessthanfivedaysafterthebloodsamplingfor
the first posthospital discharge visit to be of use in this
clinical visit and to facilitate awareness of lifelong
screening. Most results should be available within two
days of the specimen arriving in the laboratory, and
specimensshouldarriveinthelaboratorieswithinthree
days of collection.
5. Diagnostic laboratory QA programs should be enhanced
to include all conditions screened in newborns.
6. Organized systems to allow for the collection and analysis
of data about patients are important in defining the stan-
dardstobemetandimprovingourunderstandingofthese
typically very rare conditions. Data from population-
based screening are the optimal source of unbiased infor-
mationaboutconditionsandrequiredreportingshouldbe
instituted.
7. Hospitals and JCAHO have significant roles to play, and
standards need to be developed to improve quality, mini-
mize errors, and facilitate tracking of newborns requiring
active participation in testing follow-up.
8. All newborn screening laboratories should be CLIA-certi-
fied and should participate in CDC and CAP/ACMG pro-
ficiency testing programs or other equivalent programs as
applicable.
9. All States should have an active system-wide newborn
screening QA and total quality management program.
10. To bring uniformity to programs across the country and
thereby create a more equitable system for all Americans,
national oversight and authority must be provided with
adequate resources. Consideration should be given to in-
stitutionalizing the role of the HRSA-funded NNSGRC,
which currently offers on-site expert consultative reviews
to the State newborn screening programs.
C. Cost-effectiveness analysis
Thisprojectfocusedprimarilyonascientificanalysisofcon-
ditionsandthefeaturesthatshouldbeconsideredwhendecid-
ing whether they should be included in a newborn screening
program. However, costs often are the basis on which such
decisions are made. Review of the few available cost-effective-
nessstudiesofnewbornscreeningsuggeststhatoften,theymay
be too limited in scope. Some studies have focused on the
short-term costs and benefits of the screening stage and the
immediate steps following the identification of a screen-posi-
tive infant. Most address tests for only a small number of dis-
orders, and none has explored the cost savings and clinical
benefits of tests such as MS/MS.41–46
A basic cost-effectiveness analysis was conducted to better
inform our decisions. Costs and benefits related to screening
for particular conditions or groups of conditions were evalu-
atedaftermappingthemovermajordiseaseoutcomes(e.g.,life
expectancy, cerebral palsy/stroke, seizures, developmental de-
lay, hearing loss, vision loss). Costs were obtained from the
literature.2,42,43,47–51 Benefits were determined from expected
outcomes with and without early treatment or intervention.
Quality-adjusted-life years (QALYs) were then compared to
costs. Where appropriate, tests capable of being multiplexed
withothertestsfordifferentconditionswereassessedindepen-
dently and as a group. Results were found to be stable by sen-
sitivity analysis.
The results of these analyses indicate that all newborn
screening programs evaluated improved outcomes and most
reduce overall costs (Carroll and Downs, in press). Screening
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waswellwithintherangeconventionallyconsideredcosteffec-
tive. Screening for galactosemia was the only strategy that
wouldbeconsiderednotcosteffectiveinthebasecaseanalysis.
However, under some reasonable assumptions, it can be
shown to be cost effective. The identification of potentially
affected individuals at such an early time in life leads to many
yearsoverwhichthebenefitsaccrueand,inaggregate,theben-
efits outweigh the costs.
Technologies such as MS/MS further save money due to
their multiplexing capability and low screening false-positive
rates. MS/MS, used to screen for multiple conditions, had the
greatestimpactonoutcomesandsavedthegreatestamountof
money in the analysis. Virtually all screening for conditions
that are treatable with significantly beneficial outcomes can be
justified with benefits increasing as more conditions are in-
cluded.Theanalysisalsoshowedthatclinicalbenefitsandsav-
ings depend on low false positive rates and timely follow-up
and treatment of positives, emphasizing the importance of an
integrated screening and follow-up program.41–45,52
D. Information gaps and a research agenda
DataandAnalyticalNeeds
Screening
The evidence base for disorders potentially amenable to
screeningislimitedandthequestionsthatmustbeansweredto
inform our decisions about the future of our newborn screen-
ing programs are numerous and the issues complex. There are
cuttingedgenewtechnologiesemergingthatcanhaveasignif-
icant impact on screening programs. However, tech assess-
mentshavelimitedcapacitytoidentifyissuesaboutpromising
technologiesearlyintheirdevelopment(e.g.,istheresufficient
capacity in the system to test the 4.1 million United States
newborns?Arethetestsadequatelyvalidated?).Thisraisesim-
portant questions about how to implement new technologies
for screening. Historically, as new technology is validated on a
known cohort, it is then applied to a prospective screening
cohort in a linked or unlinked (e.g., HIV screening) method,
withorwithoutreporting,andwithorwithoutrandomization
(e.g., CF). Many State newborn screening programs have
awaited data from other State pilot or trial programs before
investing in the costs of incorporating new technologies into
testing and follow-up protocols. The potential for screening
beyondthefirstfewdaysoflifeisincreasing.Determininghow
best to link existing public health activities (such as immuni-
zation) that occur at specific clinical points later in life offers
opportunities to screen for additional conditions that are less
amenable to screening in the first 24 to 48 hours of life. Infor-
mation technology has opened up opportunities to improve
the systems that support the medical home’s integrated role in
newborn screening and there is always the opportunity to im-
prove informatics and communications and their integration
into public health information systems and registries.
There is an ongoing and growing need to articulate a re-
search agenda for the many conditions that are already part of
newborn screening. For example, the impact on the optimal
timing of screening of newborns in the neonatal intensive care
unitthathavereceivedhyperalimentationorpackedcelltrans-
fusions remains unclear.
Follow-Up
Many questions remain about the impact of screening for a
largernumberofraredisorders,aswellaswhatthetruesignif-
icanceisofa“false-positive”or“transientlyabnormal”screen-
ing test.53 These may require costly, long-term evaluation
projects in order to obtain the statistical power needed to bet-
terunderstandtheseissuesinrarediseases.Again,wemayneed
a broader national approach to data collection and analysis.
Diagnosis
Considerableresearchpotentialexistsintheareaofdiagno-
sis of these rare diseases. The preferred approaches and meth-
ods of diagnosis and confirmation of presumptive diagnoses
remaintobedeterminedandourunderstandingofthenatural
history of the conditions and the associated genotype-pheno-
type correlations can only improve. There are many questions
tobeansweredforeachoftheconditionsforwhichscreeningis
currently offered. For instance, there is still little information
available about the outcomes of infants identified in G6PD
screening programs. The interrelated roles of genetic risk fac-
tors and the environmental exposures that trigger disease ex-
pression are areas where large collaborative research projects
will be needed. The use of the National Children’s Study as a
component of newborn screening research offers a number of
opportunities.Similarly,weneedtounderstandtheissuesand
barriers that lead to the lack of hearing screening follow-up to
determine etiology.
Management
The emerging area of collaborative disease management of-
fers many opportunities to improve our newborn screening
programs.Thenatureofourhealthcaresystemissuchthatthe
bridgesbetweenchildhealthprofessionalsandspecialistsmust
bestrengthened.Issuesofinterestinclude:1)howbesttopart-
nerwiththemedicalhome;2)howtofacilitatethetransitionto
adultcare(childhoodcancersurvivorshipmodel);and3)what
are the expected outcomes for the adults with these now
chronicdiseases.Itisalsolikelythatsituationssimilartothatof
maternal PKU will arise with other metabolic diseases, such as
3-MCC,ortheendocrinopathies,suchasCH.Long-termout-
comes research will require organized systems of data collec-
tionandmonitoring.Therearealsogapsinourunderstanding
of treatment issues for many conditions (e.g., nonclassical
CAH).Wealsoneedtoelucidatethelong-termbehavioraland
educationalissuesassociatedwithchildrenwithconditionsde-
tected by newborn screening.
Evaluation
Program evaluation can also benefit from organized collab-
orative research programs. The creation of registries for long-
termoutcomesresearchandforsystemvalidationoffersaclear
pathway to improvement of the programs.
Health Systems And Outcomes Research
Our health care system continues to evolve in parallel with
theevolutionofthenewbornscreeningprograms.Theincreas-
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healthdisparitiesresearchasrelatestodiagnosis,management,
and long-term follow-up of patients identified in newborn
screening be enhanced.
Education
The trend toward more direct consumer involvement in
health care decisions and prevention indicates the need for
enhanced educational programs for the public. Further, the
rarityandcomplexityofthemanyconditionsalreadyscreened
suggests a need for improved educational programs for the
professionals. Opportunities remain to improve our under-
standing of the primary communication and education needs
related to a screen-positive result in newborn screening. Simi-
larly, many questions remain about the issue of appropriate
decision-makingrelativetonewbornscreening.Thereisaneed
to understand the issues that arise in the delivery of prenatal
education and determine the best models for such education
while still working to broaden overall genetics public educa-
tion.Thereisalsoaneedtoimproveourunderstandingofhow
attention to cultural diversity and literacy could contribute to
effective newborn screening programs. In order to better un-
derstandthelimitationsofandimpedimentstoeducation,best
practices models related to who provides services (e.g., birth
educators, obstetrician gynecologists, subspecialists) need to
be identified and there is need to understand how they can be
provided outside the delivery room or nursery, and when they
are best provided. The role for cross-specialty education and
continuing medical education for health care professionals is
also an area that would benefit from study. Last, there is con-
siderable opportunity for research into the ethical, legal, and
social issues that arise with expanded newborn screening and
newborn screening in general.
Health Systems As Related To Newborn Screening
A better understanding of the organization and functioning
of our newborn screening related health care systems would
also benefit the continued development of programs. In par-
ticular, studies of systems of care that would offer the highest
quality delivery of newborn screening services would improve
the programs.
Other
Therearenumerousancillaryissuesthatrelatetoimproving
newborn screening outcomes. These include: 1) expanding
screeningopportunitiesprenatallyandafterbirthwhentiming
of testing, identification, and intervention offer additional
value for health outcomes in the pediatric population; 2) on-
goingresearcheffortstoidentifybetterandnewscreeningand
intervention strategies for rare and common disorders; and 3)
continued research into outcomes of transiently abnormal
screens to determine if such test results have predictive value
for later diseases as well as to measure the psychosocial impact
of such results (e.g., costs of vulnerable child issues). Some of
the diseases for which postnatal newborn screening is recom-
mended may be additionally benefited by prenatal detection;
however, prenatal screening is not presently universally avail-
able.Wemaygainabetterunderstandingoftheincidenceand
spectrum of diseases associated with perinatal and early child-
hood mortality by implementing uniform child autopsy poli-
cies and procedures which ensure availability of appropriate
studies(includingmetabolicandgeneticstudiesforallperina-
tal deaths, including stillbirths) and early unexpected child-
hood deaths.
E. Future needs
Hopefully all screening programs can benefit from a more
robustnationalroleandincreasednationalstandardsandpol-
iciesfornewbornscreening.Becausesomanyoftheconditions
screened in newborns, or under consideration for screening,
arerare,mostStatesthatundertakeevaluationsofthescientific
basis for screening of conditions must rely on the same rela-
tively small group of patients identified throughout the world.
There is a potential national role in providing scientific evalu-
ation of conditions and defining core condition panels. This
would allow the States to apply the best science to their own
considerations when determining their role in expanded
screening. Practice guidelines also could be developed at a na-
tionallevelbyinterestedorganizations.Thereisalsoapotential
expandednationalroleinoversightandenforcement,datacol-
lection, program evaluation, and the development of educa-
tional materials to support newborn screening.
Dependingontheoverallincidenceofparticularconditions,
regional cooperatives should coordinate access to health care
professionals, serve as coordinators and repositories for data
collection, provide long-term follow-up capability when re-
sources and expertise are limited, facilitate transition (and ac-
cess) from pediatric to adult care, and provide education. The
distribution of primary, secondary, and tertiary services is
largelybasedontheincidenceofaconditionandthecomplex-
ityofitsshort-andlong-termdiagnosisandmanagement.For
morecommonconditionswitheasierdiagnosisandfollow-up,
there is likely to be sufficient local health care expertise for
patient care. As incidence decreases and complexity increas-
es—particularly for rare metabolic diseases—services become
more difficult to access. Developing resources and infrastruc-
ture to ensure that health care professionals with appropriate
expertiseareavailablelocally,regionally,andnationallywillbe
important to ensuring access to high-quality services.
States also must retain their significant roles and responsi-
bilities. They have a clear authority with regard to oversight
and evaluation, as well as enforcement. There is a need to in-
tegrate the various systems of health care coverage and pay-
ment through flexible and comprehensive financing of ser-
vices. Service coordination at both State and local levels must
be considered, as well as program integration with the State
Children’s Health Insurance Plan, early intervention pro-
grams, Title V programs, Medicaid, and similar services.
In considering the national role in newborn screening, it is
apparent that there are already significant barriers to the cre-
ation of a model newborn screening system in the United
States. For example:
1. Financing across State and county lines is constrained
by Medicaid rules;
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3. Thereislackofuniversalaccessandabilitytoaccessthe
medical home;
4. There is insufficient support to bridge geographic bar-
riers;
5. It is difficult to identify experienced health care profes-
sionals for complex care (e.g., centers of excellence for
genitalreconstructivesurgeryforCAH;confirmationof
metabolic diagnoses);
6. Misinterpretation of privacy regulations (e.g., HIPAA)
(see Appendix 5 for discussion and clarification of
HIPAA related issues in the context of a public health
program);
7. There is underutilization and lack of uniformity of in-
formation technology;
8. Collaborative management and care is constrained by
systems of reimbursement;
9. There is variability in State mandates;
10. State sovereignty sometimes dictates individual ap-
proaches; and
11. There is variability in financing of screening programs.
F. Summary
In order for expanded newborn screening to be imple-
mented universally, a well operating and standardized new-
born screening system must be in place. At the present time
there is significant variability among the State programs with
regard to policies and practices employed after screening and
in initial notification of health care professionals. The expert
group evaluated the components of the system and their asso-
ciatedfunctionswithaprimaryfocusonthepartsofthesystem
that interface specialty care professionals with either the new-
born screening program or the child health professionals.
Abasiccosteffectivenessstudyofnewbornscreeningwascon-
ducted. The results of this analysis demonstrated that newborn
screeningiscosteffectivewhencomparedtootherrecommended
medicalexpenditures.Thissupportstherecommendationsmade
in Section One of this report regarding the need to expand the
breadth of conditions that should be included in core screening
panels and the secondary target category.
The scientific analyses and systems evaluations also identi-
fied gaps in our knowledge base and pointed to areas in which
research is needed. The expert group recommends that:
● Programs continue to improve the components of the
system beyond the initial screening, communication of
those results, and ensuring that the newborn enters into
short-term follow-up. To accomplish this:
● reporting procedures should be standardized
● reports of confirmatory results should be obtained
● Thereshouldbeimprovedoversight(e.g.,JCAHO)ofthe
hospital-based screening activities to improve tracking of
screen-positive cases;
● There should be more uniformity in the language and
definition of the performance standards (e.g., repeat test,
second test) monitored and reported by programs;
● TheQAprogramsinvolvingthediagnosticandfollow-up
system should be enhanced;
● National oversight and authority with appropriate re-
sources should be provided; and
● Systems should be in place for collection of data about
individuals identified as screen-positive in newborn
screening programs.
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CONDITION VALIDATEDBY
EVIDENCELEVELS(1-4)
Condition Test Diagnosis Treatment
EndocrineDisorders
Congenital adrenal hyperplasia Maria I. New, MD
Cornell University
New York, NY
111 1
Phyllis Speiser, MD
New York Univ. Med Center
Schneider Children’s Hospital
Long Island Jewish Health System
New York, NY
333 1
Congenital hypothyroidism Phyllis Speiser, MD
New York Univ. Med Center
Schneider Children’s Hospital
Long Island Jewish Health System
New York, NY
111 1
Marvin Mitchell, MD
New England Newborn Screening Program
University of Massachusetts Medical School
Jamaica Plain, MA
111 1
Type 1 diabetes mellitus (IDDM) Marian Rewers, MD
University of Colorado School of Medicine
Denver, CO
11 1
William Tamborlane, MD
Yale University
New Haven, CT
122 1
Charles Stanley, MD
Children’s Hospital of Philadelphia
Philadelphia, PA
122 2
CarbohydrateDisorders
Classic galactosemia (GALT deficiency) Louis B. Elsas, MD
University of Miami
Miami, FL
444 4
Gerard Berry, MD
Jefferson Medical College
Philadelphia, PA
321 3
Galactokinase deficiency Louis B. Elsas, MD
University of Miami
Miami, FL
444 4
Gerard Berry, MD Jefferson Medical College
Philadelphia, PA
422 4
Galactose epimerase deficiency Louis B. Elsas, MD
University of Miami
Miami, FL
444 4
Gerard Berry, MD
Jefferson Medical College
Philadelphia, PA
422 4
Congenital disorder of glycosylation type 1b Marc Patterson, MD, FRACP
Columbia University
New York, NY
444 4
Donna Krasnewich, MD, PhD
National Human Genome Research Institute
Bethesda, MD
141 2
PrimaryImmunodeficiencies
Adenosine deaminase Deficiency Rebecca Buckley, MD
Duke University Medical Center
Durham, NC
2 N/A 1 1
Jennifer Puck, MD
National Human Genome Research Institute
Bethesda, MD
2 N/A 2 2
Newborn screening panel and system
May 2006  Vol. 8  No. 5, Supplement 67SCONDITION VALIDATEDBY
EVIDENCELEVELS(1-4)
Condition Test Diagnosis Treatment
Severe combined Immunodeficiency Rebecca Buckley, MD
Duke University Medical Center
Durham, NC
1 N/A 1 1
Jennifer Puck, MD
National Human Genome Research Institute
Bethesda, MD
1 N/A 1 1
OtherGeneticandNon-GeneticConditions
-1-antitrypsin deficiency Diane Cox, PhD
University of Alberta
Edmonton, Alberta, Canada
11
Biliary atresia Deborah K. Freese, MD
Mayo Clinic College of Medicine
Rochester, MN
232 3
Ronald J. Sokol, MD
University of Colorado School of Medicine
Denver, CO
233 3
Biotinidase deficiency Barry Wolf, MD, PhD
Connecticut Children’s Medical Center
Hartford, CT
222 2
E. Regula Baumgartner, MD
University Children’s Hospital
Basel, Switzerland
211 2
Matthias Baumgartner, MD
University Children’s Hospital
Zurich, Switzerland
211 2
Cystic fibrosis Phillip Farrell, MD, PhD
University of Wisconsin
Madison, WI
112 3
Garry R. Cutting, MD
Johns Hopkins University School of Medicine
Baltimore, MD
13 2
Duchenne (DMD)/Becker muscular dystrophy (BMD) Jon A. Wolff, MD
University of Wisconsin
Madison, WI
222 2
R. Rodney Howell, MD
University of Miami
Miami, FL
122 1
Familial hypercholesterolemia (heterozygote) Joseph P. McConnell, PhD
Mayo Clinic College of Medicine
Rochester, MN
221 2
David Wilcken, MD
Prince of Wales Hospital
Randwick, NSW, Australia
111 1
Fragile X syndrome Stephen Warren, PhD
Emory University
Atlanta, GA
1 N/A 1 1
W. Ted Brown, MD, PhD
New York State Institute for Basic Research
Staten Island, NY
222 3
Hearing Loss Cynthia C. Morton, PhD
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA
112 2
Richard Smith, MD
University of Iowa Medical School
Iowa City, IA
111 1
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Condition Test Diagnosis Treatment
Hyperbilirubinemia (kernicterus) Jeffery Maisels, MD
William Beaumont Hospital
Royal Oak, MI
333 3
Vinod Bhutani, MD
Children’s Hospital of Philadelphia
Philadelphia, PA
333 3
Neuroblastoma Garrett Brodeur, MD
Children’s Hospital of Philadelphia
Philadelphia, PA
111 1
Eizo Hiyama, MD
Hiroshima University Hiroshima, Japan
and
Hiroshi Naruse, MD
Quality Control Center for Mass Screening
Tokyo, Japan
232 3
Smith-Lemli–Opitz syndrome Robert Steiner, MD
Oregon Health Science University
Portland, OR
122 2
Mira Irons, MD
Children’s Hospital
Harvard Medical School
Boston, MA
111 3
Richard I. Kelley, MD, PhD
Johns Hopkins Medical Institution
Baltimore, MD
422 1
Turner syndrome Virginia P. Sybert, MD
Univ. of Washington
Seattle, WA
3/4 3/4 3/4 3/4
Ron G Rosenfeld, MD
Lucille Packard Foundation for Children
Palo Alto, CA
133 2
Wilson disease Benjamin Shneider, MD
New York University Medical School
New York, NY
332 2
Sihoun Haun, MD, PhD
Mayo Clinic College of Medicine
Rochester, MN
122 1
X-Linked Adrenoleukodystrophy Hugo Moser, MD
Kennedy Krieger Institute
Johns Hopkins University
Baltimore, MD
2 2 2 2-3
Robert Steiner, MD
Oregon Health Science University
Portland, OR
222 3
AminoAcidDisorders
Argininemia Stephen D. Cederbaum, MD
Mental Retardation Research Center, UCLA
Los Angeles, CA
333 3
Mendel Tuchman, MD
Children’s National Medical Center
Washington, DC
444 4
Argininosuccinic acidemia Stephen D. Cederbaum, MD
Mental Retardation Research Center, UCLA
Los Angeles, CA
131 3
Mendel Tuchman, MD
Children’s National Medical Center
Washington, DC
333 3
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Condition Test Diagnosis Treatment
Defects of biopterin cofactor biosynthesis Nenad Blau, PhD
University Children’s Hospital
University of Zurich
Zurich, Switzerland
222 3
Harvey Levy, MD
Harvard Medical School
Boston, MA
222 2
Defects of biopterin cofactor regernation Nenad Blau, PhD
University Children’s Hospital
University of Zurich
Zurich, Switzerland
222 3
Harvey Levy, MD
Harvard Medical School
Boston, MA
322 4
Carbamylphosphate synthetase deficiency Mendel Tuchman, MD
Children’s National Medical Center
Washington, DC
333 3
Mark L. Batshaw, MD
Children’s National Medical Center
George Washington University
Washington, DC
333 3
Citrullinemia(arginosuccinate synthase deficiency) Mendel Tuchman, MD
Children’s National Medical Center
Washington, DC
333 3
Mark L. Batshaw, MD
Children’s National Medical Center
George Washington University
Washington, DC
333 3
Citrullinemia type II (citrin deficiency) Mendel Tuchman, MD
Children’s National Medical Center
Washington, DC
33 3
Toshihiro Ohura, MD
Tohoku University School of Medicine
Sendai, Japan
322 3
Mark L. Batshaw, MD
Children’s National Medical Center
George Washington University
Washington, DC
333 3
Homocystinuria(cystathionine -synthase deficiency) S. Harvey Mudd, MD
NIH/NIMH
Bethesda, MD
111 4
Vivian Shih, MD
Harvard Medical School
Boston, MA
13 3
Hypermethioninemia(MAT 1/III deficiency) S. Harvey Mudd, MD
NIH/NIMH
Bethesda, MD
111 4
Vivian Shih, MD
Harvard Medical School
Boston, MA
111 4
Maple syrup (urine) disease Louis B. Elsas, MD
University of Miami
Miami, FL
331 3
Vivian Shih, MD
Harvard Medical School
Boston, MA
111 4
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EVIDENCELEVELS(1-4)
Condition Test Diagnosis Treatment
Ornithine transcarbamylase deficiency Mendel Tuchman, MD
Children’s National Medical Center
Washington, DC
333 3
Mark L. Batshaw, MD
Children’s National Medical Center
George Washington University
Washington, DC
333 3
Phenylketonuria (phenylalanine hydroxylase deficiency) Nenad Blau, PhD
University Children’s Hospital
University of Zurich
Zurich, Switzerland
222 2
Harvey Levy, MD
Harvard Medical School
Boston, MA
222 2
Vivian Shih, MD
Harvard Medical School
Boston, MA
112 4
Tyrosinemia type I (hepatorenal tyrosinemia) C. Ronald Scott, MD
University of Washington
Seattle, WA
231 2
Grant Mitchell, MD
Hospital Sainte-Justine
Montreal, Quebec, Canada
2 2/3 1 2
Tyrosinemia type II (oculocutaneous tyrosinemia) C. Ronald Scott, MD
University of Washington
Seattle, WA
232 2
Grant Mitchell, MD
Hospital Sainte-Justine
Montreal, Quebec, Canada
242 2
Tyrosinemia type III C. Ronald Scott, MD
University of Washington
Seattle, WA
333 4
Grant Mitchell, MD
Hospital Sainte-Justine
Montreal, Quebec, Canada
44
(sensitivity)
1
(technical)
44
FattyAcidOxidationDefects
Carnitine: acylcarnitine translocase deficiency Nicola Longo, MD, PhD
University of Utah
Salt Lake City, UT
221 2
Charles Stanley, MD
Children’s Hospital of Philadelphia
Philadelphia, PA
332 4
Piero Rinaldo, MD, PhD
Mayo Clinic College of Medicine
Rochester MN
332 4
Carnitine palmitoyltransferase I deficiency (CPT1a) Michael Bennett, PhD
Children’s Hospital of Philadelphia
Philadelphia, PA
343 4
Cary Harding, MD
Oregon Health Sciences University
Portland, OR
Piero Rinaldo, MD, PhD
Mayo Clinic College of Medicine
Rochester MN
444 4
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Carnitine palmitoyltransferase II deficiency Michael Bennett, PhD
Children’s Hospital of Philadelphia
Philadelphia, PA
244 3
Georgirene D. Vladutiu, PhD
Children’s Hospital
Buffalo, NY
424 4
Piero Rinaldo, MD, PhD
Mayo Clinic College of Medicine
Rochester MN
232 4
Carnitine uptake deficiency(Systemic) Nicola Longo, MD, PhD
University of Utah
Salt Lake City, UT
111 1
Charles Stanley, MD
Children’s Hospital of Philadelphia
Philadelphia, PA
433 4
Dienoyl-CoA reductase deficiency Gerard Vockley, MD, PhD
Children’s Hospital Pittsburgh
University of Pittsburgh
Pittsburgh, PA
444 4
Piero Rinaldo, MD, PhD
Mayo Clinic College of Medicine
Rochester MN
444 4
Glutaric acidemia type II Stephen I. Goodman, MD
University of Colorado Health Science Center
Denver, CO
442 4
Piero Rinaldo, MD, PhD
Mayo Clinic College of Medicine
Rochester MN
333 4
William J. Rhead, MD, PhD
Medical College of Wisconsin
Madison, WI
222 4
Long-chain 3-OH acyl-CoA dehydrogenase deficiency Michael Bennett, PhD
Children’s Hospital of Philadelphia
Philadelphia, PA
333 3
Arnold Strauss, MD
Vanderbilt University School of Medicine
Nashville, TN
233 2
Piero Rinaldo, MD, PhD
Mayo Clinic College of Medicine
Rochester MN
322 3
Medium-chain acyl-CoA dehydrogenase deficiency Arnold Strauss, MD
Vanderbilt University School of Medicine
Nashville, TN
222 2
Piero Rinaldo, MD, PhD
Mayo Clinic College of Medicine
Rochester MN
211 1
Medium/short-chain 3-OH acyl-CoA dehydrogenase deficiency Arnold Strauss, MD
Vanderbilt University School of Medicine
Nashville, TN
444 4
Piero Rinaldo, MD, PhD
Mayo Clinic College of Medicine
Rochester MN
444 4
Medium–chain ketoacyl-CoA thiolase deficiency Michael Bennett,PhD
Children’s Hospital of Philadelphia
Philadelphia, PA
444 4
Piero Rinaldo, MD, PhD
Mayo Clinic College of Medicine
Rochester MN
444 4
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Short-chain acyl-CoA dehydrogenase deficiency Gerard Vockley, MD, PhD
Children’s Hospital Pittsburgh
University of Pittsburgh
Pittsburgh, PA
211 4
Piero Rinaldo, MD, PhD
Mayo Clinic College of Medicine
Rochester MN
432 4
Dietrich Matern, MD
Mayo Clinic College of Medicine
Rochester, MN
211 2
Trifunctional protein deficiency Arnold Strauss, MD
Vanderbilt Univeristy School of Medicine
Nashville, TN
333 3
Michael Bennett, PhD
Children’s Hospital of Philadelphia
Philadelphia, PA
444 4
Piero Rinaldo, MD, PhD
Mayo Clinic College of Medicine
Rochester MN
322 3
Very long-chain acyl-CoA dehydrogenase deficiency Arnold Strauss, MD
Vanderbilt University School of Medicine
Nashville, TN
222 2
Michael Bennett, PhD
Children’s Hospital of Philadelphia
Philadelphia, PA
333 4
Piero Rinaldo, MD, PhD
Mayo Clinic College of Medicine
Rochester MN
322 3
OrganicAcidurias
2-methylbutyryl-CoA dehydrogenase deficiency Gerard Vockley, MD, PhD
Children’s Hospital Pittsburgh
University of Pittsburgh
Pittsburgh, PA
111 4
Dietrich Matern, MD
Mayo Clinic College of Medicine
Rochester, MN
211 2
2-methyl 3-hydroxybutyric-aciduria Michael Bennett, PhD
Children’s Hospital of Philadelphia
Philadelphia, PA
444 4
Dietrich Matern, MD
Mayo Clinic College of Medicine
Rochester, MN
343 3
Regina Ensenauer, MD
Von Haunershes Kinderspital
Ludwig-Maximilians-University
Munich, Germany
444 4
3-hydroxy 3-methyl glutaric aciduria (HMG) Pinar Ozand, MD, PhD
King Faisal Specialist Hospital and Research Centre
Riyadh, Saudi Arabia
411 1
Grant Mitchell, MD
Hospital Sainte-Justine
Montreal, Quebec, Canada
242 3
3-Methylglutaconic Aciduria (Type 1-hydrotase deficiency) Robert Steiner, MD
Oregon Health University
Portland, OR
222 2
Richard I. Kelley, MD, PhD
Johns Hopkins Medical Institution
Baltimore, MD
422 4
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3-methylcrotonyl-CoA carboxylase deficiency Matthias Baumgartner, MD
University Children’s Hospital
Zurich, Switzerland
212 4
Richard I. Kelley, MD, PhD
Johns Hopkins Medical Institution
Baltimore, MD
422 4
ß-ketothiolase deficiency Michael Bennett, PhD
Children’s Hospital of Philadelphia
Philadelphia, PA
444 4
Toshiyuki Fukao, MD
Gifu University School of Medicine
Gifu, Japan
333 3
Glutaric cademia type 1 Stephen I. Goodman, MD
University of Colorado Health Science Center
Denver, CO
222 3
Pinar Ozand, MD, PhD
King Faisal Specialist Hospital and Research Centre
Riyadh, Saudi Arabia
222 3
Isobutyryl-CoA dehydrogenase Deficiency Gerard Vockley, MD, PhD
Children’s Hospital Pittsburgh
University of Pittsburgh
Pittsburgh, PA
311 4
Dietrich Matern, MD
Mayo Clinic College of Medicine
Rochester, MN
221 3
Isovaleric acidemia Gerard Vockley, MD, PhD
Children’s Hospital Pittsburgh
University of Pittsburgh
Pittsburgh, PA
111 3
Dietrich Matern, MD
Mayo Clinic College of Medicine
Rochester, MN
111 1
Regina Ensenauer, MD
Von Haunershes Kinderspital
Ludwig-Maximilians-University
Munich, Germany
111 3
Malonic acidemia Michael Bennett, PhD
Children’s Hospital of Philadelphia
Philadelphia, PA
444 4
Pinar Ozand, MD, PhD
King Faisal Specialist Hospital and Research Centre
Riyadh, Saudi Arabia
444 4
Methylmalonic acidemia (CblA,B) David Rosenblatt, MD
McGill University
Montreal, Quebec, CA
444 4
William Nyhan, MD, PhD
University of California, San Diego
La Jolla, CA
211 2
Methylmalonic acidemia (Cbl C,D) David Rosenblatt, MD
McGill University
Montreal, Quebec, CA
444 4
William Nyhan, MD, PhD
University of California, San Diego
La Jolla, CA
211 2
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Methylmalonic acidemia (Mutase deficiency) David Rosenblatt, MD
McGill University
Montreal, Quebec, CA
444
William Nyhan, MD, PhD
University of California, San Diego
La Jolla, CA
211 2
Holocarboxylase synthetase deficiency Barry Wolf, MD, PhD
Connecticut Children’s Medical Center
Hartford, CT
333 3
E. Regula Baumgartner, MD
University Children’s Hospital
Basel, Switzerland
222 2
Matthias Baumgartner, MD
University Children’s Hospital
Zurich, Switzerland
222 2
Propionyl-CoA carboxylase deficiency Pinar Ozand, MD, PhD
King Faisal Specialist Hospital and Research Centre
Riyadh, Saudi Arabia
311 1
William Nyhan, MD, PhD
University of California, San Diego
La Jolla, CA
211 2
Hematology/Hemoglobinopathies
Sickle cell anemia (Hb SS disease) Carolyn Hoppe, MD
Children’s Hospital Oakland
Oakland, CA
121 1
Elliott Vichinsky, MD
Children’s Hospital Oakland
Oakland, CA
121 1
Hemoglobin SC Carolyn Hoppe, MD
Children’s Hospital Oakland
Oakland, CA
121 1
Elliott Vichinsky, MD
Children’s Hospital Oakland
Oakland, CA
121 1
Hemoglobin S/beta-thalassemia (Hb Sß-thal) Carolyn Hoppe, MD
Children’s Hospital Oakland
Oakland, CA
121 1
Elliott Vichinsky, MD
Children’s Hospital Oakland
Oakland, CA
121 1
Variant hemoglobinopathies (including HbE) Carolyn Hoppe, MD
Children’s Hospital Oakland
Oakland, CA
121 1
Elliott Vichinsky, MD
Children’s Hospital Oakland
Oakland, CA
121 1
Glucose-6-phosphate dehydrogenase deficiency (G6PD) Ernest Beutler, MD
Scripps Research Institute
La Jolla, CA
312 4
Carolyn Hoppe, MD
Children’s Hospital Oakland
Oakland, CA
221 4
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CreatineMetabolismDisorders
Guanidinoacetate methyltransferase deficiency (GAMT) William O’Brien, PhD
Baylor College of Medicine
Dallas, TX
444 4
Robert Steiner, MD
Oregon Health Science University
Portland, OR
444 4
Arginine:glycine amidinotransferase deficiency(AGAT) William O’Brien, PhD
Baylor College of Medicine
Dallas, TX
444 4
Robert Steiner, MD
Oregon Health Science University
Portland, OR
444 4
Creatine transporter defect William O’Brien, PhD
Baylor College of Medicine
Dallas, TX
444 4
Robert Steiner, MD
Oregon Health Science University
Portland, OR
444 4
LysosomalStorageDisorders
Fabry disease Gregory A. Grabowski, MD
Cincinnati Children’s Hospital
Medical Center
Cincinnati, OH
233 1
Robert J. Desnick, MD, PhD
Mount Sinai Medical Center
New York, NY
234 1
Krabbe disease Gregory A. Grabowski, MD
Cincinnati Children’s Hospital
Medical Center
Cincinnati, OH
333 4
Hurler, Scheie, Hurler-Scheie (MPS I) Gregory A. Grabowski, MD
Cincinnati Children’s Hospital
Medical Center
Cincinnati, OH
334 2
Pompe disease (glycogen storage disease type II) Gregory A. Grabowski, MD
Cincinnati Children’s Hospital
Medical Center
Cincinnati, OH
4 3 3 3/4
R. Rodney Howell, MD
University of Miami
Miami, FL
141 4
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ConditionACT(ion)Sheets
Phenylketonuria (PKU)
Disease Category
Amino Acid Disorder
You Should Take The Following Actions:
• Immediate consultation with a metabolic specialist
(seebelow*).
• Contact family to inform them of the newborn
screeningresultandarrangeavisitforanimmediate
physicalexamofthenewborn.
• Undertake definitive investigations in consul-
tation with metabolic specialist and referral as
indicated.
• Report findings to State newborn screening
program.
Meaning of Screening Result
Elevated level of phenylalanine, especially with reduced
level of tyrosine and increased phenylalanine:tyrosine ratio
suggests PKU. Elevated phenylalanine can be associated with
disorders other than PKU.
ConditionDescription
PKUisanautosomalrecessivegeneticconditioncausedbya
defectinphenylalaninehydroxylase(PAH)enzymedefectthat
impairs the breakdown of an amino acid, phenylalanine, into
its product, tyrosine.
ConfirmationOfDiagnosis
Specific diagnosis is made by confirmatory tests plasma
amino acid analysis that shows increased phenylalanine and
decreased tyrosine. It should take no more than one to two
days to confirm or exclude the diagnosis.
ClinicalExpectations
Asymptomatic in the neonate. If untreated PKU will pro-
duce irreversible mental retardation, hyperactivity, autism,
and seizures.
ResourcesforReferral
Insert local, state, and regional resource.
AdditionalInformation
NewEnglandMetabolicConsortium—EmergencyProtocols
http://www.childrenshospital.org/newenglandconsortium/
Gene Tests/Gene Clinics http://www.genetests.org
U.S. National Newborn & Genetics Resource Center
http://www.genes-r-us.uthscsa.edu
NewbornScreeningActSheet
[C8]
Medium Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency
Disease Category
Fatty acid oxidation disorder (FAOD)
You Should Take The Following Actions:
• Immediate consultation with a metabolic specialist
(seebelow*).
• Contact family to inform them of the newborn
screeningresult,providefeedinginstructions(feed-
ing every 2-4 hours.) and schedule an immediate
visit. If infant is lethargic or not feeding well, emer-
gencycareiswarranted.
• Emergencytreatmentincludesavoidingfasting,de-
terminingbloodglucoselevelandprovidingglucose
ifhypoglycemicorsymptomatic.
• Undertake definitive investigations in consultation
withmetabolicspecialist.
• ReportfindingstoStatenewbornscreeningprogram.
MeaningOfScreeningResult
Highly elevated C8 acylcarnitine (INSERT STATE SPE-
CIFICCONCENTRATION)likelyindicatesMCADD.Milder
elevations of C8 acylcarnitine (INSERT STATE SPECIFIC
CONCENTRATION) may indicate MCADD, an MCADD
variant, another condition, or transient (false-positive).
MetabolicDescription
FAOD disorders impair ketogenesis and energy homeosta-
sis. MCAD is due to a defect of the mitochondrial enzyme
medium chain acyl-CoA dehydrogenase which is responsible
foramiddlestepinfattyacidoxidation.Hallmarkfeaturescan
include critical hypoketotic hypoglycemia, especially during
times of fasting, catabolism, or illness.
ConfirmationofDiagnosis
Confirmatory biochemical testing includes plasma acylcar-
nitine and urine acylglycine profiles. Informative markers are
C6-C10 acylcarnitines in plasma, hexanoylglycine and sub-
erylglycineinurine.Bothparents,andifapplicable,allsiblings
(ofanyage)shouldalsobetested.Biochemicallyaffectedcases
are confirmed by DNA testing.
ClinicalExpectations
MCADD has variable presentation. The newborn may be
asymptomatic. However, the neonate may also have a clinical
phenotype that includes hypoglycemia causing lethargy, vom-
iting and the risk of sudden death.
ResourcesforReferral
Insert local, state, and regional resources
AdditionalInformation
New England Metabolic Consortium—Newborn Screen-
ingProtocols
http://www.childrenshospital.org/newenglandconsortium/
Gene Tests/Gene Clinics: http://www.genetests.org
U.S.NationalNewborn&GeneticsResourceCenter
http://www.genes-r-us.uthscsa.edu
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[HearingTest]
CongenitalHearingLoss
Disease Category
Hearing Loss
You Should Take The Following Actions:
• Contact family and primary care physician to in-
formthemofthenewbornhearingscreeningresult.
• Repeatthehearingtest.
• If hearing loss is confirmed, comprehensive genetic
evaluationisindicated.
Meaning Of Screening Result
Only 1-3 of 100 infants who screen positive have confirmed
hearingloss.However,hearinglossisserioussoallinfantswho
screen positive need to be further tested.
Condition Description
Defined as hearing loss that is permanent, bilateral or uni-
lateral, sensor or conductive, and averaging loss of 30 decibels
or more in the frequency range important for speech recogni-
tion. Etiologies are numerous. About 50% are due to environ-
mental factors including ototoxicity of drugs (genetically de-
termined), acoustic trauma, and bacterial or viral infections
(e.g., rubella, CMV). The remaining 50% are associated with
genetic syndromes.
Confirmation Of Diagnosis
Hearing loss is confirmed followed by etiologic diagnosis.
Disease Expectations
Even modest levels of bilateral hearing loss can lead to im-
portant problems in speech recognition and speech develop-
ment. Hearing loss can also indicate a genetic syndrome.
Resources for Referral
Local, state, regional and national
Additional Information
Gene Tests/Gene Clinics www.genetests.org
National Center for Hearing Assessment and Manage-
ment
www.infanthearing.org
Newborn Screening Act Sheet
[Citrulline]
CitrullinemiaorArgininosuccinicAcidemia
Disease Category
Urea cycle defect (UCD)
You Should Take The Following Actions:
• Immediate consultation with a metabolic specialist
(seebelow*)
• Contact family to inform them of the newborn
screeningresult,providefeedinginstructions(need
for dietary restriction of protein) and schedule an
immediatevisit
• Emergency treatment if symptomatic. Evaluate for
hyperammonemia.
• Undertake definitive investigations in consultation
withmetabolicspecialist.
• Report findings to State newborn screening pro-
gram.
Meaning of Screening Result
Elevated level of citrulline suggests either citrullinemia or
argininosuccinic acidemia.
Condition Description
Urea Cycle Disorders are caused by a defective enzyme re-
sultinginimpairmentintheabilityoftheureacycletoconvert
one of the breakdown products of protein, ammonia, to the
nontoxic product urea. The resulting accumulation of ammo-
nia causes the toxicity of the UCD defects. Citrullinemia is
caused by a deficiency of argininosuccinic acid synthetase.
Argininosuccinicacidemiaiscausedbeadeficiencyofargini-
nosuccinic acid lyase.
Confirmation Of Diagnosis
Takes one to three days to sort out initial follow-up tests
including repeat newborn screening; however, critical labora-
tories such as ammonia should be obtained in the interim. A
specific diagnosis can be made by confirmatory tests such as
plasma amino acids, urine organic acids, and a urine orotic
acid. In citrullinemia these tests show increased plasma and
urinecitrullineandincreasedurineoroticacid.Inarginino-
succinic acidemia, the tests will show the presence of argini-
nosuccinicacidinurineandplasma(usuallymoreprominent
in urine than in plasma) and increased orotic acid in urine.
Clinical Expectations
Citrullinemia and argininosuccinic acidemia can present in
the newborn period with hyperammonemia, failure to thrive,
lethargy, and coma. Later signs include mental retardation. In
argininosuccinic acidemia, liver disease may also be present.
Resources for Referral
Insert local, state, and regional resources
Additional Information
New England Metabolic Consortium – Emergency Proto-
cols
http://www.childrenshospital.orrg/newenglandconsortium/
Gene Tests/Gene Clinics http://www.genetests.org
ACMG Newborn Screening Expert Group
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Newborn Screening Act Sheet
[TSH,T4]
CongenitalHypothyroidism(CH)
Disease Category
Endocrinopathy
You Should Take the Following Actions:
• Contact family to inform them of the newborn
screeningresult.
• Schedule office visit for the newborn within 1 -3
days for repeat screening and/or confirmatory test-
ing.
• Consultpediatricendocrinologist;referraltoendo-
crinologistifconsideredappropriate.
• Report findings back to State newborn screening
program.
Meaning of Screening Result
Decreased thyroxine (T4) accompanied by increased thy-
roid stimulating hormone (TSH) suggests primary hypothy-
roidism;decreasedT4anddecreasedTSHsuggestssecondary
hypothyroidism.
Some programs screen only for primary hypothyroidism by
only measuring TSH. An increase in TSH suggests congenital
hypothyroidism.
Metabolic Description
Lack of adequate thyroid hormone production.
Confirmation Of Diagnosis
Takes 1-3 days. Diagnostic tests include reduced serum T4,
T3uptake,freeT4orT4index,andserumTSH,whichwillbe
increased in primary hypothyroidism and reduced in second-
ary hypothyroidism.
Clinical Expectations
Asymptomatic in the neonate. If untreated, results in devel-
opmental delay/mental retardation and poor growth.
Resources for Referral
Insert local, state and regional resources
Additional Information
Gene Tests/Gene Clinics www.genetests.org
Appendix 4
Programstandards
InitialNewbornScreeningActivities
1. Document complete reporting of all results of all liveborn
newbornswithinthreemonthsofthecloseoftheyear(tar-
get 100%).
a. Initial screening specimens should be collected after 24
hours, but as close to discharge as possible. Newborns
with prolonged hospital stays should be tested before
day seven, regardless of reason for hospitalization.
b. The number of newborns discharged from hospitals
without screening and the number of these infants in-
volved in follow-up testing should be documented.
c. Thenumberofnewbornsdischargedwithoutscreening
for which screening occurred through follow-up at
some later time should be documented.
2. Documentandreportthenumberofout-of-hospitalbirths
(e.g., using birth certificates) and the numbers of those
tested versus those not tested.
3. Documentthenumberofunsatisfactoryspecimensforany
reason (target is 0%). This includes specimens considered
unsatisfactory due to:
a. laboratory/analytical issues (e.g., a poor specimen);
b. clinical issues (e.g., timing of specimen acquisition);
and
c. information issues (i.e., inadequate demographics such
asname,datacompletenesssuchasnodischargetimeor
specimen collection times noted)
4. Document rate of unsatisfactory specimens followed up
with a satisfactory test (target 100%)
a. document the number of newborns discharged prior to
24 hours and retest all;
b. document the number of newborns discharged prior to
24 hours and initiate a retest of all within 6 days of life;
and
c. monitor unsatisfactory specimen data and report plans
for corrective action.
5. Document the number of newborns screened positive or
not normal for each disorder on the screening panel. For
programs that universally require a second screen, docu-
ment the number of newborns receiving the required sec-
ond screen.
6. Document the rates and types of disorders with a con-
firmed clinical diagnosis.
7. Document time from birth to reporting of all presumptive
positive screens.
8. Document time from birth to:
a. testing to establish diagnosis; and
b. initiation of intervention or treatment by condition.
9. Document:
a. thatconfirmedpositivesaretreatedwhereindicatedand
comply with the therapeutic program;
b. appropriateoutcomevariables,long-termhealthstatus,
and development, at least annually; and
c. the offering of services and utilization for positive cases
(consider matched controls).
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ofeachdisorder,andestimatedcostavoidance.Ensurethat
the impact on families is considered.
11. Document(costsmaydictatethatasamplingprocedurebe
employed) that information/education was provided to:
a. parents(e.g.,distributedmaterials,withanopportunity
for parents to ask questions); and
b. health care providers (e.g., via a program practitioner
manual).
12. Document the effect of identification as screen positive on
access to services and insurance
3.
13. Document monetary and other costs of diagnosis and fol-
low-up (include impact on families).
14. Document that programs have a mechanism in place to
provide for consumer input, as well as the rates of con-
sumer complaints related to all parts of the program.
15. Documenttheuseofastandingexternalmultidisciplinary/
advisory committee for program guidance that includes
consumers.
TransitionBetweenScreeningProgramandDiagnostic/
Follow-upPhase
16. Educational materials should exist that clearly explain
screen-negative results to parents and health care provid-
ers (including materials to guide their initial response to
notification of a screen-positive infant).
17. Maintainalistingofqualifiedsubspecialtyprovidersavail-
able to confirm diagnoses, conduct follow-up testing of
screen-positive infants, and manage treatment of those
identified by screening.
18. Document the number of newborns with an identifiable
medical home.
4
DiagnosisandFollow-up
19. Integrate reporting and follow-up information systems,
including communication with specialists and laborato-
ries diagnosing conditions that are part of newborn
screening:
a. so that no child is lost to follow-up;
b. to allow identification and communication back to
programsofcasesidentifieddiagnostically(clinical,en-
zymatic, biochemical, or molecular confirmation for
each test leading to the final diagnosis), but missed by
screening programs; and
c. to include screening laboratory and diagnostic fol-
low-up laboratory identification and location to facili-
tate physician referral.
[Note:Anemergingissueiswhetheranewbornscreen-
ingprogramshouldincludediagnosisandfollow-upin
its fees. In addition, in developing referral networks,
consideration will have to be given to which tests re-
quire such a network (e.g., metabolic) and which have
more stable technologies (e.g., thyroid)]
20. Develop a QA system that includes
a. total quality management (TQM)/continuous quality
improvement (CQI);
b. auditing; and
c. documentation of corrective actions.
SocietalOutcomeGoals
21. Programs should collect outcome data to accrue knowl-
edge about the natural history of conditions. For condi-
tions for which there is a limited knowledge of the impli-
cations of results (e.g., ancillary information from MS/
MS), there is the potential to enhance knowledge of
implications through research and/or tracking of out-
comes. Since such data collection is largely a research-
based initiative, it may best be done as special studies.
a. Identify individuals who might benefit from involve-
ment in research or who should be more closely
watchedinaneonatalintensivecareunitenvironment.
Appendix 5
HIPAAguidanceforpublichealthprograms
Recently, there have been significant changes to federal pri-
vacy regulations related to protected health information
(PHI). On April 14, 2003, the federal privacy regulations (re-
ferredtohereasthePrivacyRule)becameeffectiveasaresultof
HIPAA (45 CFR Parts 160 and 164).
These new regulations provide specific exemptions and al-
lowances for public health activities and to those providing
services associated with those activities. A work group of the
expert group was asked to provide guidance regarding these
regulations and their impact on the various participants in
newborn screening program activities.
The Privacy Rule applies only to “covered entities” (health
careplanssuchasHMOs;healthcareclearinghousesthatassist
providers with billing; or health care providers who transmit
PHI in electronic format for financial or administrative activ-
ities[forwhichtheSecretaryofDHHShasestablishedaformat
related to health care]). The goal is to protect confidential pa-
tienthealth,identifiabledemographicinformation,andbilling
information. The Privacy Rule does not apply to employers,
insurers, schools, or other entities, except to the extent that
they perform activities as a covered entity. The rule does apply
tofederal,state,andlocalgovernmentsintheirroleascovered
entities (e.g., through Medicare, Medicaid, the Indian Health
Service).
HIPAA covers both the use and disclosure of PHI. Use is
defined as “the sharing, employment, application, utilization,
examination, or analysis of such information within an entity
that maintains such information.” Disclosure refers to “the
release, transfer, provision of access to, or divulging in any
other manner of information outside the entity holding the
information.”However,exceptionsaremadeforpublichealth
activities. Newborn screening is mandated by law in all 50
statesandtheDistrictofColumbia,withrequiredreportingto
relevant public entities and the patient’s treatment team. It is
beyond the scope of this document to describe each state’s
laws.
5
AcoveredentitymayuseanddisclosePHIwithoutthecon-
sentorauthorizationoftheindividualfortreatment,payment,
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activities of a covered entity. Research is not included in oper-
ations as defined by the regulations.
Uses and disclosures of PHI beyond treatment, payment, or
health care operations are only lawful if 1) pursuant to a valid
authorization; or 2) pursuant to an exception set out in the
Privacy Rule.
PHI can be disclosed to third parties with an individual’s
written authorization. (“Individual” is defined in the regula-
tions as a competent adult or a personal representative acting
onbehalfofanincompetentperson.)Forthepurposesofnew-
born screening, the newborn is represented by parent(s) or a
legal guardian.
State laws “serving a compelling need related to public
health, safety or welfare” remain in effect after April 14, 2003.
Specifically, state laws concerning the reporting of disease and
the conduct of public health surveillance, investigation, or in-
terventionremainineffect(45CFRSection160.203).Further,
coveredentitiescandiscloseotherwiseprotectedpatientinfor-
mation for public health activities without prior notice to the
individual or the signing of an authorization. Pursuant to sec-
tion164.512(a)and(b)oftheregulations,coveredentitiesmay
disclose information for public health surveillance, public
health intervention, and other public health purposes. These
provisions make it clear that state newborn screening and re-
porting laws and programs remain in effect.
UnderthePrivacyRule,acoveredentitymayuseordisclose
PHI without consent, authorization, or an opportunity to
agree or object by the patient where:
1. theuseordisclosureisrequiredbylaw(includingapub-
lic health law such as a newborn screening law); or
2. the disclosure is to a public health authority authorized
by law to receive the information for public health activ-
ities (164.512(a) and (b)); or
3. thedisclosureisfortreatmentneedsofthepatient.Treat-
ment includes provision, coordination, or management
of health care and related services by one or more pro-
viders, including coordination and management by a
provider with a third party.
ThePrivacyRulepermitspublichealthreporting,butitdoes
not require it. Reporting requirements are established by pro-
visions of state and local laws.
There are two kinds of public health disclosures under the
Privacy Rule—mandatory and permissive. Mandatory disclo-
sures are those required by law, and the Privacy Rule places no
limit on the amount of information disclosed. Section
164.512(b) also permits covered entities to disclose PHI to
public health authorities and their authorized representatives
for public health surveillance, investigations, and interven-
tions. A “minimum necessary” requirement applies to “per-
missive” disclosures, thereby limiting such disclosures to the
“minimum necessary to accomplish the intended purpose of
the use, disclosure, or request” (Section 164.502 (b) (1.).
A “Public Health Newborn Screening Program” includes
initial screening, QA, diagnosis, follow-up, contracts with ac-
ademic laboratories and consultants, and management of the
research uses of the stored data. A program must share data
among state agencies, laboratories, physicians, and state- and
InstitutionalReviewBoard(IRB)-approvedresearcherstoful-
fill the public health mandate. Because each state’s program is
run in different ways, each needs to consult with its advisors
aboutitsstatusasa“coveredentity,”“provider,”orotherpub-
lic health-related status. For example, under the Privacy Rule,
if data are collected as surveillance data under 164.512(b) by a
public health authority authorized by law to collect or receive
such information for the purpose of preventing or controlling
disease, any subsequent use or disclosures are not required to
comply with the Privacy Rule. State law may provide added
protections. If the public health authority is also a covered
entity, the Privacy Rule would apply for subsequent uses, for
example, research (see discussion below).
Once screening has occurred, the results, the diagnosis, a
care plan, and follow-up treatment can be transmitted to the
laboratory,thepublichealthdepartment,andthephysician(s)
providing care. This is allowed under the regulations because
of the public health mandate and because once a patient has
received and acknowledged the Notice of Privacy Practices (a
document that explains the patient’s rights and the actions the
provider will take to protect privacy), the PHI can be used and
disclosed.Thepatientwouldreceiveanoticefromthehospital
wherethebirthoccurredandfromtheprimarycarephysician.
Security
If PHI is transmitted electronically (which means by com-
puter, not by phone or fax), transmission must be secure. The
security conditions required are set forth in HIPAA security
regulations found in relevant parts of 45 CFR Parts 160 and
164. Those regulations become effective April 21, 2005. They
require adequate firewalls, encryption, password protection,
and backup so that electronic transmissions can protect the
confidentiality of the PHI.
Research
Research conducted by state or federal programs as man-
dated by relevant law is permitted as a public health activity.
For research by private researchers or research not man-
dated by law (e.g., a prevalence study using identifiable names
linked to DNA), the rules of research would apply. Research
with human subjects conducted with federal funding (or in-
volving researchers otherwise covered by federal law) is regu-
lated by 45 CFR Part 46.
Because research is not considered to be part of treatment,
payment, or operations, a researcher wishing to access PHI
from a covered entity must either:
1. de-identify the PHI so that the patient cannot be deter-
mined.De-identificationoccursoncethefollowingitems
are redacted from the data to be used by the researcher:
● names;
●allgeographicsubdivisionssmallerthanastate,includ-
ing address, except for the initial 3 digits of a zip code
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● all dates, except the year including birth date;
● telephone number;
● fax number;
● electronic mail address;
● Social Security number;
● medical record number;
● health plan beneficiary number;
● account numbers;
● certificate/license numbers;
● vehicle identification and serial numbers;
● device identifiers and serial numbers;
● URLs;
● IP address numbers;
● biometric identifiers;
● full-face photos or comparable images; and
● any other unique identifying number, characteristic or
code.
OR
2. have the patient authorize access to the PHI, unless a
Privacy Board or an IRB waives the need for authoriza-
tion in accordance with specific requirements designed
to protect privacy. Those requirements include a finding
that the research could not practicably be conducted
without the waiver, that data will not be reused or dis-
closedtoathirdparty,andthatthereisanadequateplan
to protect privacy (164.512(i)).
OR
3. constructaLimitedDataSet,wherethedataareprovided
to a researcher who has signed a Data Use Agreement. A
LimitedDataSetcanincludedatesandgeographicinfor-
mation, but not street addresses or other direct identifi-
ers listed above. A Data Use Agreement establishes the
permitted uses of the limited data set and says the re-
searcher will not further use or disclose the information,
will protect it, and will not identify or contact the indi-
viduals whose data are in the set.
For research using DNA derived from dried-bloodspots:
a. theremustbede-identification,whichcanmosteasilybe
accomplished by simply snipping off a piece of the spec-
imen and providing no other information; or
b. theremustbeparentalorlegalguardianwrittenauthori-
zation on a Privacy Rule compliant form; or
c. there must be a waiver of the need for authorization
properly granted by a Privacy Board or IRB; or
d. theremustbeaLimitedDataSetcontainingonlygeneral
geographicinformationandrelevantdates,coupledwith
a data use agreement signed by the researcher (see priva-
cyrulesandresearch.nih.gov/).
Conclusion
Because newborn screening and related activities are per-
mitted under 45 CFR Section 164.512 (a) and (b) and are re-
quiredbystatelaw,theseactivitiesandassociatedresearchcan
proceed under the Privacy Rule. The greatest challenge is to
confronttheoftenpervasivemisinformationaboutthePrivacy
Rule that sometimes has been used to justify the nondisclo-
sureof newborn screening and other public health informa-
tion.
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